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Abstract 
Malaria is a mosquito-borne disease caused by parasites of the Plasmodium genus. There 
is no malaria vaccine available. The most lethal form of malaria in humans is caused by 
infection with Plasmodium falciparum parasites. The protein PfC0760c from P. falciparum was 
identified as a potential malaria vaccine candidate based on the presence of alpha-helical 
coiled-coil motifs. This protein is conserved, and homologous proteins have been identified in 
Plasmodial species infecting humans, monkeys, mice and birds. PfC0760c has not been 
characterised and has no known function. Conditions for the recombinant expression of a 297 
amino acid fragment (N2360 – N2656) from PfC0760c was optimized. The recombinant 
PfC0760c protein (denoted further as rPfC0760c297) was expressed as an insoluble 56 kDa 
his6-tagged fusion protein. Different conditions for the expression of soluble rPfC0760c297 were 
evaluated, including expression in the presence of ethanol and co-expression with Escherichia 
coli chaperones. Under different expression conditions, rPfC0760c297 remained insoluble, and 
was thus solubilized before nickel chelate affinity purification. 1 g cell biomass yielded ~22 mg 
purified rPfC0760c297 protein. Bioinformatics analyses of PfC0760c revealed three conserved 
peptides. B-cell epitopes, and several T-cell epitopes were also predicted. PfC0760c is 
expressed during the blood stages of the P. falciparum lifecycle and is found in the parasite 
nucleus. The absence of transmembrane domains and functional PEXEL motifs suggests that 
the protein is unlikely to be secreted. Chicken anti-rPfC0760c297 IgY antibodies were able to 
detect the homologous protein in P. berghei-infected mouse red blood cells. Far western blot 
analysis revealed protein-protein interactions between human U937 and mouse J774A.1 
monocyte proteins with the rPfC0760c297. Mice immunized with rPfC0760c297 were able to raise 
antibodies against the protein, however succumbed to a P. berghei mouse malaria challenge 
infection. Various factors may have contributed to this outcome and further research is required 
in this endeavour. Further research is required for the development of a suitable malaria 
vaccine candidate. 
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Chapter 1: Literature review 
1.1 Introduction 
Malaria is a disease caused by the mosquito-borne parasite of the Plasmodium genus. 
Malaria affects the tropical and subtropical regions of the world. The Plasmodium falciparum 
parasite causes the most lethal form of malaria in humans (WHO, 2018). Other species of 
Plasmodium known to infect humans include P. malariae, P. ovale and P. vivax (Birkett, 2016; 
Muerhoff et al., 2010). The simian-infecting parasite P. knowlesi was identified as a 
human-infecting parasite, due to the recent increase in human P. knowlesi infections occurring 
in South East Asia (Antinori et al., 2012; Singh et al., 2004). Sub-Saharan Africa has the 
highest mortality caused by P. falciparum malaria (Targett and Greenwood, 2008; Gardner et 
al., 2002). Children younger than five years old, and pregnant women are the most vulnerable 
(Srinivasan et al., 2017; Birkett, 2016). South America, Europe, the Middle East, and Asia are 
also affected by malaria (Birkett, 2016). In South Africa, the KwaZulu-Natal, Mpumalanga and 
Limpopo provinces are affected (Maharaj et al., 2013).  
A malaria infection is characterised by intermittent febrile episodes occurring every 48 – 72 
hours following infection (Kyes et al., 2001) depending on which Plasmodium species a human 
host is infected with. Febrile episodes occur every day in P. knowlesi, every second day in 
P. vivax, every three days in P. falciparum infections, and every fourth day in P. malariae and 
P. ovale (Daneshvar et al., 2009; Collins and Jeffery, 2007; Garcia et al., 2001). These periods 
of fever coincide with the rupture of infected red blood cells releasing merozoites into the 
bloodstream which then invade new red blood cells, wherein they replicate (Absalon et al., 
2016; Tuteja, 2007). Parasite-associated debris and metabolites released from rupturing red 
cells contribute to fever (Markwalter et al., 2016). Headaches and chills are common 
symptoms, as well as myalgia, abdominal pain, nausea, vomiting, malaise, and less frequently 
diarrhoea, cramps, loss of appetite, decreased energy, dizziness and body pains ( Bartoloni 
and Zammarchi, 2012; Hlongwana et al., 2009; Trampuz et al., 2003). 
Problems threatening malaria eradication efforts include mosquito resistance to insecticides 
and parasite resistance to various antimalarial drugs (Krzywinska et al., 2016; Pavadai et al., 
2016; Srinivasan et al., 2017). The liver stage of the parasite lifecycle is asymptomatic, and 
this also circumvents the elimination of malaria as the infection is undetected (Dhangadamajhi 
et al., 2010; Targett and Greenwood, 2008). Clinical symptoms of malaria become evident 
during parasite asexual replication during the blood stages of the parasite lifecycle (Absalon 
et al., 2016; Srinivasan et al., 2017). Thus, an individual infected with malaria only realises that 
infection has begun when they experience symptoms associated with the blood stage. New 
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drug targets and an effective vaccine would help prevent malaria, provide new treatments to 
bypass parasite drug resistance, and possibly eradicate malaria in the long-term.  
1.2 Malaria transmission and control 
The Plasmodium parasites are transmitted by female Anopheles mosquitoes (Birkett, 2016; 
Gardner et al., 2002). Transmission of P. knowlesi occurs zoonotically from infected macaques 
to humans (Singh et al., 2004), although human to human transmission of P. knowlesi is 
uncommon (Beeson et al., 2016). Transmission of malaria can occur through blood 
transfusions, although this is not common (Muerhoff et al., 2010). Prevention of malaria 
transmission would require eradication of all parasites in a community (Targett and 
Greenwood, 2008).  
Malaria persists, despite efforts to eradicate and control the spread of the disease (Gardner 
et al., 2002). Control measures include the use of insecticide residual spraying (Sharp et al., 
2007) and insecticide-treated bed nets, improved accessibility to diagnosis of the early stages 
of infection, and effective malaria drug combination therapy with artemisinin (Beeson et al., 
2016). Interruption of the parasite lifecycle as a malaria control measure would require control 
of the mosquito vector. The possibility of transgenically producing male-only offspring in 
Anopheles mosquitoes for malaria control programs is being explored (Krzywinska et al., 
2016).  
1.3 The Plasmodium falciparum parasite 
The genome of P. falciparum is rich in adenine and thymine residues, which contribute to 
approximately 82% of the genome (Weber, 1987). The P. falciparum genome comprises 
23 megabases, condensed into 14 chromosomes (Gardner et al., 2002), and a total of 
5,369 proteins are expressed (www.uniprot.org). Whilst the genome of P. falciparum has been 
completely sequenced (Gardner et al., 2002), there are still many proteins expressed by the 
parasite that has not yet been characterised (Florens et al., 2002). Determining the roles of 
these proteins will greatly expand the understanding of parasite biochemistry and the pathways 
enabling the parasite to develop drug resistance and evade host immune responses. Analysis 
of the parasite proteome may help identify prospective malaria vaccine candidates and new 
drug targets. 
In 2017, there were 219 million reported cases of malaria, and 435 000 documented deaths 
related to malaria (WHO, 2018). Approximately 99% of malaria cases in Africa were caused 
by P. falciparum infections (WHO, 2018). This may be due to the capacity of P. falciparum to 
cause severe malaria, as well as limited access to diagnosis and treatment in Africa.  
3 
1.4 The lifecycle of Plasmodium parasites 
The complex lifecycle of P. falciparum is characterised by an exogenous sexual stage within 
an Anopheles mosquito, and a liver and blood stage in a human host (Florens et al., 2002; 
Antinori et al., 2012), depicted in Figure 1.1 (Bousema et al., 2014). The antigens of interest 
that have been studied as potential vaccine candidates will be identified at the individual stages 
of the parasite lifecycle. These malaria vaccine candidates will be discussed further in Section 
1.9. 
1.4.1 The sporozoite stage of the Plasmodium lifecycle 
During a blood meal, sporozoites pass from the salivary glands of an infected mosquito 
through the dermis of the human host (Krettli and Miller, 2001). Once in the host, sporozoites 
travel via the bloodstream to the liver, where they invade hepatocytes (Todryk and Walther, 
2005) and develop into tissue schizonts (Antinori et al., 2012). Mature schizonts contain 
numerous merozoites which rupture from the hepatocytes and enter the bloodstream. Notable 
sporozoite antigens are the circumsporozoite protein (CSP) and the liver-stage antigen-1 
(LSA-1). CSP in the form of the RTS,S vaccine is being evaluated as a malaria vaccine 
candidate (Khan et al., 2019; Hill, 2011; Targett and Greenwood, 2008). 
1.4.2 The merozoite stage of the Plasmodium lifecycle 
The merozoite stage invades red blood cells and undergoes asexual replication. Within the 
host red blood cells, the parasites enter a 48-hour cycle of asexual replication and division ( 
Boyle et al., 2013; van Dooren et al., 2005), during which they mature into ring, trophozoites 
and blood schizonts. Mature blood schizonts rupture, releasing merozoites that begin a new 
cycle of red blood cell invasion. Merozoite antigens of interest for malaria vaccine development 
include merozoite surface protein (MSP) -1, -2 and -3, apical membrane antigen-1 (AMA-1), 
reticulocyte-binding homologue 5 (RH5) and glutamate-rich protein (GLURP) (Todryk and 
Walther, 2005).  
1.4.3 The ring stage of the Plasmodium lifecycle 
The merozoite matures into the ring stage which has minimal biosynthetic and metabolic 
activity (Hawthorne et al., 2004). As the ring stage matures, the parasite becomes larger and 
comprises multiple organelles (Kozicki et al., 2015). Haemoglobin is catabolised by 
haemoglobinases (Xie et al., 2016) into heme, which is then transformed into brown haemozoin 
crystals (Bannister et al., 2000). Formation of haemozoin signals the conversion of the ring 
stage to the trophozoite stage (Kozicki et al., 2015). The ring-infected erythrocyte surface 
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antigen (RESA) is a malaria vaccine candidate expressed at this stage (Bozdech et al., 2003b; 
Newton et al., 2001; Brown et al., 1985). 
1.4.4 The trophozoite stage of the Plasmodium lifecycle 
The trophozoite stage is characterised by high concentrations of nucleic acids and 
increased metabolism of haemoglobin and nutrients from the erythrocyte cytoplasm (Dekel 
et al., 2017; Bozdech et al., 2003a; Bozdech et al., 2003b; Florens et al., 2002; Francis et al., 
1997). Increased synthesis of ribosomes in the cytoplasm and swift development of parasite 
organelles is observed (Bozdech et al., 2003a). This stage of the lifecycle is committed to 
cellular division (Bozdech et al., 2003a ; Florens et al., 2002). From the trophozoite stage of 
the lifecycle, the trophozoite exported protein-1 (Tex-1) is being evaluated as a potential 
vaccine candidate (Tiendrebeogo et al., 2019; Kulangara et al., 2012). 
1.4.5 The schizont stage of the Plasmodium lifecycle 
The schizont stage of the parasite lifecycle occurs in both the liver (tissue schizont) (Soulard 
et al., 2015) and the blood stages (blood schizont) (Bannister et al., 2000). The primary function 
of the schizont stage is for the maturation of merozoites (Bozdech et al., 2003a). Within the 
parasitophorous vacuole in infected red blood cells, newly synthesised DNA aggregates and 
forms nuclei (Bozdech et al., 2003a; Bannister et al., 2000). Exhaustion of haemoglobin and 
subsequent crystallization of haemozoin is associated with this stage (Bannister et al., 2000). 
Clusters of large lipid vacuoles are reserved, to be used later for membrane formation 
(Bannister et al., 2000). Organelles are subdivided into segments within the schizont, for 
subsequent merozoite development in a controlled series of steps (Bannister et al., 2000). 
Mature schizonts contain merozoites that rupture out of the parasitophorous vacuole 
membrane and the erythrocyte membrane to invade and replicate in new red blood cells 
(Soulard et al., 2015; Bozdech et al., 2003a). 
1.4.6 The gametocyte stage of the Plasmodium lifecycle 
After the blood stage cycle is repeated several times, a portion of the merozoites 
differentiates into male and female gametocytes (Miller et al., 2013). Gametocytes undergo 
five stages of maturation. The bone marrow is enriched for early gametocyte development 
(Joice et al., 2014) and only the stage V gametocytes circulate in the blood. Gametocytes are 
ingested by mosquitoes during feeding.  
Upon entry into the mosquito midgut, the development of gametes from the ingested 
gametocytes begins as a response to a change in several environmental factors (Kuehn and 
Pradel, 2010). These include the change in host body temperature and secretion xanthurenic 
acid (Kuehn and Pradel, 2010). In the mosquito midgut, fertilization of gametes results in 
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zygotes that mature into ookinetes. The ookinete leaves the mid-gut lumen enclosed in a 
membrane, forming an oocyst. The oocyst ruptures as it leaves the mid-gut lumen, releasing 
sporozoites that invade the salivary glands (Dhangadamajhi et al., 2010). Transmission to the 
next host occurs at the mosquito’s next blood meal. The gametocyte surface antigens Pfs230 
and Pfs48/45 (Kapulu et al., 2015) are potential transmission-blocking vaccine candidates. In 
the mosquito midgut, Pfs25 is expressed in the developing parasites (Barr et al., 1991). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Lifecycle of Plasmodium falciparum in Anopheline and human hosts. The human host 
is infected with sporozoites during a blood meal by an infected female Anopheles mosquito. Sporozoites 
flow through the bloodstream and enter the liver cells, where they mature into a tissue schizont 
containing merozoites. Merozoites are released into the bloodstream where they begin a cycle of 
asexual replication. A portion of the merozoites will undergo sexual replication to produce gametocytes, 
which are transmitted to mosquitoes upon consumption of a blood meal. Within the midgut of the 
mosquito, gametocytes mature into sporozoites. These sporozoites invade the mosquito salivary glands 
and are then able to infect a host. Adapted from Bousema et al. (2014).  
1.5 Severe malaria 
Severe malaria is typically caused by P. falciparum, however, P. knowlesi, and rarely, 
P. vivax and P. ovale have also been implicated (Barber et al., 2013; Fatih et al., 2012; William 
et al., 2011;Trampuz et al., 2003). Complications of severe malaria include cerebral malaria, 
renal failure, anaemia, hypoglycaemia and acidosis (Trampuz et al., 2003). Some of the clinical 
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presentations of severe malaria include a high fever, cerebral malaria, respiratory distress, 
multi-organ failure, vascular obstructions, severe anaemia and metabolic acidosis (Craig et al., 
2012). Respiratory distress or impaired consciousness were identified as indicators for high 
risk of malaria-associated mortality in African children (Marsh et al., 1995).  
Cytoadherence of P. falciparum-infected red blood cells contribute to sequestration in major 
organs (Rowe et al., 2009; Craig et al., 2012). The P. falciparum erythrocyte membrane 
protein-1 (PfEMP-1) family of proteins are ligands expressed on the surface of infected red 
blood cells. Binding of PfEMP-1 proteins to CD36, chondroitin sulfate A (CSA) and intracellular 
adhesion molecule-1 receptors on the surface of endothelial cells, placenta and the brain 
respectively, has been associated with of severe malaria (Pehrson et al., 2016; Turner et al., 
2013; Patel et al., 2004).  
Cerebral malaria is characterised by a coma associated with a Plasmodium infection. 
Haemorrhage and lesions on the brain and sequestration of infected red blood cells was 
detected post-mortem in cerebral malaria patients (Storm and Craig, 2014). The exact 
mechanism for the development of cerebral malaria is unknown (Storm and Craig, 2014). 
1.6 Malaria diagnostic tests 
The correct diagnosis of malaria, particularly in underdeveloped subtropical rural areas, is 
imperative for the proper course of treatment to be followed. Malaria symptoms are often 
flu-like, and fevers may be misdiagnosed as dengue, typhoid or other fever-associated tropical 
diseases. Because P. falciparum malaria may become severe or progress to cerebral malaria, 
it is critical to correctly diagnose the infective Plasmodial species.  
Microscopy and rapid diagnostic tests are the most widely used malaria diagnostic tools 
(Kho et al., 2016). Polymerase chain reaction analysis, loop-mediated isothermal amplification 
and enzyme-linked immunosorbent assays are also used for malaria diagnosis.  
1.6.1 Microscopy for malaria diagnosis 
Microscopic examination of Giemsa-stained blood smears for malaria diagnosis is regarded 
as the “gold-standard” against which other malaria diagnostic methods are compared 
(Wongsrichanalai et al., 2007). The Giemsa stain differentially stains the nucleus of cells. Red 
blood cells are devoid of a nucleus, thus parasite-infected red blood cells are easily 
distinguished from uninfected red blood cells (Dekel et al., 2017). Thick blood films are more 
sensitive for the detection of low levels of parasitaemia, and thin blood films allow for species 
differentiation (Moody, 2002). However, very low parasitaemia or mixed infections where the 
parasite species’ morphology is similar may not always be detected (; Mahende et al., 2016; 
Chew et al., 2012; Noedl et al., 2006). 
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1.6.2 Rapid diagnostic tests for the detection of malaria 
The rapid diagnostic test (RDT) is one of the major malaria diagnostic tools used in 
underdeveloped areas and is designed to detect infections within approximately 15 minutes. 
The RDT comprises an immunochromatographic test strip impregnated with colloidal-gold 
coupled monoclonal antibodies against key malaria proteins (Maltha et al., 2013). The blood 
sample is applied to the test strip and flows across the strip by capillary action. A control line 
indicates that the blood has flowed across the test strip. In addition to the control line, a 
coloured line where the gold labelled antibodies complexed with a malaria antigen is captured 
indicates a malaria infection (Davis et al., 2014; Maltha et al., 2013). Malaria antigens used in 
RDTs include the parasite-specific glycolytic enzymes aldolase and lactate dehydrogenase 
(LDH), and the P. falciparum-unique blood stage protein histidine-rich protein 2 (HRP-2) 
(Moody, 2002). The thioredoxin peroxidase 1 protein is a conserved blood stage Plasmodium 
protein and has recently been evaluated as a potential diagnostic target (Hakimi et al., 2015). 
The urine malaria test is a non-invasive RDT used to detect a P. falciparum infection (Oyibo 
et al., 2017). Similar to RDTs that test blood, the urine malaria test detects HRP-2 in urine with 
recombinant monoclonal anti-HRP-2 antibodies on an immunochromatographic test strip in the 
form of a dipstick (Oyibo et al., 2017; Oguonu et al., 2014).  
Diagnostic tests that detect HRP-2 are able to distinguish P. falciparum infections from other 
infecting species, and treatment or further testing can be managed accordingly. However, 
HRP-2 persists in the body fluids including blood and urine after an infection has cleared, and 
this could lead to false positives (Mahende et al., 2016).  
1.6.3 Polymerase chain reaction detection and diagnosis of malaria  
Polymerase chain reaction (PCR) is a method that is more sensitive than microscopy and 
can detect mixed infections (Moody, 2002; Johnston et al., 2006). Real-time and conventional 
PCR assays have been developed for the identification and differentiation of Plasmodium 
species (Johnston et al., 2006). Genes encoding the small-subunit 18S rRNA and 
circumsporozoite proteins have been used to distinguish between the different Plasmodial 
species (Moody, 2002), using parasite-specific primers (Snounou et al., 1993). Despite its 
sensitivity and specificity, PCR is an expensive procedure requiring specialised equipment, 
trained personnel, adequate time to process samples, and stable reagents. This prevents the 
test from being useful in rural settings (Mahende et al., 2016).  
1.6.4 Loop-mediated isothermal amplification for detection and diagnosis of malaria 
The loop-mediated isothermal amplification (LAMP) technique is based on the amplification 
of nucleic acids at a constant temperature (Notomi et al., 2000). The LAMP diagnostic test 
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detects a malaria infection by amplifying Plasmodium-specific genes (Poon et al., 2006; Ocker 
et al., 2016). For the detection of a Plasmodium infection, the 18S rRNA gene is amplified 
using species-specific primers (Poon et al., 2006). There are several advantages of using 
LAMP over PCR, including the simplicity and cost of the test, the time required, and the DNA 
does not have to be purified first (Poon et al., 2006). However, the PCR remains more sensitive 
and specific for the detection of Plasmodium infections (Poon et al., 2006; Ocker et al., 2016). 
LAMP may detect asymptomatic malaria where an RDT may not (Cook et al., 2015). 
1.6.5 Enzyme-linked immunosorbent assay to detect malaria 
The enzyme-linked immunosorbent assay (ELISA) employs the use of enzyme-linked 
antibodies to detect malaria antigens. Plasmodium LDH (Nambati et al., 2018) is used for 
malaria diagnosis, and detection of HRP-2 is specific for P. falciparum (Gibson et al., 2017). 
Similar to PCR, an HRP-2 based ELISA was shown to be more sensitive than microscopy 
(Noedl et al., 2006). However, the cost of antibodies, time, expertise required, and the stability 
of reagents involved make ELISA a problematic method for malaria diagnosis under field 
conditions. The ELISA is better suited to laboratories analysing numerous samples for 
research purposes. 
1.7 Antimalarial drugs 
Many therapeutic drugs are available to treat malaria infections. Most drugs target the 
asexual blood stage (Bousema et al., 2006). Antimalarial drugs such as mefloquine are often 
used as prophylaxis before an individual enters a malaria endemic area (Steffen et al., 1993). 
Combination therapy with artemisinin and another antimalarial drug helps prevent 
recrudescence and combats antimalarial drug resistance (Bousema et al., 2006; Nandakumar 
et al., 2006). Malaria may also be treated symptomatically to aid patient comfort. 
Antimalarial drug treatment is an effective mechanism for malaria control. However, 
Plasmodium parasites are developing resistance to frontline drugs including artemisinin, 
chloroquine, mefloquine, quinine, sulfadoxine-pyrimethamine and others (Fairhurst and 
Dondorp, 2016; Achan et al., 2011; Gatton et al., 2004; Wellems and Plowe, 2001; Nosten et 
al., 1996). Resistance to various artemisinin-combination therapies is prevalent in Southeast 
Asia (Fairhurst and Dondorp, 2016). 
1.8 Survival of Plasmodium within a host 
Plasmodium parasites have developed mechanisms to evade the host immune system to 
avoid clearance by antibodies, phagocytic cells or the spleen (Kyes et al., 2001). During the 
liver stage, the parasite envelopes itself in a parasitophorous vacuole, which protects it from 
host-cell proteolytic degradation (Vaughan et al., 2010). P. vivax and P. ovale produce dormant 
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hypnozoites which can revive many years later and introduce reinfection, (Beeson et al., 2016; 
Bartoloni and Zammarchi, 2012; Wipasa et al., 2002).  
Sequestration and cytoadherence of Plasmodium-infected red blood cells in the organs 
prevent splenic clearance (Turner et al., 2013). The PfEMP-1 family of proteins is implicated, 
and are capable of antigenic variation, weakening the ability of the host to clear parasitaemia 
(Scherf et al., 2008). 
Plasmodium-infected mosquitoes retain higher levels of glycogen for energy storage. 
Infected mosquitoes increase food intake and survive better under starvation conditions 
compared to uninfected mosquitoes (Zhao et al., 2012).  
1.9 Malaria vaccines 
An effective malaria vaccine should provide long-lasting protection and prevent 
transmission to mosquitoes (Ishizuka et al., 2016; Targett and Greenwood, 2008; Sinigaglia et 
al., 1988). Such a vaccine should be directed against a protein or region of a protein that is 
conserved within the parasite and should therefore elicit an immune response in all immunized 
individuals, and stimulate both B-cell and T-cell responses (Sinigaglia et al., 1988). There is 
currently no licensed malaria vaccine approved for use by the World Health Organization 
(WHO, 2018). The availability of an effective vaccine against malaria would help prevent 
infection in malaria-endemic areas, circumvent the spread of the disease, and decrease the 
mortality rate caused by the disease. 
There is an urgent need for an effective malaria vaccine. Parasite resistance to many 
antimalarial drugs and artemisinin combination therapy has developed and is spreading 
(Pavadai et al., 2016). Anopheles mosquitoes are becoming increasingly resistant to 
insecticides (Beeson et al., 2016; Gardner et al., 2002).  
1.9.1 Pre-erythrocytic stage vaccines 
Vaccines formulated against the pre-erythrocytic liver stage are designed to prevent parasite 
invasion of the red blood cells (Targett and Greenwood, 2008). During the liver stage, there is 
a lower parasitaemia, and sufficient time for an active immune system to clear the parasitaemia 
(Dundas et al., 2018). Antigens used in the development of malaria vaccines targeting the pre-
erythrocytic stage include the circumsporozoite protein and RTS,S vaccine, liver stage antigen-
1, sporozoite surface protein, and attenuated sporozoites. These antigens have been shown 
to induce weak antibody, CD4+ and CD8+ T-cell responses (Trieu et al., 2011).  
1.9.1.1 Circumsporozoite protein and the RTS,S malaria vaccine 
The circumsporozoite protein (CSP) is a well-conserved protein and is the major coat 
protein of sporozoites (Coppi et al., 2005). The structure of CSP is comprised of a central 
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NANP repeat region flanked by an N- and C-terminus (Plassmeyer et al., 2009). Peptides 
derived from the NANP-repeat region of the CSP protein were chosen as a target for vaccine 
development, as the peptides were shown to elicit sporozoite-deactivating antibodies (Egan et 
al., 1987).  
Mice immunized with full-length CSP were able to elicit strong immune responses against 
challenge infection and were protected (Espinosa et al., 2017). However, it was shown that 
progression to the blood stage of development circumvents the immune response against CSP 
(Keitany et al., 2016).  
The RTS,S vaccine is made up of the NANP tandem-repeat tetrapeptide (R) and T-cell 
epitopes from the C-terminal region of CSP (T), fused to the hepatitis B surface antigen (S) 
and unfused S-antigen (S) (Hill, 2011; Targett and Greenwood, 2008). 
Early studies of the RTS,S vaccine showed that it was able to protect against a challenge 
malaria infection (Stoute et al., 1997). The RTS,S vaccine is capable of eliciting high 
concentrations of antibodies against the conserved NANP repeat region, which may be able 
to clear sporozoites before liver cell invasion, and moderate T-cell immunogenicity (Hill, 2011). 
However, this vaccine candidate has not demonstrated sufficient long-term protection against 
a challenge malarial infection (Gosling and von Seidlein, 2016). In a phase III clinical trial, the 
RTS,S vaccine was more efficient when a booster dose was included for African infants (RTS,S 
Clinical Trial Partnership, 2015). Due to the short-term efficacy of this vaccine, it has been 
suggested that it may be used in future strategies to prevent transmission by vaccinating 
people who are at high risk of contracting malaria (Gosling and von Seidlein, 2016). Protection 
by this vaccine appears to be mediated by IgG1 and IgG3 antibodies raised against the 
C-terminus of CSP and NANP (Ubillos et al., 2018). 
1.9.1.2 Liver stage antigen-1 
The liver stage antigen-1 (LSA-1) is expressed during the sporozoite stage of the 
P. falciparum life cycle (Zhu and Hollingdale, 1991). LSA-1 localises to the parasitophorous 
vacuole, and is composed of conserved non-repeat N- and C- terminal regions, and 17-mer 
repeat regions (Hollingdale et al., 1990; Zhu and Hollingdale, 1991). LSA-1 is a conserved 
P. falciparum protein able to produce B- and T-cell responses (Fidock et al., 1994; Kurtis et al., 
2001). 
In a pre-clinical trial conducted in rhesus monkeys, LSA-1 induced IFNɣ- and IL-2-secreting 
CD4+ T-cells. This vaccine was deemed safe to administer on its own, or in conjunction with 
the RTS,S vaccine (Pichyangkul et al., 2007). In a clinical trial, volunteers immunized with low 
doses of LSA-1 were able to produce higher quantities of IFNɣ- and IL-2-secreting CD4+ 
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T-cells than high doses. However, regardless of dose and adjuvant used, this vaccine did not 
protect individuals from a challenge infection (Cummings et al., 2010). 
Falciparum malaria protein 011 (FMP011) is a 54 kDa protein derived from LSA-1 and 
encodes the N- and C-terminal peptides, and two 17-mer repeat units that vary slightly (Brando 
et al., 2007). A pre-clinical trial in mice showed that FMP011 was a promising malaria vaccine 
candidate due to its ability to stimulate antibody responses and IFNɣ secreted by CD4+ T-cells 
(Brando et al., 2007; Hillier et al., 2005). However, in a different strain of mice, minimal cellular 
and humoral responses were observed (Brando et al., 2007). Curiously, no LSA-1 homologue 
is found in Plasmodium species infecting monkeys or mice (Kurtis et al., 2001). 
1.9.1.3 Sporozoite surface protein/thrombospondin related anonymous protein 
Sporozoite surface protein-2, also known as thrombospondin related anonymous protein 
(TRAP) facilitates invasion of liver cells (Labaied et al., 2007). Host cell integrins were shown 
to interact directly with TRAP (Dundas et al., 2018).  
CD8+ T-cell activity is associated with protection in mice and humans by TRAP in 
attenuated sporozoites and viral vector systems (Bliss et al., 2017; Ewer et al., 2013; Khusmith 
et al., 1994). Clinical trials evaluating viral-vectored TRAP with multiple epitopes elicited strong 
immune responses in African adults and children (Bliss et al., 2017; Ogwang et al., 2015). 
Immunization with TRAP in combination with the RTS,S vaccine was deemed safe and 
tolerable (Kester et al., 2014; Walsh et al., 2004). However, conflicting results were obtained 
regarding the value of the addition of TRAP to the RTS,S vaccine (Kester et al., 2014; Walsh 
et al., 2004). 
1.9.1.4 Radiation attenuated sporozoites 
Attenuation of live sporozoites may be achieved by radiation or genetic modification. 
Attenuation of sporozoites prevents their development, halting the lifecycle and preventing 
clinical manifestation of malaria (Lyke et al., 2017; Bijker et al., 2015).  
Immunization with radiation attenuated sporozoites (RAS) produces mutant schizonts that 
cannot rupture to release invasive merozoites (Hill, 2011; Hoffman et al., 2002; Clyde et al., 
1975; Nussenzweig et al., 1967). RAS produces antigens capable of stimulating an immune 
response (Hill, 2011). RAS were shown to confer sterile immunity, and protect volunteers from 
repeated challenge infection with nearly 100% efficacy (Lyke et al., 2017; Hoffman et al., 2002). 
P. falciparum RAS were shown to confer sterile protection mediated by IFNɣ-secreting T-cells, 
against homologous and heterologous controlled human malaria infections, (Lyke et al., 2017; 
Ishizuka et al., 2016). Antibodies, CD4+ and CD8+ T-cell responses against PfCSP and PfRAS 
antigens were correlated with protection (Seder et al., 2013). CD8+ T-cells are implicated in 
the removal of infected liver cells (Hill, 2011; Weiss et al., 1988). 
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The use of mosquitoes for RAS vaccine delivery proved to be unrealistic for conventional 
use (Hollingdale and Sedegah, 2016). Mosquito infection can only be confirmed after 
dissection of the salivary glands. It is debatable whether immunization with a needle and 
syringe can replace the salivary gland fluids of a mosquito to induce sufficient immunogenicity 
and efficiency in humans (Hill, 2011).  
1.9.1.5 Genetically attenuated sporozoites 
Genetic attenuation of sporozoites involves the selective knockout of genes that are 
associated with the development of liver stage parasites, generating mutants that are 
incapable of progressing to the blood stage (Bijker et al., 2015). Such genes include the P52, 
P36, sporozoite asparagine-rich protein-1, b9, and slarp (Mikolajczak et al., 2014; van Schaijk 
et al., 2014; Aly et al., 2008). Immunization with P52, P36, sporozoite asparagine-rich protein-
1, b9 and slarp knockouts inhibited the parasites’ ability to produce invasive merozoites 
(Mikolajczak et al., 2014; van Schaijk et al., 2014). Immunization with b9 and slarp knockout 
parasites resulted in complete protection from a homologous sporozoite challenge (van Schaijk 
et al., 2014). In a clinical study, P52 and P36 knockout parasites were able to confer complete 
sterile protection. Protection was mediated by IFNɣ and cytokine-secreting CD4+ and CD8+ 
T-cells (Spring et al., 2013).  
In comparison to attenuated sporozoite approaches for a malaria vaccine, the RTS,S 
vaccine has failed to produce similar levels of protection against challenge malaria infections. 
1.9.2 Malaria blood stage vaccines 
In order to combat malaria-induced mortality and prevent the manifestation of clinical 
symptoms of malaria, blood stage vaccines were developed (Zhu et al., 2017). These vaccines 
are aimed at diminishing morbidity, mortality and the development of severe malaria (Lu et al., 
2017; Thera et al., 2011; Ellis, et al., 2010; Goodman and Draper, 2010). Many of the blood 
stage vaccines comprise a protein antigen co-administered with an adjuvant intended to 
produce protective antibodies that impair parasite growth with or without other effector cells 
(Hill, 2011). Numerous blood-stage vaccines are based on the merozoite surface protein 
(MSP) and apical membrane antigen (AMA) (Hill, 2011). Other blood stage antigens include 
erythrocyte binding antigen (EBA), ring-infected erythrocyte surface antigen (RESA), 
reticulocyte-binding protein homolog (RH), glutamate-rich protein (GLURP), hypoxanthine-
guanine-xanthine phosphoribosyltransferase (HGXPRT) and trophozoite exported protein 
(Tex). Three challenges have been encountered in the development of blood stage vaccines. 
Firstly, large quantities of the protein antigens may be difficult to express in the correct 
conformation. Secondly, only moderate antibody responses have been generated, even with 
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a range of adjuvants tested. Thirdly, the antigens may exhibit extensive polymorphism (Hill, 
2011).  
1.9.2.1 Apical membrane antigen 
The apical membrane antigen-1 (AMA-1) protein is expressed in sporozoites and on the 
surface of merozoites and is possibly implicated in both liver and red blood cell invasion 
(Schussek et al., 2013; Silvie et al., 2004; Triglia et al., 2000). This vaccine candidate aims to 
induce high titres of growth inhibiting antibodies. The antibodies were shown to be strain-
specific in rabbits and humans (Spiegel et al., 2017; Schussek et al., 2013; Malkin et al., 2005). 
AMA-1 was able to provide sterile protection against challenge blood stage infections in 
mice (Schussek et al., 2013). Mice were protected from a homologous, but not heterologous 
blood-stage challenge infection when immunized with refolded AMA-1 (Crewther et al., 1996). 
Importantly, the data presented by Crewther et al. (1996) suggests that protection is conferred 
by the adjuvant alone; which contradicts what is stated in the document, as it is unlikely that 
immunization with adjuvant alone would result in protection from challenge infection. 
Aotus vociferans monkeys were protected against challenge P. falciparum blood stage 
infection when immunized with the AMA-1 protein (Stowers et al., 2002). AMA-1 in combination 
with Plasmodium rhoptry neck protein 2 (RON-2) was protective against challenge blood stage 
infections in rats and A. nancymae monkeys (Srinivasan et al., 2017; Srinivasan et al., 2014). 
Superior protection was achieved with AMA-1/RON-2 compared to AMA-1 alone, although 
antibody titres were similar, suggesting protection is not mediated by antibodies alone 
(Srinivasan et al., 2017).  
In a phase I clinical trial, AMA-1 formulated with Alhydrogel was shown to be safe and well 
tolerated (Malkin et al., 2005). Malaria naïve adults immunized with the AMA-1 ectodomain 
vaccine in different adjuvant systems were not protected against sporozoite challenge infection 
(Spring et al., 2009). 
1.9.2.2 Merozoite surface protein  
The merozoite surface protein-1 (MSP-1) protein is a conserved Plasmodium protein 
expressed on the surface of merozoites (Ling et al., 1994). The MSP-1 protein is approximately 
200 kDa, which is cleaved into smaller fragments of 83 kDa, 28 – 30 kDa, 38 kDa and 42 kDa 
upon release into the blood (Holder et al., 1992). The 42 kDa C-terminal component (MSP-142) 
is further processed into a 33 kDa and a 19 kDa fragment (MSP-133 and MSP-119 respectively) 
(Holder et al., 1992). The MSP-119 fragment remains attached to the parasite membrane, and 
prompts an antibody response, whereas the MSP-133 contains T-cell epitopes (Pusic et al., 
2011; O’Donnell et al., 2001; Holder et al., 1992). Correctly folded MSP-1 proteins are likely to 
be immunogenic (Ling et al., 1994). 
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Mice immunized with MSP-119 were protected from a homologous challenge infection 
(Zhang et al., 2005; Ling et al., 1994). A heterologous immunization treatment using AMA-1 
and MSP-142 was able to protect Aotus monkeys from a challenge blood stage infection 
(Obaldia et al., 2017). MSP-142 from the P. falciparum 3D7 and FVO strains was found to be 
safe and tolerable in a clinical trial. Serum antibodies raised against the recombinant refolded 
protein was able to recognise the native protein (Malkin et al., 2007). A phase IIb trial assessing 
MSP-142 produced high titres of antibodies, which were not protective in children (Ogutu et al., 
2009).  
1.9.2.3 Erythrocyte binding antigen  
Erythrocyte binding antigen (EBA) is a blood stage malaria vaccine candidate expressed in 
the merozoite stage of the parasite life cycle. The EBA-175 is a 175 kDa protein that has been 
implicated in the invasion of red blood cells by binding sialic acid on glycophorin A (Camus 
and Hadley, 1985).  
Mice immunized with the conserved N-terminus of EBA-175 developed a robust antibody 
response that prevented parasite invasion of red blood cells (Pattnaik et al., 2007). Blood stage 
challenge of A. nancymae monkeys immunized with EBA-175 region II resulted in lower 
parasitaemia compared to the control group, most notably in monkeys immunized with a 
regimen including both plasmid DNA and protein (Jones et al., 2001). Higher titres of antibodies 
were elicited in monkeys immunized with the protein compared to immunization with plasmid 
DNA or a regimen of both (Jones et al., 2001). Non-glycosylated EBA-175 region II was 
evaluated in phase I clinical trials and was found to be safe and immunogenic in healthy 
malaria-naïve adults (El Sahly et al., 2010). Antibodies raised against EBA-175 region II in a 
phase Ia clinical trial in semi-immune individuals were able to prevent parasite growth in vitro 
(Koram et al., 2016). 
1.9.2.4 Glutamate-rich protein 
The glutamate-rich protein (GLURP) is a conserved, immunogenic protein expressed during 
the liver and blood stages of the Plasmodium life cycle (Borre et al., 1991). The composition 
of GLURP is made up of a central repeat region flanked by an N-terminal non-repeat region 
and an immunogenic C-terminal repeat region (Theisen et al., 1995).  
A synthetic peptide derived from GLURP was evaluated in a phase I clinical trial, and was 
shown to have some adverse effects, while stimulating antibodies that are capable of inhibiting 
in vitro parasite growth (Hermsen, et al., 2007). The carboxy terminus was found to be the 
most antigenic region in Liberian individuals and was shown to be immunogenic in mice 
(Theisen et al., 1995). A correlation was observed between protection against malaria infection 
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and cytophilic antibodies against GLURP in Ghana, Burkina Faso and Myanmar (Meraldi et 
al., 2004; Soe et al., 2004; Dodoo et al., 2000). 
1.9.2.5 Hypoxanthine-guanine-xanthine phosphoribosyltransferase 
The hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT) enzyme is 
involved in the purine salvage pathway. HGXPRT is a tetrameric enzyme that catalyses the 
conversion of hypoxanthine to inosine 5’-monophosphate, guanine to guanosine 
5’-monophosphate and xanthine to xanthosine 5’-monophosphate (Mbewe et al., 2007; Belen 
Cassera et al., 2011). The enzyme appears to be vital for Plasmodium parasite survival, as 
parasites do not produce nucleotides by the de novo pathway (Mbewe et al., 2007). 
Plasmodium HGXPRT was found in both the parasite and infected red blood cell cytoplasm 
(Shahabuddin et al., 1992).  
Immunization with P. falciparum HGXPRT was shown to stimulate a T-cell response 
associated with protection in mice (Makobongo et al., 2003). HGXPRT is immunogenic in 
humans, stimulating in vitro T-cell proliferation in individuals naturally exposed to malaria 
(Woodberry et al., 2009). Antibodies against HGXPRT were not detected (Woodberry et al., 
2009). 
However, Plasmodium HGXPRT is homologous to human HGPRT (Good and Doolan, 
2010; Makobongo et al., 2003). This means that the number of people responding to the 
vaccine, and generating an immune response could be limited (Good and Doolan, 2010). 
1.9.2.6 Reticulocyte-binding protein homolog 5 
The reticulocyte-binding protein homolog 5 (RH5) antigen is a well-conserved protein 
expressed on the rhoptries at the parasite apex, and is involved in red blood cell invasion 
(Rodriguez et al., 2008; Baum et al., 2009). Antibodies directed against RH5 prevents parasite 
invasion of red blood cells in vitro (Bustamante et al., 2013; Baum et al., 2009). Mouse 
monoclonal antibodies raised against RH5 was able to prevent parasite invasion of red blood 
cells (Ord et al., 2014). A. nancymae monkeys were protected from a P. falciparum challenge 
infection after immunization with RH5, and protection was associated with a strong antibody 
response (Douglas et al., 2015). In a phase Ia clinical trial, a robust antibody response was 
rasied against the RH5 protein, and these antibodies were also shown to inhibit Plasmodium 
parasite growth in vitro. The vaccine was safe and well tolerated (Payne et al., 2017). For 
protection, it is suggested that the conformation of the protein is critical (Bustamante et al., 
2013). 
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1.9.2.7 Ring-infected erythrocyte surface antigen 
The ring-infected erythrocyte surface antigen (RESA) is expressed during the late schizont 
stage, and at the infected red blood cell membrane during the ring stage (Brown et al., 1985; 
Coppel et al., 1984). This protein was found to have regions of repetitive amino acid sequences 
(Coppel et al., 1984).  
Immunization of Peruvian Aotus monkeys with the RESA repeat regions elicited high titres 
of antibodies associated with protection against a P. falciparum blood stage challenge (Collins 
et al., 1986). In young Gambian children, an association between resistance to clinical malaria 
and antibodies against the tetrapeptide repeat region was observed (Riley et al., 1991). 
Antibodies raised against a RESA octapeptide experimentally in rabbits and naturally in 
humans was able to prevent P. falciparum merozoite invasion of red blood cells in vitro (Berzins 
et al., 1986). However, the RESA protein is no longer considered a malaria vaccine candidate. 
1.9.2.8 Trophozoite exported protein 1 
Trophozoite exported protein 1 (Tex-1) is expressed during the blood stages of the parasite 
lifecycle, and its expression is significantly upregulated during the trophozoite stage 
(Kulangara et al., 2012). Tex-1 is expressed as a soluble protein in the cytoplasm, before 
becoming bound to the Maurer’s Cleft membrane during the trophozoite stage (Kulangara et 
al., 2012). The P27 antigen is conserved and is found at the C-terminus of Tex-1, and is one 
of three alpha-helical coiled-coil domains (Kulangara et al., 2012; Villard et al., 2007). The 
second antigen identified within the Tex-1 protein is the N-terminal P27A fragment and is 
predicted to be intrinsically unstructured (Kulangara et al., 2012). Nanoparticle delivery of the 
P27 and P27A fragments were shown to be immunogenic in mice, both as individual proteins 
and as a combination (Karch et al., 2017). These nanoparticles were recognised by serum 
antibodies present in individuals from Burkina Faso (Karch et al., 2017). The P27A antigen has 
been evaluated in a phase I clinical trial (Steiner-Monard et al., 2018). The vaccine was safe 
and tolerable, and stimulated a strong antibody response that inhibited parasite invasion in red 
blood cells (Steiner-Monard et al., 2018). 
1.9.2.9 Whole parasite blood stage vaccine 
Immunization with whole blood stage parasites allows for the exposure of the host to 
multiple antigens. Such vaccinations may be with killed or live attenuated parasites (Stanisic 
and Good, 2015). Problems often encountered with whole parasite vaccines include their 
synthesis, storage and safety (Giddam et al., 2016). 
Low doses of killed P. chabaudi chabaudi AS parasites were able to protect mice from a 
lethal blood stage challenge (Pinzon-Charry et al., 2010). Internalization of killed blood stage 
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parasites in liposomes was tested as an alternative vaccine delivery in mice. Mice immunized 
with these parasite-containing liposomes survived blood stage challenge and had a low 
parasite burden (Giddam et al., 2016). 
Varying degrees of protection against homologous and heterologous challenge was 
observed in mice immunized with killed blood stage parasites (McColm and Dalton, 1983). 
A. trivirgatus monkeys immunized with mature merozoites were protected from a P. falciparum 
challenge infection (Siddiqui, 1977).  
In a clinical study, immunity against P. falciparum was established by immunization with 
ultra-low doses of live P. falciparum-infected red blood cells (Pombo et al., 2002). In vitro 
analyses indicated protection was mediated by parasite-specific CD4+ T-cell responses. A 
CD8+ T-cell response and upregulation of IFNɣ secretion was also prevalent, with minimal 
parasite-specific antibody response in all volunteers (Pombo et al., 2002).  
1.9.3 Transmission blocking vaccines 
Transmission blocking vaccines are based on the sexual stages of the Plasmodium 
lifecycle. Vaccination of individuals against the sexual stages of the parasite lifecycle would 
not necessarily prevent clinical manifestation of malaria. Transmission blocking vaccines 
prevent parasite development in the mosquito midgut and hence blocks transmission (Moorthy 
et al., 2004).  
1.9.3.1 The Pfs25 antigen 
Pfs25 is expressed on the surface of P. falciparum zygotes and ookinetes in the mosquito 
midgut (Barr et al., 1991; Kaslow et al., 1988). Pfs25 is capable of inducing a strong antibody 
response in mice (Radtke et al., 2017; Goodman, et al., 2011). In one study, mosquitoes were 
fed red blood cells containing gametocytes, combined with Pfs25 immune sera from mice and 
monkeys (Barr et al., 1991). The antibodies from monkeys and mice inhibited the development 
of oocysts in the mosquitoes (Kapulu et al., 2015; Farrance et al., 2011a; Barr et al., 1991).  
Systemic adverse events were observed in a phase Ia clinical trial evaluating Pfs25 and 
P. vivax Pvs25 as vaccines (Wu et al., 2008). Evaluation of Pfs25 coupled to Pseudomonas 
aeruginosa ExoProtein A in a phase I clinical trial showed that it was relatively safe. High titres 
of anti-Pfs25 antibodies were raised and were associated with transmission blocking activity 
(Talaat et al., 2016). This suggests that the Pfs25 vaccine may be developed further.  
1.9.3.2 The Pfs48/45 antigen 
Pfs48/45 is expressed on the surface of Plasmodium gametocytes within the blood of a 
human host (Kapulu et al., 2015). The conformation of the Pfs48/45 antigen was shown to be 
important for transmission blocking activity (Milek et al., 1998). It is possible to synthesise 
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correctly folded Pfs48/45 that is capable of stimulating transmission blocking antigen-specific 
antibodies in mice and Papio Anubis baboons (Chowdhury et al., 2009; Outchkorov et al., 
2008). This protein has potential for evaluation in a clinical trial (Theisen et al., 2017). 
1.9.3.3 The Pfs230 antigen 
Pfs230 is expressed on the surface of Plasmodium gametocytes within the human host and 
has a 6-cysteine-rich domain in its structure (MacDonald et al., 2016; Kapulu et al., 2015). 
Antibodies raised in mice against a region of the Pfs230 protein were shown to block 
transmission to mosquitoes (Kapulu et al., 2015). Rabbits immunized with a Pfs230 construct 
were able to produce a strong antibody response capable of preventing transmission 
(MacDonald et al., 2016; Farrance et al., 2011b). A clinical trial of the Pfs230 protein is yet to 
be evaluated as a malaria vaccine (MacDonald et al., 2016). 
1.9.4 Multi subunit vaccines 
Multi-subunit vaccines use more than one antigen, sometimes from different stages, or 
include multiple antigens from the same stage. By including antigens from different stages of 
the parasite lifecycle in a multi-subunit vaccine the immune system is primed against these 
stages.  
1.9.4.1 NYVAC-Pf7 vaccine 
The NYVAC-Pf7 malaria vaccine is composed of the sporozoite antigens CSP and 
sporozoite surface protein-2, LSA-1 from the liver, AMA-1, MSP-1 and serine repeat antigen 
from the merozoite, and the sexual stage Pfs25 antigen (Tine et al., 1996). This vaccine was 
safe and well tolerated in monkeys and humans (Ockenhouse et al., 1998; Tine et al., 1996). 
Clinical trial evaluation of NYVAC-Pf7 demonstrated that this vaccine was capable of 
completely protecting one individual from a challenge infection (Ockenhouse et al., 1998). A 
weak antibody, but strong cellular response was observed (Ockenhouse et al., 1998). The 
antibody response was enhanced in mice primed by immunization with Plasmodium 
antigen-encoding plasmid DNA, when followed by boosting with NYVAC-Pf7 (Sedegah et al., 
2004).  
1.9.4.2 Multi-antigen peptide vaccines 
Mouse antibodies raised against three P. falciparum multiple-antigen peptide (MAP) 
constructs were evaluated. MAP-1 consisted of epitopes from CSP. MAP-2 contained epitopes 
from CSP, LSA-1, MSP-142 and MSP-3b and MAP-3 contained epitopes from serine repeat 
antigen, MSP-142, and rhoptry-associated protein (RAP) -1 and RAP-2. Antibodies raised in 
mice against MAP-1 was able to prevent sporozoite invasion of liver cells in vitro, and 
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anti-MAP-2 and anti-MAP-3 antibodies inhibited parasite blood stage development in vitro 
(Mahajan et al., 2010). 
A multi-epitope malaria vaccine was designed to include B- and T-cell epitopes based on 
nine P. falciparum membrane and secretory proteins. The nine proteins are CSP, SEL-1 
protein, protein kinase, protein tyrosine phosphatase, the erythrocyte membrane protein-1 
ATS1 and ATS2 domains, VAR2CSA, StAR-related lipid transfer protein, and a conserved 
Plasmodium protein PFB0190. This multi-subunit vaccine has been modelled and underwent 
physicochemical characterisation, and is yet to be experimentally evaluated (Pandey et al., 
2018). 
1.9.4.3 SPf66 malaria vaccine 
The SPf66 vaccine is made up of synthetic immunogenic peptides from P. falciparum 
schizont and merozoite stages (Patarroyo et al., 1988). Polymers of the SPf66 molecule tested 
in mice and guinea pigs were found to be non-toxic, safe and immunogenic (López et al., 
1994). Mice and monkeys immunized with SPf66 encapsulated in poly-(d,l-lactide-co-glycolic) 
biodegradable microspheres developed robust and long-lasting immune responses (Rosas et 
al., 2002). Immunized monkeys developed high antibody titres, and were challenged with blood 
stage P. falciparum parasites. Of the seven monkeys, two were completely protected, one had 
delayed parasitaemia, and the remaining four developed patent parasitaemia (Rosas et al., 
2002).  
Initial clinical studies of SPf66 vaccination followed by P. falciparum blood stage challenge, 
showed recipients developing a slight parasitaemia, which was gradually resolved (Patarroyo 
et al., 1988). In a phase III clinical trial conducted in Venezuela and a follow-up study in 
Colombia, the SPf66 vaccine showed promise as a malaria vaccine candidate (Valero et al., 
1996; Noya et al., 1994). However, further clinical studies of the SPf66 vaccine in Gambia, 
Thailand and Tanzania failed to show protection in children (Acosta et al., 1999; Nosten et al., 
1996; D’Alessandro et al., 1995). 
1.10 PfC0760c as a potential malaria vaccine candidate 
PfC0760c is a conserved, uncharacterised protein found in all strains of P. falciparum. 
Homologous proteins are found in species of Plasmodium that infect humans, monkeys, mice 
and birds. The gene for the 405 kDa protein is located on chromosome 3 and is 10 185 bp 
coding for 3394 amino acids (http://plasmodb.org).  
PfC0760c from the 3D7 strain was amongst the P. falciparum proteins identified as a 
potential malaria vaccine candidate due to the exhibition of alpha-helical coiled-coil protein 
motifs, allowing it to fold easily within the parasite (Villard et al., 2007). This characteristic of 
the protein could allow for the in vivo production of antibodies, which can be implicated in 
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protection. This protein has been recognised by antibodies in infected human sera, however, 
it has not yet been determined if this protein is capable of protection against malaria challenge 
infection in mice, humans or other animals (Villard et al., 2007).  
1.11 Aims and objectives 
This study aimed to express and purify the region spanning N2360 – N2656 of the PfC0760c 
protein. The recombinant protein comprised of 297 amino acids including a 23mer conserved 
peptide. Partial characterisation of the protein was carried out by determining its interaction 
with human and mouse monocyte proteins. Bioinformatics analyses was used to predict the 
likelihood of certain characteristics of PfC0760c. The rPfC0760c297 protein was evaluated for 
antibody production in mice. To determine whether rPfC0760c297 could protect mice against a 
heterologous malaria challenge infection, mice were immunized with rPfC0760c297 followed by 
a P. berghei malaria challenge infection. 
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Chapter 2: Materials and methods 
This chapter describes the materials and methods used for expression and partial 
characterisation of rPfC0760c297 
2.1 Materials  
All reagents were purchased from Merck, Sigma or ThermoScientific with the following 
exceptions: methanol was purchased from RadChem (Gauteng, South Africa). Goat 
anti-mouse HRPO-IgG and rabbit anti-chicken HRPO-IgG were purchased from Jackson 
Immunochemicals (Pennsylvania, USA).  
2.2 Bacterial recombinant protein expression 
Expression of recombinant eukaryotic proteins is most often carried out in prokaryotic host 
cells. One of the most common expression systems includes the use of the Gram-negative 
bacterial host, Escherichia coli (E. coli) (Baneyx, 1999). The advantages of using this well-
studied organism include its ability to grow and replicate rapidly, using cheap substrates. The 
competent BL21(DE3) strain of E. coli is commonly used for recombinant protein expression 
as it is devoid of proteases (Rosano and Ceccarelli, 2014). 
2.2.1 E. coli growth curves in different media 
All procedures were performed under aseptic conditions. Fresh 15% (v/v) glycerol stocks of 
E. coli BL21(DE3) transformed either with pET32a (pET32a-rPfC0760c297) or pET28a 
(pET28a-rPfC0760c297) plasmids encoding the rPfC0760c297 protein were prepared and stored 
at -70°C. The glycerol stocks were streaked onto LB agar (1% (w/v) tryptone, 0.5% (w/v) yeast 
extract, 0.085 M NaCl, 0.011 M glucose, 1.5% (w/v) bacto-agar) containing the appropriate 
antibiotic. Ampicillin (50 µg/ml) was used for pET32a-rPfC0760c297 cells, and kanamycin 
(34 µg/ml) was used for pET28a-rPfC0760c297 cells. The agar plates were inverted and 
incubated overnight (37°C). A single colony was inoculated into 10 ml LB media (1% (w/v) 
tryptone, 0.5% (w/v) yeast extract, 0.085 M NaCl, 0.011 M glucose) containing the appropriate 
antibiotic with a sterile tip. The cells were grown for 3 h (37°C, 220 RPM), after which 
absorbance at 600 nm (OD600) was measured hourly for 3 h. The experiment was carried out 
in triplicate flasks. Growth curves were established in a similar manner for 2×YT media 
(1% (w/v) yeast extract, 1.6% (w/v) tryptone, 0.085 M NaCl) and terrific broth (1.2% (w/v) 
tryptone, 2.4% (w/v) yeast extract, 0.4% (v/v) glycerol, 0.017 M KH2PO4, 0.072 M K2HPO4).  
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2.2.2 Optimization of bacterial expression of recombinant rPfC0760c297 
2.2.2.1 Expression of rPfC0760c297 in LB or 2×YT media 
E. coli cells harbouring either the pET32a-rPfC0760c297 or the pET28a-rPfC0760c297  
plasmids were used. A single colony was picked off an agar plate and inoculated into 10 ml 
media containing the appropriate antibiotic and grown (37°C, 220 RPM, 16 h). The overnight 
culture was diluted to 1% (v/v) in 10 ml fresh media, and grown (37°C, 220 RPM) until the 
OD600 was between 0.500 and 0.600. The cells were then induced with 0.3 mM isopropyl β-D-
1-thiogalactopyranoside (IPTG) and grown (37°C, 220 RPM, 4 h). Cells were harvested using 
the Avanti J-26 XPI (Beckman Coulter, California, USA) (6000 g, 4°C, 5 min) with a C0850 
rotor and the supernatant was discarded. Cell pellets were resuspended in 1% of the original 
culture volume in phosphate buffered saline (PBS) (0.014 M NaCl, 0.003 M KCl, 0.0085 M 
NaH2PO4, 0.0015 M KH2PO4; pH 7.2). Cells were lysed by sonication (8W, 10 s). E. coli 
harbouring the pET32a-rPfC0760c297 plasmid was chosen for further experiments. For SDS-
PAGE analysis, identical volumes were taken from each sample. 
2.2.2.2 Expression of rPfC0760c297 in terrific broth 
A single colony from an agar plate was aseptically inoculated into 10 ml terrific broth and 
grown (37°C, 220 RPM, 16 h). The cells were harvested and prepared as described previously.  
2.2.2.3 Influence of different temperatures on the expression of rPfC0760c297 
A single colony was inoculated into 10 ml terrific broth and incubated at 25°C, 30°C or 37°C 
(220 RPM, 16 h). Bacterial cells were harvested and prepared as described previously. Each 
experiment was performed in triplicate.  
2.2.2.4 Influence of shaking speed on the expression of rPfC0760c297  
A single colony was inoculated into 10 ml terrific broth and incubated (37°C, 16 h), shaken 
at 200 RPM, 220 RPM or kept static. The experiment was performed in triplicate, and bacterial 
cells were harvested and prepared as described previously. 
2.2.2.5 Influence of time on the expression of rPfC0760c297 
A single colony was inoculated into terrific broth, and cultures were incubated (37°C, 
200 RPM) for either 12, 16 or 18 h. The experiment was performed in triplicate, and bacterial 
cells were harvested as described previously. 
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2.2.2.6 Effect of IPTG concentration in LB media on the expression of rPfC0760c297 
Cultures were grown in LB media as described in Section 2.2.2.1. IPTG concentrations of 
0.1 mM and 0.3 mM were compared in triplicate. 
2.2.3 Modification of expression conditions to yield soluble rPfC0760c297 
The conditions used for expression of high yields of rPfC0760c297 were modified for 
expression of soluble rPfC0760c297. E. coli transformed with pET32a-rPfC0760c297 was grown 
in terrific broth. In the first experiment, cultures were grown (37°C, 200 RPM) in triplicate, and 
the duration of expression was terminated after 2, 4, 6 and 8 h. In the second experiment, 
cultures were grown (200 RPM, 16 h) in triplicate at 20°C. In the third experiment, terrific broth 
was supplemented with 1%, 2% and 3% (v/v) ethanol and grown (37°C, 200 RPM, 16 h). 
Bacterial cells were harvested and prepared as previously described. 
In LB media, E. coli transformed with pET32a-rPfC0760c297 was grown (37°C, 200 RPM) 
and induced with 0.3 mM IPTG when the cells were in the stationary phase (OD600 above 
0.700). 
2.2.4 Solubilization of rPfC0760c297 
A single colony was inoculated into 50 ml terrific broth and grown under optimized conditions 
(37°C, 200 RPM, 16 h), and cells were harvested (6000 g, 4°C, 20 min). Proteins were 
solubilized as described (Schlager et al., 2012) with modifications. Briefly, the bacterial pellet 
was resuspended in 2 ml Triton-PBS (1% (v/v) Triton X-100 in PBS), and sonicated at 8 W for 
10 s to resuspend. The suspension was frozen (-20°C, 16 h or -70°C, 1 h) then thawed at room 
temperature (RT), followed by centrifugation (9000 g, 4°C, 20 min). The supernatant was 
removed, and the pellet was resuspended in 5 ml lysis buffer (8 mM Na2HPO4, 286 mM NaCl, 
1.4 mM KH2PO4, 2.6 mM KCl, 1% (w/v) SDS; pH 7.4) supplemented with 1 mM dithiothreitol. 
The solution was sonicated at 8 W twice for 2 min on ice, with a 1 min interval. The lysate was 
then incubated on ice for a minimum of 30 min to facilitate precipitation of SDS, after which it 
was centrifuged (10 528 g (maximum speed of C0850 rotor), 4°C, 35 min). The supernatant 
containing the solubilized material was ultracentrifuged (99398 g, 4°C, 30 min) or filtered 
through a 0.45 µm filter. Samples taken at various points during the solubilization were 
prepared for SDS-PAGE.  
2.2.5 Purification of rPfC0760c297 
A 1 ml bed volume of His60 Ni Superflow Resin was transferred to a plastic column. The 
resin was equilibrated with 10 ml wash buffer (8 mM Na2HPO4, 1.4 mM KH2PO4, 2.6 mM KCl, 
0.1% (w/v) N-lauroyl sarcosine; pH 7.4). The solubilized material was applied to the resin and 
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equilibrated on an end-over-end rotor (1 h, RT). The unbound fraction was collected, and the 
resin was washed extensively with wash buffer containing 20 mM imidazole until the 
absorbance at 280 nm was ≤0.02. Bound protein was eluted (8 mM Na2HPO4, 286 mM NaCl, 
1.4 mM KH2PO4, 2.6 mM KCl, 0.1% (w/v) N-lauroyl sarcosine, 500 mM imidazole; pH 7.4) with 
a linear gradient of imidazole ranging from 20 – 270 mM in 500 µl fractions. The absorbance 
of all the eluted samples was measured at 280 nm and an elution profile was generated. A 
concentration of 150 mM imidazole was chosen for further purifications. The Bradford assay 
(Section 2.7) was used to determine the concentration of the final pooled purified product 
(Bradford, 1976). 
2.2.6 Regeneration of nickel chelate affinity matrix 
Following purification, the resin was washed with 2 bed-volumes of MES buffer (0.02 M 
2-(N-morpholino)ethanesulfonic acid; pH 5.0) on an end-over-end rotor for 20 min. This was 
followed by washing with 20 bed-volumes of distilled water (dH2O), then the resin was stored 
in storage buffer (20% (v/v) ethanol, 0.01% (w/v) NaN3) at 4°C.  
Complete regeneration of the nickel affinity matrix was carried out as per manufacturer’s 
instructions. Briefly, the nickel was stripped with 10 bed-volumes of EDTA (0.2 M EDTA; 
pH 7.0), then washed with 10 bed-volumes double-dH2O. The resin was charged with 2 
bed-volumes of nickel sulfate (0.1 M NiSO4•7H2O). The column was washed with 7 
bed-volumes of double-dH2O, followed by 3 bed-volumes of NaCl (0.3 M NaCl), then washed 
once more with 10 bed-volumes of double-dH2O. The column was used immediately or 
maintained in storage buffer at 4°C until further use. 
2.3 Co-expression of rPfC0760c297 with chaperones 
2.3.1 Generation of competent E. coli BL21(DE3) cells 
All procedures were performed aseptically. Generation of competent cells was performed 
as described (Sambrook et al., 1989). Briefly, untransformed E. coli BL21(DE3) cells from a 
glycerol stock were three-way streaked onto LB agar without antibiotic and incubated 
overnight. A single colony was inoculated into 100 ml LB media without antibiotic and 
incubated (37°C, 200 RPM) until the cells were in the exponential phase. The culture was 
aseptically transferred to falcon tubes and cooled on ice for 10 min. Cells were harvested 
(4000 g, 10 min, 4°C) and the media discarded. The bacterial cell pellets were resuspended in 
20 ml ice-cold CaCl2 (0.1 M CaCl2, filter sterilised with 0.2 µm filter), and incubated on ice for 
20 min. This was centrifuged as before, and the supernatant removed. The competent cell 
pellet was resuspended in 4 ml CaCl2, which was used immediately. The remaining cells were 
stored at -70°C as 15% (v/v) glycerol stocks.  
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For generation of competent E. coli cells containing pET32a-rPfC0760c297, ampicillin was 
added to the LB agar and media, and the procedure was performed as described above. 
2.3.2 Transformation of competent E. coli BL21(DE3) cells with chaperone plasmids 
The chaperone plasmids used were pGro7, pKJE7 and pG-KJE8. Co-transformation was 
performed as described (Sambrook et al., 1989). Briefly, a 200 µl aliquot of competent cells 
was transferred to a cold 1.5 ml tube, and 50 ng (10 µl) of chaperone plasmid DNA was added 
and swirled gently. The preparation was incubated on ice for 30 min, then heat-shocked (42°C, 
90 s). The cells were chilled on ice for 2 min, and rescued with the addition of 800 µl SOC 
media (0.5% (w/v) yeast extract, 2% (w/v) tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 
20 mM MgSO4, 20 mM glucose). This was incubated (37°C, 45 min), and 200 µl of the 
preparation was plated onto SOB agar (0.5% (w/v) yeast extract, 2% (w/v) tryptone, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM MgSO4, 1.5% (w/v) agar) containing 20 µg/ml 
chloramphenicol. Plates were inverted and incubated overnight at 37°C. Single colonies on the 
plates indicated successful transformation. Glycerol stocks were prepared by picking single 
colonies and growing them as overnight cultures in LB media containing chloramphenicol. A 
700 µl aliquot of the overnight culture was combined with 300 µl of 50% (v/v) glycerol and 
stored at -70°C.  
For co-transformation of E. coli cells containing pET32a-rPfC0760c297 with a chaperone 
plasmid, the procedure was carried out as described. Ampicillin was included in the SOB agar, 
and glycerol stocks were prepared in media containing both chloramphenicol and ampicillin. 
2.3.3 Isolation of chaperone plasmid DNA from E. coli cells 
All procedures were performed under aseptic conditions. Glycerol stocks of E. coli cells 
harbouring the pGro7, pKJE7 or pG-KJE8 plasmids were streaked onto LB agar-
chloramphenicol plates and incubated overnight (37°C). A single colony was inoculated into 
2 ml LB media containing chloramphenicol, and grown overnight (37°C, 200 RPM). A 1.5 ml 
aliquot of the culture was transferred to a 2 ml tube and centrifuged (12 000 g, 30 s, 4°C). The 
media was removed, and the pellet resuspended in 100 µl cold glucose-Tris-EDTA buffer (50 
mM glucose, 25 mM Tris-HCl, 10 mM EDTA; pH 8), then incubated on ice for 30 min. 200 µl 
lysis buffer (0.2 M NaOH, 1% (w/v) SDS) was added and the tube was inverted 5 times to mix. 
This was incubated on ice for 5 min, then 150 µl cold potassium acetate (3 M potassium, 5 M 
acetate) solution was added. The solution was vortexed briefly, and incubated on ice for 5 min, 
followed by centrifugation (12 000 g, 5 min, 4°C). The supernatant was transferred to a fresh 
sterile 2 ml tube, and 100 % ethanol was added at twice the supernatant volume. This was 
allowed to stand at RT for 2 min, then centrifuged (12 000 g, 5 min, 4°C). The supernatant was 
removed, and the pellet was rinsed with 1 ml cold 70% (v/v) ethanol, and centrifuged (12 000 
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g, 5 min, 4°C). The supernatant was aspirated, and the purified DNA pellet was resuspended 
in 50 µl Tris-EDTA (10 mM Tris-HCl, 1 mM EDTA), and 20 µg/ml RNAse was added. 
2.3.4 Co-expression of rPfC0760c297 with E. coli chaperones 
Glycerol stocks of the co-transformed cells were streaked onto LB agar containing 
chloramphenicol and ampicillin, then incubated at 37°C overnight. A single colony was 
inoculated into LB media containing chloramphenicol and ampicillin, and cultures were 
incubated overnight (37°C, 200 RPM). The overnight culture was diluted to 1% (v/v) into fresh 
media containing the antibiotics and supplemented with 1 mg/ml L-arabinose for induction of 
chaperone plasmid expression. Where the pG-KJE8 plasmid was used, 1 mg/ml tetracycline 
was also added. Cultures were grown (37°C, 200 RPM) until they reached the exponential 
phase. Induction of rPfC0760c297 expression was initiated by the addition of IPTG (0.3 mM) for 
4 h. Cells were harvested and prepared for SDS-PAGE analysis as described in Section 2.4.1. 
2.3.5 Modification of co-expression conditions   
The temperature and shaking speed were kept constant (37°C, 200 RPM). Media 
supplemented with L-arabinose (1 mg/ml) was evaluated, and tetracycline (1 mg/ml) was 
included where the pG-KJE8 plasmid was used.  
The effect of the duration of co-expression in terrific broth was evaluated with the pKJE7 
plasmid, as outlined in Section 2.2.3.  
Induction of rPfC0760c297 expression with different concentrations of IPTG was tested. In 
LB media, overnight cultures were prepared and diluted to 1% (v/v) in fresh LB media 
supplemented with L-arabinose. Induction with IPTG was always for 4 h. The following 
concentrations of IPTG were tested: 0, 0.05 mM, 0.1 mM, 0.2 mM and 0.3 mM.  
In a separate experiment, the following concentrations of L-arabinose were tested: 0 mM, 
0.25 mM, 0.5 mM, 0.75 mM and 1 mg/ml in LB media. Cultures were induced with IPTG 
(0.3 mM).  
2.4 Electrophoretic techniques 
2.4.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a biochemical 
technique developed by Laemmli (1970), that is used to separate proteins by size and assess 
protein purity.  
The reagents used were as follows: monomer solution (30% (w/v) acrylamide, 0.8% (w/v) 
bisacrylamide), running gel buffer (1.5 M Tris-HCl; pH 8.8), SDS stock solution (10% (w/v) 
SDS), initiator stock (10% (w/v) ammonium persulfate), stacking gel buffer (0.5 M Tris-HCl; 
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pH 6.8), and tank buffer (0.25 M Tris-HCl, 0.192 M glycine, 0.1% (w/v) SDS; pH 8.3). The 
monomer solution, running and stacking gel buffers were filtered through Whatman No.1 filter 
paper. All reagents except the SDS stock solution were stored at 4°C. The monomer solution 
and initiator were stored in amber bottles. The tank buffer was always freshly prepared. 
For SDS-PAGE analysis, samples were combined 1:1 with treatment buffer (0.125 M 
Tris-HCl, 4% (w/v) SDS, 20% (w/v) glycerol, 10% (v/v) β-mercaptoethanol, bromophenol blue 
tracker dye; pH 6.8). From the E. coli culture experiments described in Sections 2.2.2 and 
2.2.3, identical volumes from each culture were analysed. The treatment buffer was stored 
without β-mercaptoethanol, (which was also omitted for non-reducing SDS-PAGE gels). 
Samples were boiled (95°C, 5 min) prior to analysis. A reduced, unstained molecular weight 
marker (Catalog number 26610, ThermoScientific, Gauteng, South Africa) containing proteins 
of known molecular weight was run alongside samples. 
The running gel was prepared according to Table 2.1, and the gels were cast in a BioRad™ 
Mini-PROTEAN® Tetra vertical electrophoresis gel casting system. Gels were overlaid with 
dH2O and allowed to polymerise. The dH2O was removed, and the stacking gel was pipetted 
on top of the polymerised running gel, and a comb was inserted to form the wells. The gels 
were assembled onto the gasket and immersed in the SDS-PAGE tank containing tank buffer. 
5 – 10 µl of prepared SDS-PAGE samples were loaded onto SDS-PAGE gels. 
A current of 20 mA per gel was applied until the tracker dye migrated to the bottom of the 
gel. The gels were stained overnight with Coomassie Brilliant Blue R250 staining solution 
(1.25% (w/v) Coomassie Brilliant Blue R250, 50% (v/v) methanol, 10% (v/v) acetic acid). Gels 
were rinsed with dh2O, then destained (50% (v/v) methanol, 10% (v/v) acetic acid) until protein 
bands were clearly visible. The gels were placed into dH2O until they reverted to their original 
size, then photographed.  
Table 2.1: Components used in SDS-PAGE gels. 
Reagent 12.5% running gel 4% stacking gel 
Monomer solution 6.25 ml 940 µl 
Running gel buffer 3.75 ml - 
Stacking gel buffer - 1.75 ml 
dH2O 4.75 ml 4.3 ml 
SDS stock solution 150 µl 70 µl 
TEMED 7.5 µl 15 µl 
Initiator 150 µl 70 µl 
2.4.2 Western blotting 
An effective, sensitive and accurate method to determine the presence of a protein in a gel, 
is to transfer the proteins from the gel onto a nitrocellulose membrane and probe the blot with 
antigen-specific antibodies (Towbin et al., 1979).  
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Following SDS-PAGE, gels, nitrocellulose membranes (6 × 8 cm) and blotting paper 
(8 × 10 cm) were equilibrated in western blotting buffer (0.05 M Tris, 0.192 M glycine, 
20% (v/v) methanol, 0.01% (v/v) SDS) for 5 min. Following equilibration, the components were 
assembled into the western blot apparatus. The tank was filled with western blotting buffer, 
and a current of 40 mA was applied for 16 h. After protein transfer, nitrocellulose was stained 
with Ponceau S (0.1% (w/v) Ponceau S in methanol), and the molecular weight markers were 
marked in pencil. The western blot was destained by rinsing with dH2O and a few drops of 
concentrated NaOH. The blot was blocked with 5% (w/v) milk powder in Tris-buffered saline 
(TBS) (0.02 M Tris, 0.2 M NaCl; pH 7.4) (2 h, RT or overnight, 4°C). Blots were washed with 
TBS (3 × 5 min), and incubated with primary antibody (2 h, RT or overnight, 4°C). Blots were 
washed as before, then incubated with secondary antibody (1 h, RT), then washed as before. 
The substrate was prepared by combining 2 ml of a 4-chloro-1-naphthol stock solution 
(0.017 M 4-chloro-1-naphthol in methanol, stored at -20°C) with 8 ml TBS and 4 µl H2O2 to 
yield the substrate (0.0034 M 4-chloro-1-naphthol, 3.92 mM H2O2). The substrate was 
prepared fresh each time before use. The blot was incubated with the substrate in the dark 
until a coloured precipitate developed. 
Antibodies were prepared in 0.5% (w/v) BSA in TBS. The chicken anti-rPfC0760c297 IgY 
(affinity purified in-house; Addicott, 2014) was used at a concentration of 1 µg/ml. Mouse anti-
hexahistidine tagged (his6tag) IgG and goat anti-mouse HRPO-IgG were prepared 1:6000. The 
rabbit anti-chicken HRPO-IgG was prepared at 1:15 000. 
To test for endogenous peroxidase activity, proteins were electrophoretically transferred or 
dotted onto nitrocellulose. The blots were blocked with 5% (w/v) milk powder-TBS (2 h, RT). 
The enhanced chemiluminescence (ECL) substrate (Section 2.4.3) was applied to the western 
blot, and the 4-chloro-1-naphthol substrate was applied to the dot blot. 
2.4.3 Far western blotting 
The far western blot is performed identically to a western blot, apart from an additional 
incubation step, and some amendments (Wu et al., 2007). Monocyte proteins were analysed 
by non-reducing SDS-PAGE and western blot.  
A total of 5 µg of control proteins was loaded. Following SDS-PAGE and transfer to 
nitrocellulose, blots were blocked (8% (w/v) milk powder TBS, 0.1% Tween-20) (2 h, RT or 
overnight, 4°C). Blots were probed with 100 µg rPfC0760c297 (2 h, RT or overnight, 4°C). 
Protein-protein interactions were detected with mouse anti-his6tag IgG (2 h, RT or overnight, 
4°C) and goat anti-mouse HRPO-IgG (1 h, RT). Blots were washed between incubations (3 × 
8 min) with TBS-T (TBS, 0.1% (v/v) Tween). Both antibodies and rPfC0760c297 were prepared 
in 0.5% (w/v) BSA-TBS-T. The ECL substrate was used for increased sensitivity. Stocks of p-
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iodophenol (0.1 M p-iodophenol in DMSO) and luminol (40 mg/ml luminol in DMSO) were 
prepared and stored at -20°C. The ECL reagent (0.5 mM p-iodophenol, 1.13 mM luminol, 
24.5 mM H2O2) was prepared in Tris-HCl (0.1 M Tris-HCl; pH 8.5). A 500 µl aliquot of the 
substrate was pipetted onto the blot directly before image capture. The far dot or western blot 
schematic is depicted in Figure 2.1. Following incubation of the prey proteins on the blot with 
rPfC0760c297, anti-his6tag antibodies detect the his6tagged-rPfC0760c297 protein bound to 
proteins on the blot. Positive and negative controls are included to ensure that the results are 
not non-specific in nature. 
 
Figure 2.1: Schematic representation of far dot blot or far western blot probed with rPfC0760c297. 
Prey protein is dotted or transferred onto nitrocellulose. After blocking with milk-TBS, blots are probed 
with the bait protein, his6tagged-rPfC0760c297. Mouse anti-his6tag IgG and goat anti-mouse HRPO-IgG 
are used for detection. The blots are then developed with the substrate. 
2.5 Far dot blot 
Dot blots allow for the detection of an antigen within a sample using antigen-specific 
antibodies. The far dot blot is performed similarly to that of a far western blot, however, proteins 
are not transferred electrophoretically, but rather, are dotted directly onto a nitrocellulose 
membrane.  
Amounts of 1 µg, 10 µg and 50 µg chicken anti-rabbit albumin IgY and chicken anti-
rPfC0760c297 IgY were dotted onto nitrocellulose and airdried. A volume of 0.5 µl was used. 
Blots were probed with 5 µg rPfC0760c297 (1 h, RT), followed by incubation with mouse anti-
his6tag IgG (1:6000) (2 h, RT) and goat anti-mouse HRPO-IgG (1:6000) (1 h, RT). The 
rPfC0760c297 protein and antibodies were prepared in 0.5% (w/v) BSA-TBS. The 
4-chloro-1-naphthol substrate was applied. 
For the detection of peroxidase activity, a maximum volume of 0.5 µl monocyte lysates and 
1 µg control proteins were dotted onto a nitrocellulose membrane and airdried. Blots were 
blocked (5% (w/v) milk powder in TBS) (2 h, RT), then the 4-chloro-1-naphthol substrate was 
applied. 
Protein 
anti -Histag-IgG
His6tagged rPfC0760c297
anti-mouse-IgG HRPO
BSA
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2.6 Cell culture techniques 
Tissue culture of mammalian cells is a useful research tool allowing for the cultivation of 
cells derived from humans or animals. These cells can be used for various in vitro studies 
aimed at determining cell-interactions with other materials, such as drugs, proteins, cytokines 
or chemokines. 
2.6.1 Culture of human U937 and mouse J774A.1 cells 
Cell culture of malaria-naïve monocytes was performed as recommended by the European 
Collection of Authenticated Cell Cultures under aseptic conditions. Briefly, human U937 
monocytes were cultured in RPMI 1640 media (90% (v/v) RPMI, 10% (v/v) FBS, 1% (v/v) 
PenStrep) and mouse J774A.1 monocytes were cultured in DMEM (90% (v/v) DMEM, 
10% (v/v) FBS, 1% (v/v) PenStrep), stored at 4°C. PenStrep (Catalog number P4333, Sigma-
Aldrich, Gauteng, South Africa) constituted 10 000 U penicillin and 10 mg/ml streptomycin 
before dilution. 4 ml pre-warmed media (37°C) was transferred to a 25 cm3 culture flask and 
equilibrated (37°C, 5 % CO2). Stock cultures preserved in liquid nitrogen containing 1 ml 
monocytes was thawed (37°C). Thawed monocytes were gently pipetted into the respective 
pre-warmed media. The flasks were incubated (37°C, 5 % CO2) until they reached confluency. 
2.6.2 Monocyte subculture 
Confluent cells were harvested (1000 g, 5 min) and the spent media was removed. The 
cells were resuspended in 3 ml of the appropriate media. In three 25 cm3 flasks, 1 ml of the 
cell suspension was added to each flask containing 4 ml of fresh, equilibrated media and 
incubated (37°C, 5% CO2). Once the cells reached confluency, one of the three flasks were 
sub-cultured as outlined. The cells from the remaining two flasks were harvested (1000 g, 
5 min). These cells were washed twice with 5 ml cold PBS (1000 g, 5 min). The cell pellets 
were resuspended in 100 µl cold PBS and kept on ice. The Halt™ Protease Inhibitor Cocktail 
(100×) (ThermoFisher, Gauteng, South Africa) was added to each cell suspension, and cells 
were lysed by sonication (3 W, 10 s). Cells were stored at -20°C until further use. 
2.6.3 Trypan blue assay 
The trypan blue assay was used to assess cell viability (Strober, 2001). A volume of 50 µl 
of cells was combined with 50 µl of the trypan blue dye (0.4% (w/v) trypan blue in PBS), and 
equilibrated for 1 min. Cell viability was assessed microscopically using a haemocytometer. 
Viable cells remain unstained, and non-viable cells were stained dark blue. 
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2.7 The Bradford assay 
The Bradford assay was used to determine the concentration of protein samples (Bradford, 
1976). A protein standard curve was prepared using BSA at concentrations ranging from 
0 – 100 µg in triplicate. These were made up to 100 µl, followed by addition of 900 µl of the 
Bradford reagent. Solutions equilibrated for 2 min, and the absorbance was measured at 
595 nm.  
To measure the concentration of a protein sample, 900 µl of the Bradford reagent was 
combined with 95 µl dH2O and 5 µl of the protein sample. Samples were equilibrated and 
measured as above. The protein concentration was estimated using the standard curve. 
2.8 Immunization of mice 
Mouse models provide an important tool to allow for the study of human diseases (Perlman, 
2016), that may provide valuable insight into the pathology and progression of human 
diseases. P. berghei, P. chabaudi and P. yoelii are species that specifically infect mice, and 
are used to mimic different aspects of human Plasmodial infections (Huang et al., 2015; Wykes 
and Good, 2009). 
2.8.1 Mice used in this study  
Female BALB/c mice (8 – 10 weeks) were housed at the UKZN Animal House Unit under 
recommended conditions. Food, water and enrichment were provided ad libitum. Once a week, 
mice were given sunflower seeds and apple slices. Immunized and control mice were housed 
in separate labelled cages, and mouse tails were labelled with permanent marker. Ethical 
approval was obtained from the University of KwaZulu-Natal Animal Ethics Committee 
(004/15/animal). 
2.8.2 Generation of anti-rPfC0760c297 antibodies in mice 
An experimental group of 5 mice were immunized with 100 µg rPfC0760c297, and the control 
group consisting of 2 mice received the elution buffer (Section 2.2.5). Antigen was emulsified 
in Freund’s Complete Adjuvant for primary immunization, and Freund’s Incomplete Adjuvant 
for subsequent immunizations, and triturated. Mice were immunized intraperitoneally with a 
26G needle with a final volume of 100 µl on days 0, 14 and 28. On day 42, mice were 
anaesthetized with isoflurane and sacrificed by cervical dislocation. Blood was harvested by 
cardiac puncture and collected in EDTA-coated or heparinised vacutainers. The blood was 
transferred to a sterile 2 ml tube and allowed to separate overnight at 4⁰C. Serum was collected 
in a sterile 2 ml tube for further analysis.  
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2.8.3 Enzyme-linked immunosorbent assay  
ELISA is sensitive immunochemical technique that is used for the detection and 
quantification of an antigen using antigen-specific antibodies. 
A Nunc Maxisorp ELISA plate was coated overnight at 4°C with 1 µg/ml rPfC0760c297 (100 
µl). Plates were washed 3 times with PBS-T (0.1% (v/v) Tween-20 in PBS), then inverted and 
tapped to remove excess buffer. Plates were blocked with 200 µl 5% (w/v) powdered 
milk-PBS-T (2 h, 37°C), then washed as before. The antibodies were diluted in 0.5% (w/v) 
BSA-PBS-T. Mouse serum was diluted 10-3 – 10-7 (100 µl) and incubated (2 h, 37°C). The 
serum from a non-immune mouse was included. Plates were washed as before. The goat 
anti-mouse HRPO-IgG antibody was prepared (1:6000 in 0.5% (w/v) BSA-PBS-T) and 100 µl 
was incubated (1 h, 37°C). The ABTS substrate (0.97 mM ABTS, 4.9 mM H2O2) was prepared 
in citrate-phosphate buffer (0.15 M citrate-phosphate; pH 5.0). The substrate was added 
(150 µl) and plates were incubated in the dark (1 h, RT) before the absorbance was measured 
at 405 nm. 
2.8.4 Immunization of mice with rPfC0760c297 and challenge with P. berghei parasites 
In the challenge model, female BALB/c mice (6 – 8 weeks old) were immunized on the same 
schedule as outlined (Section 2.8.1), and challenged with 105 P. berghei ANKA infected red 
blood cells on day 40. Parasitaemia was monitored every second day by collecting blood via 
tail-prick and smeared onto a glass slide. After challenge, mice were anaesthetized and 
sacrificed as before when the parasitaemia was higher than 15%. All rPfC0760c297-immunized 
mice were sacrificed on the same day. 
2.8.5 Giemsa staining of P. berghei infected blood samples 
Glass slides with blood smears were fixed with 100% methanol for 30 s and allowed to 
airdry, then stained with Giemsa (10% (v/v) Giemsa stain in PBS). Slides were viewed with a 
Zeiss microscope under oil immersion at 1000× magnification. A total of 500 blood cells were 
counted, and the percentage parasitaemia calculated. 
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Chapter 3: Recombinant expression, solubilization and purification of 
rPfC0760c297 
3.1 Introduction 
3.1.1 E. coli as a bacterial host for recombinant protein expression 
Bacteria are advantageous hosts used for recombinant protein expression. The benefits of 
using Escherichia coli for bacterial recombinant expression include rapid growth in inexpensive 
media, and high yield of recombinant protein (Larentis et al., 2014; Baneyx, 1999). Optimizing 
conditions that improve cell mass generally leads to a greater yield of target protein (Kilikian 
et al., 2000). The BL21 (DE3) strain of E. coli is a commonly used host, as it lacks functional 
Lon and OmpT proteases. These proteases are responsible for cleaving foreign proteins 
including recombinant proteins (Ahmad et al., 2018; Rosano and Ceccarelli, 2014).  
Media used for cultivation of bacteria, such as E. coli used in expression systems primarily 
comprise tryptone, yeast extract and NaCl. Yeast extract is a source of vitamins and minerals, 
and tryptone provides nitrogen (Lessard, 2013). Luria Bertani (LB) media includes glucose, 
whereas 2× yeast-tryptone (2×YT) media and terrific broth do not. Terrific broth contains 
glycerol. Metabolism of glycerol produces acidic products which help to delay an increase in 
pH, and the potassium phosphate salts buffer the media (Kram and Finkel, 2015). Depletion 
of carbohydrates during bacterial cultivation causes the cells to metabolise amino acids, which 
releases ammonia into the culture medium, leading to an increase in pH (McFall and Newman, 
1996).  
Terrific broth is an autoinduction media, which does not require the addition of IPTG to 
initiate recombinant protein expression. Cells grown in autoinduction media preferentially 
metabolise glucose during proliferation. Glucose depletion results in the cells switching to 
glycerol and lactose metabolism. Metabolism of lactose initiates recombinant protein 
expression of lac-controlled proteins (Rosano and Ceccarelli, 2014). 
3.1.2 pET expression vectors 
The pET expression vectors use the inducible bacteriophage T7 promoter, which when 
induced, activates host T7 RNA polymerase (Studier, 2005; Rosenberg et al., 1987). 
Endonucleases are used to insert the complementary DNA of the target gene, which is cloned 
into the multiple cloning site region downstream of the T7 promoter. An antibiotic resistance 
marker is incorporated into the vector to select for transformed cells (Lodish et al., 2000; 
Baneyx, 1999). Recombinant protein expression is induced by binding of lactose or its 
analogue, isopropyl β-D-1-thiogalactopyranoside (IPTG) to the lac promoter (Ahmad et al., 
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2018). Often with the use of expression vectors, recombinant proteins are expressed with 
fusion tags. 
His6tagged fusion proteins can easily be affinity purified from E. coli lysates by passing 
soluble material over an immobilised metal ion affinity chromatography matrix (Baneyx, 1999). 
The column is comprised of nickel or cobalt attached to nitrilotriacetic acid (NTA) or 
carboxylmethylaspartate respectively, which is coupled to a support resin (Rosano and 
Ceccarelli, 2014; Bornhorst and Falke, 2000). The imidazole-ring on the histidine molecule 
forms coordination bonds with the metal ions (Bornhorst and Falke, 2000). The contaminating 
E. coli proteins remain unbound. Bound protein is eluted using imidazole, or changes in the 
ionic strength or pH of the elution buffer.  
3.1.3 Expression of rPfC0760c297 
A region spanning the amino acids N2360 – N2656 from the N-terminus of the PfC0760c 
protein (denoted further as rPfC0760c297) was previously cloned into pET32a and pET28a 
expression vectors and transformed into E. coli BL21 (DE3) host cells. The predicted size of 
untagged rPfC0760c297 is 36 kDa (Gasteiger et al., 2005). The expected size of rPfC0760c297 
from pET32a is 56 kDa, and pET28a is 42 kDa. The larger sizes are attributed to the presence 
of a his6tag, S-tag and thioredoxin on pET32a, and a his6tag and T7 tag on pET28a. The T7 
tag is used to enhance recombinant protein expression, and the his6tag and S-tags are used 
for detection of the fusion protein (Bornhorst and Falke, 2000; Raines et al., 2000; Olins, et al., 
1988). The thioredoxin tag contributes to protein solubility (LaVallie et al., 1993).  
In this chapter, growth profiles for transformed E. coli were established in different media. 
The conditions for high levels of rPfC0760c297 expression were optimized. Adjustment of 
expression conditions was evaluated for the expression of soluble rPfC0760c297.  
3.2 Results 
3.2.1 Growth profiles of transformed E. coli cells in different media 
E. coli BL21(DE3) cells containing either pET32a-rPfC0760c297 or pET28a-rPfC0760c297 
were grown in LB or 2×YT and were not induced, or grown in terrific broth. The absence of 
turbidity after the first 2 h post-inoculation indicated minimal growth and likely constituted the 
lag phase. After 3 h post-inoculation, the OD600 was measured hourly. The results shown are 
the mean absorbance of triplicate cultures, and the standard deviation for each triplicate set is 
indicated.  
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Figure 3.1: Growth profiles of E. coli BL21(DE3) transformed with pET32a-rPfC0760c297 or 
pET28a-rPfC0760c297 in three types of media. The absorbance of triplicate cultures was measured at 
600 nm hourly from 3 – 6 h. The mean absorbance and standard deviations are indicated for cultures 
grown in (A) LB media, (B) 2×YT media and (C) terrific broth.  
Measurable growth begins after approximately 3 h, which increases as the exponential 
phase begins. The stationary phase is reached when the cell growth slows down. There 
appears to be more bacteria present at 3 h in the LB cultures (Figure 3.1A) than in cultures 
grown in 2×YT and terrific broth (Figure 3.1B and C). This is likely due to the number of cells 
used to inoculate the media. Individual colonies were picked to inoculate cultures, which 
contributed to the observed variations in the standard deviations.  
3.2.2 Evaluation of different culture conditions for rPfC0760c297 expression 
The conditions for the expression of high quantities of rPfC0760c297 were explored. The 
temperature and shaking speed were kept constant for all three types of media tested. Where 
LB and 2×YT media were used, the concentration of IPTG and the duration of induction was 
kept constant. 
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Figure 3.2: E. coli BL21(DE3) cells transformed with pET32a-rPfC0760c297 or pET28a-
rPfC0760c297 grown in different media. Bacterial lysates were resolved on 12.5% reducing 
SDS-PAGE and proteins were stained with Coomassie Blue. Lane 1: molecular weight marker. 
Uninduced and induced lysates were from cultures grown in LB (lanes 3 – 6) and 2×YT (lanes 8 – 11) 
media. Lanes 3 and 4, 8 and 9: pET32a-rPfC0760c297. Lanes 5 and 6, 10 and 11: pET28a-rPfC0760c297. 
Lanes 13 and 14: pET32a-rPfC0760c297 and pET28a-rPfC0760c297 respectively in terrific broth. 
The size of rPfC0760c297 expressed from pET32a and pET28a was approximately 56 kDa 
and 42 kDa respectively. The protein expression profiles of uninduced and induced E. coli is 
illustrated (Figure 3.2). The rPfC0760c297 is absent in uninduced E. coli grown in LB media 
(lanes 3 and 5) and 2×YT media (lanes 8 and 10). A 56 kDa band is present in IPTG-induced 
E. coli cells containing pET32a-rPfC0760c297 grown in LB and 2×YT media (lanes 4 and 9). 
There is a large amount of the 56 kDa rPfC0760c297 protein produced in terrific broth with the 
pET32a plasmid (lane 13). A thin band of 42 kDa is present in induced E. coli cells containing 
pET28a-rPfC0760c297, irrespective of the media used (lanes 6, 11 and 14). The 42 kDa 
rPfC0760c297 expressed with pET28a is not clearly visible (lane 14). A prominent band at 
approximately 30 kDa is present in all induced E. coli containing pET32a (lanes 4, 9 and 13) 
which is absent in uninduced cultures. A lower protein band intensity is noted in IPTG-induced 
E. coli in proteins ranging in size from 14 kDa to >116 kDa in cultures (lanes 4, 6, 9 and 11) 
compared to uninduced cultures (lanes 3, 5, 8 and 10). E. coli cells transformed with pET32a-
rPfC0760c297 grown in terrific broth were chosen for further evaluation. 
  
1 2 3 4 76 85 9 1110 12 13 14
kDa
116
66
45
35
14
56 kDa
42 kDa
37 
 
Figure 3.3: Expression of rPfC0760c297 in terrific broth at three temperatures. Bacterial lysates 
were resolved on 12.5% reducing SDS-PAGE, and proteins were stained with Coomassie Blue. Lane 
1: molecular weight marker. Cultures were grown in triplicate at the following temperatures: Lanes 2 – 
4: 25°C. Lanes 5 – 7: 30°C. Lanes 8 – 10: 37°C.  
Three different temperatures, 25°C, 30°C and 37°C were tested for host cell growth and 
protein expression. The 56 kDa rPfC0760c297 band is prominent in cultures grown at all three 
temperatures (Figure 3.3, lanes 2 – 10). At 25°C, there is less rPfC0760c297 that is expressed 
(lanes 2 – 4) compared to cultures incubated at 30°C (lanes 5 – 7) and 37°C (lanes 8 – 10). 
The amount of rPfC0760c297 expressed at 30°C and 37°C are similar. 
As 37°C had previously been used to express the protein (Addicott, 2014), this temperature 
was used in subsequent experiments.  
 
 
 
 
 
 
 
Figure 3.4: Expression of rPfC0760c297 in terrific broth at different shaking speeds. Bacterial 
lysates were resolved on 12.5% reducing SDS-PAGE, and proteins were stained with Coomassie Blue. 
Lane 1: molecular weight marker. Lanes 2 – 4: static cultures. Lanes 5 – 7: 200 RPM. Lanes 8 – 10: 
220 RPM.  
The shaking speeds at 200 and 220 RPM were compared to static cultures. The 
rPfC0760c297 protein is expressed at all the shaking speeds tested (Figure 3.4, lanes 2 – 10). 
Poor cell growth and hence poor expression of rPfC0760c297 is observed in static cultures 
(lanes 2 – 4). Higher concentrations of rPfC0760c297 and E. coli proteins are observed in 
cultures shaken at 200 RPM (lanes 5 – 7) compared to cultures shaken at 220 RPM (lanes 8 
– 10). Thus, 200 RPM was used in further experiments.  
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Figure 3.5: Expression of rPfC0760c297 for different time periods. Bacterial lysates were resolved 
on 12.5% reducing SDS-PAGE, and proteins were stained with Coomassie Blue. Lane 1: molecular 
weight marker. Lysates were analysed from triplicate cultures incubated for: lanes 2 – 4: 12 h; lanes 
5 – 7: 16 h; and lanes 8 – 10: 18 h.  
Durations of 12, 16 and 18 h incubation in terrific broth was tested. The rPfC0760c297 protein 
is expressed along with E. coli host proteins in all cultures (Figure 3.5). There is noticeably 
less protein present in the cultures incubated for 12 h (lanes 2 – 4) compared to cultures that 
were incubated longer (lanes 5 – 10). The amount of host and recombinant proteins expressed 
is comparable in cultures incubated for 16 h and 18 h. A duration of 16 h was chosen for further 
experiments.  
 
Figure 3.6: Comparison of IPTG concentrations for the expression of rPfC0760c297 in LB media. 
Bacterial lysates were resolved on 12.5% reducing SDS-PAGE and proteins were stained with 
Coomassie Blue. Lane 1: molecular weight marker. Lanes 2, 3: duplicate uninduced samples. Duplicate 
samples of three cultures induced with 0.1 mM IPTG (lanes 4 and 5, 6 and 7, 8 and 9), and 0.3 mM 
IPTG (lanes 10 and 11, 12 and 13, 14 and 15).  
Concentrations of 0.1 mM and 0.3 mM IPTG were compared for induction of rPfC0760c297 
expression in LB media. There is a distinct difference between the uninduced culture (lanes 2 
and 3) and the induced cultures (lanes 4 – 15), regardless of the IPTG concentration used for 
induction (Figure 3.6). Similar to Figure 3.2, there appears to be less protein present in the 
induced cultures compared to the uninduced cultures. The 56 kDa rPfC0760c297 protein band 
is present in all the induced cultures, as well as a band at approximately 30 kDa (lanes 4 – 15). 
Better expression of rPfC0760c297 was achieved by induction with 0.1 mM IPTG (lanes 4 – 9) 
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compared to 0.3 mM IPTG (lanes 10 – 15). A higher concentration of the rPfC0760c297 protein 
is present in one of the cultures induced with 0.1 mM (lanes 6 and 7) compared to replicates 
induced with the same concentration, and cultures induced with 0.3 mM IPTG. There is slightly 
better production of E. coli host proteins in the presence of 0.1 mM IPTG (lanes 4 – 9) 
compared to 0.3 mM (lanes 10 – 15). 
Overall, better expression of rPfC0760c297 was achieved using terrific broth. Terrific broth 
was therefore used for the subsequent expression and purification of rPfC0760c297. Cultures 
were grown at 37°C for 16 h and shaken at 200 RPM. 
 
Figure 3.7: Optimized conditions for expression of rPfC0760c297. (A) Bacterial cell lysates were 
resolved on 12.5% reducing SDS-PAGE. Proteins were stained with Coomassie Blue. Lane 1: molecular 
weight marker. Lanes 2 – 4: samples from triplicate cultures. (B) Western blot of an identical gel was 
probed with mouse anti-his6tag IgG and detected with goat anti-mouse HRPO-IgG. 
Expression under the chosen conditions resulted in overexpression of rPfC0760c297 (Figure 
3.7A). The 56 kDa rPfC0760c297 protein was detected with monoclonal mouse anti-his6tag IgG 
(Figure 3.7B). Two additional bands at approximately 34 kDa and 30 kDa were also detected.  
The conditions used to express high quantities of rPfC0760c297 resulted in the formation of 
insoluble protein aggregates called inclusion bodies (data not shown). Soluble rPfC0760c297 is 
required to study the protein.  
3.2.3 Modification of expression conditions to improve solubility of rPfC0760c297 
Modifications of the expression conditions were evaluated to determine whether soluble 
rPfC0760c297 could be expressed. The changes in expression conditions included the duration 
of expression under optimal conditions, a lower temperature of expression (Flick et al., 2004; 
Baneyx, 1999), expression in the presence of ethanol (Chhetri et al., 2015; Steczko et al., 
1991), and induction of rPfC0760c297 expression in LB media during the stationary phase (Flick 
et al., 2004).  
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Figure 3.8: Expression of rPfC0760c297 for 6 – 8 h. Cultures were grown for 6 and 8 h in terrific broth. 
Bacterial lysates were resolved on 12.5% reducing SDS-PAGE, and proteins were stained with 
Coomassie Blue. (A) Lane 1: molecular weight marker. Insoluble and soluble fractions were analysed 
respectively. Lanes 3 and 4, 5 and 6, 7 and 8: triplicate after 6 h expression; and lanes 10 and 11, 12 
and 13, 14 and 15: triplicate cultures after 8 h expression. (B) Western blot of an identical gel probed 
with mouse anti-his6tag IgG and detected with goat anti-mouse HRPO-IgG.  
The duration of expression was shortened. After 4 h of incubation, minimal growth was 
observed. Samples were therefore taken after 6 and 8 h. The 56 kDa rPfC0760c297 protein is 
undetected in both the insoluble and soluble fractions after 6 h of expression (Figure 3.8A and 
B, lanes 3 – 8). An increase in E. coli host protein expression is observed after 8 h, and the 56 
kDa rPfC0760c297 protein is visible in the insoluble fraction (Figure 3.8A and B, lanes 10 – 15). 
Soluble rPfC0760c297 is undetected (Figure 3.8A and B, lanes 11, 13 and 15). Interestingly, 
the 34 kDa and 30 kDa protein bands that were present after 16 h of expression (Figure 3.7B) 
are absent after half the incubation time (Figure 3.8B, lanes 10 – 15). Reducing the duration 
of expression under optimal conditions does not produce soluble rPfC0760c297. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Expression of rPfC0760c297 at 20°C. Bacterial lysates were resolved on 12.5% reducing 
SDS-PAGE, and proteins were stained with Coomassie Blue. Lane 1: molecular weight marker. Lanes 
3, 5, 7 contain insoluble fractions, and lanes 4, 6 and 8 contain soluble fractions from triplicate cultures.  
Expression at a lower temperature was evaluated to determine if soluble recombinant 
protein could be produced (Sørensen and Mortensen, 2005). Figure 3.3 showed substantial 
growth at a temperature as low as 25°C. Growth at a lower temperature of 20°C was evaluated 
in terrific broth for 16 h. Expression at 20°C resulted in very little overall protein expression 
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(Figure 3.9). A 56 kDa rPfC0760c297 protein band is indistinguishable in the soluble and 
insoluble fractions (lanes 3 – 8).  
 
 
 
 
 
 
Figure 3.10: Expression of rPfC0760c297 in the presence of 0 – 3% (v/v) ethanol. Bacterial lysates 
were resolved on 12.5% reducing SDS-PAGE, and proteins were stained with Coomassie Blue. Lane 
1: molecular weight marker. Insoluble and soluble fractions were analysed for each culture 
supplemented with the following concentrations of ethanol: lanes 2 and 3: 0%; lanes 4 and 5: 1% (v/v); 
lanes 6 and 7: 2% (v/v); lanes 8 and 9: 3% (v/v). 
Expression of rPfC0760c297 was evaluated in the presence of ethanol. Terrific broth was 
prepared with increasing concentrations of ethanol and cultures were grown under the 
conditions outlined previously. The presence of ethanol in the culture media shows a marked 
decrease in the expression of rPfC0760c297 as the concentration of ethanol increases 
(Figure 3.10, lanes 4 – 9). The absence of ethanol shows the highest expression of 
rPfC0760c297, with the majority remaining in the insoluble fraction (lanes 2 and 3). There is no 
detectable rPfC0760c297 in the soluble fractions (lanes 5, 7 and 9). 
 
 
 
 
 
 
 
Figure 3.11: Induction of rPfC0760c297 expression at the stationary phase in LB media. Bacterial 
lysates were resolved on 12.5% reducing SDS-PAGE, and proteins were stained with Coomassie Blue. 
Lane 1: molecular weight marker. Lanes 3 and 4: cell lysates from uninduced E. coli. Lanes 5 and 6, 7 
and 8, 9 and 10 contain insoluble and soluble fractions from triplicate induced cultures. 
Cultures grown in LB media were induced with 0.3 mM IPTG in the stationary phase when 
the OD600 was between 0.7 and 0.8 (Figure 3.11). The 56 kDa rPfC0760c297 band was absent 
in uninduced cultures (lanes 3 and 4). Induction at the stationary phase of cell growth resulted 
in improved expression levels of rPfC0760c297, which was insoluble (lanes 5 – 10). Presence 
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of soluble rPfC0760c297 protein is not evident in induced cultures (lanes 6, 8 and 10). The 
30 kDa band is prominent in the insoluble fractions (lanes 5, 7 and 9). There is considerably 
more recombinant protein expressed when cultures were induced during the stationary phase 
in LB media compared to induction in the exponential phase (Figure 3.2, lanes 3 – 6).  
Since none of the adjustments that were tested allowed for the expression of soluble 
rPfC0760c297, the rPfC0760c297 protein was solubilized before purification for downstream 
experiments. 
3.2.4 Solubilization and purification of rPfC0760c297 
After expression of rPfC0760c297, the insoluble fraction of the E. coli lysate was solubilized 
in a buffer containing the chaotropic detergent SDS under reducing conditions (Schlager et al., 
2012).  
 
 
Figure 3.12: Solubilization and purification of rPfC0760c297 expressed under optimal conditions. 
The rPfC0760c297 protein was solubilized with SDS before affinity purification using nickel chelate affinity 
chromatography. Proteins were resolved on 12.5% reducing SDS-PAGE and stained with Coomassie 
Blue. (A) Lane 1: molecular weight marker. Lane 2: supernatant after Triton X-100 wash. Lane 3: pellet 
after SDS solubilization. Lane 4: solubilized material applied to the nickel column. Lane 5: unbound 
fraction. Lane 6: final wash with 20 mM imidazole. Lane 7: pooled purified rPfC0760c297. (B) Elution of 
rPfC0760c297 from a nickel column using an imidazole gradient from 20 – 270 mM. 
The solubilization and purification of rPfC0760c297 from an E. coli lysate is illustrated (Figure 
3.12A). Proteins are released after the bacterial cell pellet is washed with Triton X-100, and a 
faint band corresponding to rPfC0760c297 is noted (lane 2). Fewer insoluble proteins remain 
after treatment with SDS (lane 3), and the majority of rPfC0760c297 and many E. coli host 
proteins are solubilized (lane 4). The solubilized material was loaded onto a nickel NTA resin 
for purification, and the unbound fraction contained some rPfC0760c297 (lane 5). No protein 
was detected in the final wash (lane 6). The purified protein fractions were pooled (lane 7). The 
concentration of purified rPfC0760c297 was determined by the Bradford assay, and 22 mg of 
rPfC0760c297 was purified from 1 g of cell biomass from a 50 ml culture. From the imidazole 
gradient, a concentration of 150 mM imidazole was chosen for further purifications (Figure 
3.12B).  
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3.3 Discussion  
3.3.1 Recombinant expression of rPfC0760c297 
To study and determine the biological functions of a protein, it must first be made available 
in a native, purified form. Proteins may be isolated from tissues however, a sufficient protein 
yield may be costly to acquire (Villaverde and Carrió, 2003). Isolation of sufficient native 
PfC0760c would require large volumes of P. falciparum-infected red blood cells. Recombinant 
expression of proteins is an important technique, which can overcome these drawbacks 
(Tsumoto et al., 2003).  
3.3.2 Recombinant expression of P. falciparum proteins 
P. falciparum proteins are difficult to recombinantly express, as they tend to aggregate, or 
are not expressed (Mehlin et al., 2006). Expression of 1000 P. falciparum open reading frames 
in E. coli revealed only 63 soluble proteins (Mehlin et al., 2006). Proteins rich in asparagine-
repeat regions such as PfC0760c are more likely to form insoluble aggregates (Muralidharan 
and Goldberg, 2013). The genome of P. falciparum is rich in adenine and thymine residues, 
which is thought to contribute to recombinant proteins forming insoluble inclusion bodies (Flick 
et al., 2004; Gardner et al., 2002). As a result, P. falciparum proteins require codons that are 
rarely used by E. coli (Birkholtz et al., 2008). The genomic sequence of PfC0760c is 49% 
adenine and 30% thymine residues. Unexpectedly, it was found that the adenine-thymine 
richness did not influence the solubility of P. falciparum proteins (Vedadi et al., 2007; Mehlin 
et al., 2006).  
3.3.3 Bacterial inclusion bodies 
Expression of large amounts of foreign protein in a bacterial host expression system is likely 
to form insoluble inclusion bodies (Schlager et al., 2012; Singh and Panda, 2005). Typically, 
inclusion bodies comprise inactive, misfolded protein aggregates that require solubilization and 
refolding before purification (Singh and Panda, 2005; Villaverde and Carrió, 2003; Baneyx, 
1999).  
Reducing conditions in bacterial cytosol prevent the formation of disulfide bonds, 
contributing to protein aggregation (Singh and Panda, 2005; Prinz et al., 1997). The full-length 
PfC0760c protein contains 34 cysteine residues, 5 of which are present in rPfC0760c297. These 
cysteines may participate in disulfide bonding, which stabilises the protein structure 
(Wedemeyer et al., 2000). The 5 cysteine residues are possibly unable to form disulfide bonds 
or are not paired correctly. This has not been evaluated. 
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Other factors that contribute to inclusion body formation include the expression conditions, 
the size and amino acid sequence of the protein, thermal stress, a basic pI, and higher degree 
of disorder. (Mehlin et al., 2006; Villaverde and Carrió, 2003; Schein, 1989).  
3.3.4 Growth profiles of bacterial cells 
As expected, the growth profiles of transformed E. coli cells exhibited variations in growth 
rate. Different colonies were used for replicates as opposed to using a single seed culture. 
In the transformed E. coli cells, minimal metabolic activity and cell density was observed in 
the lag phase (Madar et al., 2013), accounting for the first 2 h post-inoculation (Figure 3.1). 
During the lag phase, cells adapt to the growth conditions. Cells are not necessarily increasing 
in number, but the expression of genes that utilize the carbon source for the production of 
energy and building blocks is upregulated (Madar et al., 2013).  
A sharp increase in cell growth indicates the exponential phase (Figure 3.1) (Maier, 2000). 
Cultures are usually induced to express recombinant protein in this phase, ensuring a large 
population of healthy cells, which should result in the high expression of recombinant protein.  
The stationary phase constitutes equal amounts of multiplying and dying cells (Maier, 2000). 
Cell death is likely attributed to an accumulation of toxic metabolites, decreasing nutrients, or 
cell death signals, and is indicated by a plateau in the growth curve (Kram and Finkel, 2015). 
3.3.5 Terrific broth expresses high levels of rPfC0760c297 
E. coli bacteria transformed with pET32a and grown in terrific broth expressed large 
quantities of rPfC0760c297 (Figure 3.2). pET32a was chosen as it allowed the expression of a 
thioredoxin fusion protein (LaVallie et al., 1993). Terrific broth is a nutrient-rich auto-induction 
media (Lessard, 2013), that enhanced the expression of rPfC0760c297 and E. coli host proteins 
(Figure 3.2). The adenine-thymine richness of the P. falciparum genome can cause premature 
termination of the mRNA translation, which leads to truncated protein production (Flick et al., 
2004). This could account for the 34 kDa and 30 kDa bands detected on the western blot by 
the mouse anti-his6tag IgG antibodies (Figure 3.7B). 
3.3.6 The thioredoxin fusion tag 
The solubility of previously insoluble proteins was improved when expressed as thioredoxin 
fusion proteins. These included mammalian cytokines, WT1 tumour suppressor and its zinc 
finger domain expressed at a low temperature, and sea cucumber lysozyme (Cong et al., 2014; 
Fagerlund et al., 2012; LaVallie et al., 1993). Although rPfC0760c297 was expressed as a 
thioredoxin fusion protein, it remained insoluble. The Canis IFNα and IL-2 tyrosine kinase 
remained insoluble as thioredoxin fusion proteins (Yang et al., 2015; Joseph and Andreotti, 
2008). Soluble Canis IFNα was obtained by fusion to the Nus tag, or by expression at a low 
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temperature when fused to thioredoxin (Yang et al., 2015). Thioredoxin fusion proteins may 
not be expressed as soluble proteins at higher temperatures, hence lower temperatures of 
expression should be evaluated.  
3.3.7 Induction of recombinant protein expression with IPTG 
IPTG is not metabolised by the cells and may have a toxic effect on bacterial host cells 
(Ahmad et al., 2018; Larentis et al., 2014; Kosinski et al., 1992). This is demonstrated by 
decreased protein synthesis, and upregulation of stress proteins similar to the response 
caused by heat shock (Kosinski et al., 1992). Presence of high concentrations of IPTG 
impaired the expression of E. coli host proteins (Figure 3.2 and 3.6). 
The solubility and yield of the PfEMP-1 domains were improved when expression was 
induced during the late stationary phase (Flick et al., 2004). A lower rate of protein expression 
during the stationary phase may facilitate correct protein folding (Flick et al., 2004). The yield 
of rPfC0760c297 was improved when cells were induced at the stationary phase, yet it remained 
insoluble. This could possibly be attributed to the high concentration of the accumulated 
protein. 
3.3.8 Expression of recombinant protein at low temperatures 
Expression at lower temperatures is known to improve the solubility of proteins (Sørensen 
and Mortensen, 2005; Schein, 1989). Slower growth of cells may allow for efficient protein 
folding, but sacrifices the yield of recombinant protein (Flick et al., 2004; Schein, 1989). 
Therefore, a lower temperature was expected to result in lower rPfC0760c297 and host protein 
expression (Figure 3.3). No soluble rPfC0760c297 was detected. 
The falcipain-2 protease enzyme from P. falciparum was expressed as an inclusion body in 
E. coli, and failed to express in Pichia pastoris (Goh et al., 2003). Expression of falcipain-2 
protease in E. coli TB1 as a maltose binding protein-fusion protein at a low temperature 
produced soluble protein (Goh et al., 2003). Thus, a lower temperature of recombinant protein 
expression in E. coli host cells may be a feasible avenue to explore to produce soluble 
recombinant protein.  
3.3.9 Protein recombinant expression in the presence of ethanol  
The presence of ethanol could possibly enhance protein solubility by inducing a stress 
response, forcing the cell to upregulate the expression of heat shock proteins (HSPs) 
(Ziemienowicz et al., 1993; Steczko et al., 1991; Lindquist and Craig, 1988). HSPs, also known 
as chaperones, help prevent protein aggregation by correctly folding misfolded proteins. On 
the contrary, increasing concentrations of ethanol suppressed the expression of rPfC0760c297 
and host proteins, and did not improve rPfC0760c297 solubility (Figure 3.10). 
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3.3.10 Solubilization of recombinant proteins 
Solubilization of inclusion bodies requires protein unfolding using high concentrations of a 
denaturant (Tsumoto et al., 2003). Solubilization is usually performed under reducing 
conditions to prevent oxidation of cysteine residues, and remove existing disulfide bonds within 
the inclusion bodies (Wingfield, 2001; Fischer et al., 1993). Solubilization of proteins with 
detergents is likely to form an ordered structure, folded into alpha-helices (Schlager et al., 
2012; Tsumoto et al., 2003).  
Protein solubilization with SDS is advantageous as it is cheap, the procedure is rapid and 
simple, and excess detergent is easily removed by cooling and centrifugation (Schlager et al., 
2012). N-lauroyl sarcosine is a milder detergent compared to SDS, and is used for 
solubilization and refolding (Schlager et al., 2012; Burgess, 1996). The majority of the 
rPfC0760c297 protein was solubilized with SDS (Figure 3.12A) and was maintained in the 
soluble form with a low concentration of N-lauroyl sarcosine. SDS was successfully used to 
solubilize 17 different his6tagged proteins and muscle proteins from different types of fish 
(Schlager et al., 2012; Rehbein and Karl, 1985). N-lauroyl sarcosine was used to solubilize 
RNA polymerase σ factors (Burgess, 1996). 
3.3.11 Refolding and purification of rPfC0760c297 
Gradual removal of the denaturant allows the protein to refold at an intermediate 
concentration of the denaturant (Tsumoto et al., 2003; Burgess, 1996). In this case, replacing 
SDS with a lower concentration of N-lauroyl sarcosine facilitates protein refolding (Schlager et 
al., 2012; Rogl et al., 1998). Aggregation during refolding and purification is prevented by the 
N-lauroyl sarcosine likely coating the exposed hydrophobic surfaces of the protein (Burgess, 
1996). 
For further analysis, the his6tagged rPfC0760c297 protein was purified by nickel chelate 
affinity chromatography. A concentration of 20 mM imidazole was used in the wash buffer to 
help prevent non-specific binding of contaminant proteins to the resin. N-lauroyl sarcosine was 
included in the wash and elution buffers to maintain soluble rPfC0760c297. 
3.3.12 Alternative solubilization methods 
Other methods of protein solubilization from inclusion bodies include the use of urea or 
guanidine-HCl, which both denature protein (Singh and Panda, 2005; Wingfield, 2001). Using 
urea or guanidine-HCl for protein solubilization results in a flexible, disordered protein structure 
(Tsumoto et al., 2003). Solubilization with urea would require the urea solubilization solution 
to be freshly prepared before each experiment, as urea solutions have a propensity to 
decompose into ammonium cyanate, which would need to be removed (Wingfield, 2001). 
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Before further analysis, an additional dialysis step is necessary to remove the urea. Low 
concentrations of urea coupled with an alkaline pH shock was able to solubilize purified 
inclusion bodies containing human growth hormone (Singh and Panda, 2005).  
There are several advantages of using SDS for solubilization rather than urea or guanidine-
HCl. These include the low cost of SDS, ease of use, and the speed of protein solubilization 
(Schlager et al., 2012). In the SDS and N-lauroyl sarcosine protocol (Schlager et al., 2012), 34 
mM of SDS was used, compared to 6 – 8 M urea or guanidine-HCl. 
Various strategies may still be investigated to determine whether the solubility of 
rPfC0760c297 may be improved while maintaining a satisfactory yield. These include 
expression at low temperatures for longer periods of time, co-expression with E. coli 
chaperones, co-expression of Plasmodium chaperones, or expression with other vectors, 
fusion tags, or hosts. All these strategies would have to be evaluated and compared to the 
current strategy for yield and solubility.  
3.3.13 Conclusion 
Although high levels of the rPfC0760c297 protein was produced, rPfC0760c297 was prone to 
aggregation in inclusion bodies. The rPfC0760c297 protein was therefore solubilized and 
purified before subsequent studies. 
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Chapter 4: E. coli chaperone co-expression for the recombinant 
expression of soluble rPfC0760c297 
4.1 Introduction 
4.1.1 Chaperones 
Proteins that prevent anomalous interactions between macromolecules are known as 
molecular chaperones (Bell et al., 2011). Heat shock proteins (HSPs) are a group of molecular 
chaperones that help to correctly fold misfolded or aggregated proteins to allow for correct 
protein conformation (Ryabova et al., 2013; Nishihara et al., 1998). As the name suggests, 
HSPs are expressed as a stress response to increased temperatures and other stresses in the 
cell (Bell et al., 2011; Lindquist and Craig, 1988). In bacterial recombinant protein expression, 
co-expression with chaperones may aid in the expression of soluble recombinant protein 
(Sørensen and Mortensen, 2005; Hartl and Hayer-Hartl, 2002).  
4.1.2 E. coli chaperones 
After bacterial ribosomal protein synthesis, some proteins may require chaperones to fold 
correctly (de Marco, 2007). These proteins may be E. coli host proteins, or plasmid-encoded 
recombinant proteins. Two plasmid-encoded E. coli chaperone systems were investigated for 
the expression of soluble rPfC0760c297. The pGro7 plasmid carries the GroEL-GroES 
chaperone system, the pKJE7 plasmid carries the dnaKdnaJgrpE chaperone system, and the 
pG-KJE8 plasmid carries both the GroEL-GroES and dnaKdnaJgrpE chaperone systems 
(Nishihara et al., 1998). These plasmids all encode a chloramphenicol resistance marker, and 
an araB promoter triggered by L-arabinose for expression of the chaperones (Nishihara et al., 
1998). The pG-KJE8 plasmid encodes a Pzt-1 promoter, which requires the addition of 
tetracycline for induction (Nishihara et al., 1998).  
4.1.3 The GroEL-GroES chaperones  
Correct folding of misfolded proteins by the GroEL-GroES chaperone system occurs in a 
controlled series of steps. The GroEL protein (60 kDa) forms a double-ringed cylinder, where 
each ring is composed of seven identical subunits (Ryabova et al., 2013; Mayhew et al., 1996). 
After protein synthesis, misfolded protein binds to the inner surface of GroEL. GroES (10 kDa) 
binds to the top of the GroEL cylinder and folding of the misfolded protein occurs within the 
GroEL chamber (Ryabova et al., 2013; Martin, 1998). The correctly folded protein is released 
from the chamber upon hydrolysis of ATP, along with dissociation of GroES from GroEL 
(Mayhew et al., 1996). 
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4.1.4 The dnaKdnaJgrpE chaperones 
The dnaKdnaJgrpE chaperone system consists of a chaperone and two co-chaperones. 
The dnaK chaperone (70 kDa) belongs to the HSP70 protein family (Bell et al., 2011; Glover 
and Lindquist, 1998; Schönfeld et al., 1995; Schröder et al., 1993). The dnaJ co-chaperone 
(40 kDa) is a HSP40 protein (Schönfeld et al., 1995; Glover and Lindquist, 1998), and the co-
factor grpE (22 kDa) acts as a nucleotide exchange factor (Gamer et al., 1996; Schönfeld et 
al., 1995). The mechanism of protein folding with the dnaKdnaJgrpE chaperones occurs as 
follows: firstly, the dnaJ co-chaperone binds to the misfolded protein, and this complex 
interacts with the dnaK chaperone. The ATP attached to the dnaK chaperone is hydrolysed to 
ADP (Szabo et al., 1994). The dnaJ co-chaperone speeds up hydrolysis of ATP to ADP (Bell 
et al., 2011). The release of ADP is facilitated by grpE (Szabo et al., 1994), allowing fresh ATP 
to bind, which triggers the release of the correctly folded protein (Szabo et al., 1994). 
In this chapter, co-expression of rPfC0760c297 with the GroEL-GroES and dnaKdnaJgrpE 
chaperone systems was explored under different expression conditions, aiming to express 
soluble rPfC0760c297. 
4.2 Results 
4.2.1 Co-expression of rPfC0760c297 with E. coli chaperones in LB media 
Competent E. coli BL21(DE3) cells containing pET32a-rPfC0760c297 were co-transformed 
with plasmids encoding E. coli chaperones.  
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Figure 4.1: Co-expression of rPfC0760c297 with E. coli chaperones. E. coli BL21(DE3) cells 
expressing rPfC0760c297 were grown with the chaperones: A, B: GroEL-GroES; C, D: dnaKdnaJgrpE; 
E, F: GroEL-GroES and dnaKdnaJgrpE. A, C, E: Proteins were resolved on 12.5% reducing SDS-PAGE 
and stained with Coomassie Blue. Lane 1: molecular weight marker. Insoluble and soluble fractions 
were loaded for each sample in consecutive lanes. Lanes 2 – 5 contain pET32a-rPfC0760c297 cell 
lysates. Lanes 2 and 3: uninduced, lanes 4 and 5: induced. Lanes 7 – 14 contain lysates from co-
transformed cells. Lanes 7 and 8: uninduced cells, lanes 9 and 10: co-transformed cells expressing 
rPfC0760c297, lanes 11 and 12, 13 and 14: duplicate cultures co-expressing rPfC0760c297 and 
chaperones. B, D, F: Western blots of gels in A, C, E were probed with chicken anti-rPfC0760c297 IgY 
and rabbit anti-chicken HRPO-IgG. 
Expression of rPfC0760c297 was not detected in uninduced cultures (Figure 4.1A – F, lanes 
2, 3, 7 and 8). Induced cultures express rPfC0760c297 (56 kDa), along with a 34 kDa and a 
30 kDa band detected by the chicken anti-rPfC0760c297 IgY in the western blot. Most of these 
proteins were in the insoluble fraction (Figure 4.1A – F, lanes 4, 5, and 9 – 14). Where 
expression of the chaperones was not induced, the expression of rPfC0760c297 was unaffected 
(Figure 4.1A – F, lanes 7 and 8). Co-expression of any of these chaperones does not improve 
the solubility of rPfC0760c297 (Figure 4.1A – F, lanes 11 – 14). The GroEL and dnaK 
chaperones are shown at 60 kDa (Figure 4.1A and C, lanes 11 – 14) and 70 kDa respectively 
(Figure 4.1C and E, lanes 11 – 14). These chaperones are present in low concentrations in 
cells that have not been co-transformed (Figure 4.1A, C and E, lanes 2 – 5) and in uninduced 
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cells (Figure 4.1A, C and E, lanes 7 – 10). Overall, the chaperones did not improve the solubility 
of rPfC0760c297 under the conditions evaluated. 
4.2.2 Co-expression of rPfC0760c297 with E. coli chaperones in terrific broth 
Conditions for high yields of rPfC0760c297 were established in Chapter 3 (Figure 3.2). These 
conditions were used to evaluate the co-expression of the E. coli chaperones with 
rPfC0760c297. 
 
 
 
 
 
Figure 4.2: Co-expression of rPfC0760c297 with E. coli chaperones in terrific broth. (A) Proteins 
were resolved on 12.5% reducing SDS-PAGE and stained with Coomassie Blue. Lane 1: molecular 
weight marker. Insoluble and soluble fractions were analysed for each sample in consecutive lanes. 
Lanes 3 and 4: uninduced GroEL-GroES. Lanes 5 – 10: induced co-expression of rPfC0760c297 and 
E. coli chaperones. Lanes 5 and 6: GroEL-GroES. Lanes 7 and 8: dnaKdnaJgrpE. Lanes 9 and 10: 
GroEL-GroES and dnaKdnaJgrpE. (B) Western blot of an identical gel probed with chicken anti-
rPfC0760c297 IgY and rabbit anti-chicken HRPO-IgG. 
Similar quantities of rPfC0760c297 were produced in terrific broth in the presence and 
absence of GroEL-GroES chaperones, with the majority of rPfC0760c297 found in the insoluble 
fraction (Figure 4.2A and B, lanes 3 – 6). Soluble rPfC0760c297 was not detected upon co-
expression with dnaKdnaJgrpE, or both chaperones (Figure 4.2A and B, lanes 7 - 10). Low 
concentrations of the insoluble 34 kDa protein detected in the presence and absence of GroEL-
GroES (lanes 3 and 5). The 30 kDa band is detected in all the insoluble fractions (lanes 3, 5, 
7, and 9). 
 
 
 
 
 
 
Figure 4.3: Co-expression of rPfC0760c297 with the dnaKdnaJgrpE chaperones for 8 h in terrific 
broth. rPfC0760c297 was co-expressed with dnaKdnaJgrpE and samples were removed every 2 h. (A) 
Proteins were resolved on 12.5% reducing SDS-PAGE and stained with Coomassie Blue. Lane 1: 
molecular weight marker. Insoluble and soluble fractions were analysed in consecutive lanes: lanes 2 
and 3: 2 h, lanes 4 and 5: 4 h, lanes 6 and 7: 6 h, lanes 8 and 9: 8 h. (B) Western blot of an identical gel 
was probed with chicken anti-rPfC0760c297 IgY and rabbit anti-chicken HRPO-IgG. 
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Previously, rPfC0760c297 was expressed as an insoluble protein in terrific broth between 6 
and 8 hours (Figure 3.8). rPfC0760c297 was co-expressed with the dnaKdnaJgrpE chaperones 
in terrific broth and samples were taken every 2 hours. No protein is detected after the first 2 
h of co-expression, as there is little cell growth (Figure 4.3A, lanes 2 and 3). After 4 h, a few 
proteins are seen, and rPfC0760c297 is not detected by western blot (Figure 4.3A and B, lanes 
4 and 5). Similar to the result presented in Figure 3.9, a small amount of insoluble rPfC0760c297 
was detected after 6 h, which increased after 8 h expression and remained insoluble (Figure 
4.3B, lanes 6 – 9). The presence of the dnaKdnaJgrpE chaperones had no effect on the 
solubility of rPfC0760c297 when grown in terrific broth. 
4.2.3 Induction of rPfC0760c297 expression with various concentrations of IPTG in LB 
media 
 
 
 
 
 
 
Figure 4.4: Different IPTG concentrations for the induction of rPfC0760c297 co-expression with 
GroEL-GroES chaperones. (A) Proteins were resolved on 12.5% reducing SDS-PAGE and stained 
with Coomassie Blue. Lane 1: molecular weight marker. Insoluble and soluble fractions were analysed 
for each sample in consecutive lanes. Cells were induced with the following concentrations of IPTG: 
lanes 2 and 3: 0 mM, lanes 4 and 5: 0.05 mM, lanes 6 and 7: 0.1 mM, lanes 8 and 9: 0.2 mM, and lanes 
10 and 11: 0.3 mM. (B) Western blot of an identical gel was probed with chicken anti-rPfC0760c297 IgY 
and rabbit anti-chicken HRPO-IgG. 
The concentration of IPTG for soluble rPfC0760c297 expression was evaluated in Chapter 3 
(Figure 3.6). Co-expression of rPfC0760c297 in the presence of 0 – 0.3 mM IPTG with the 
GroEL-GroES chaperones were evaluated (Figure 4.4, lanes 2 – 11). A concentration of 
0.2 mM IPTG reduces the expression of GroEL (Figure 4.4A, lanes 6 and 7). Soluble 
rPfC0760c297 was not detected when the concentrations of IPTG was varied in the presence 
of GroEL (Figure 4.4B, lanes 5, 7, 9, 11). The amount of rPfC0760c297 expressed with the 
different concentrations of IPTG is similar in the presence of induced GroEL-GroES (Figure 
4.5B, lanes 4, 6, 8 and 10). 
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4.2.4 Induction of chaperone co-expression with L-arabinose 
To determine whether soluble rPfC0760c297 could be expressed with lower amounts of the 
E. coli chaperones present, the concentration of L-arabinose was varied. Tetracycline and 
IPTG were kept at a fixed concentration.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Induction of chaperone co-expression with different concentrations of L-arabinose. 
L-arabinose from 1 – 0 mg/ml was used to induce chaperone co-expression with rPfC0760c297. Proteins 
were resolved on 12.5% reducing SDS-PAGE stained with Coomassie Blue. rPfC0760c297 was co-
expressed with (A) GroEL-GroES, (B) dnaKdnaJgrpE, (C) GroEL-GroES and dnaKdnaJgrpE. Lane 1: 
molecular weight marker. Insoluble and soluble fractions were analysed for each sample in consecutive 
lanes. Lanes 2 and 3: cells expressing rPfC0760c297. The following concentrations of L-arabinose were 
used: lanes 4 and 5: 1 mg/ml, lanes 6 and 7: 0.75 mg/ml, lanes 8 and 9: 0.5 mg/ml, lanes 10 and 11: 
0.25 mg/ml and lanes 12 and 13: 0 mg/ ml.  
rPfC0760c297 is present at similar concentrations, regardless of the chaperone used or the 
concentration of L-arabinose (Figure 4.5A – C). As expected, a decrease in the L-arabinose 
concentration decreases the amount of the GroEL and dnaKdnaJgrpE chaperones expressed 
(Figure 4.5A – C, lanes 4 – 13). A change in the amount of the E. coli chaperones expressed 
did not influence the expression of soluble rPfC0760c297.  
4.4 Discussion 
4.4.1 rPfC0760c297 is an insoluble recombinant protein  
The rPfC0760c297 protein was expressed in insoluble inclusion bodies under different 
growth conditions (Chapter 3). The data obtained after chaperone co-expression under the 
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different conditions indicate that co-expression of the E. coli chaperones did not have a 
detectable influence on the expression of soluble rPfC0760c297.  
Chaperones have been shown to improve the solubility of proteins that are prone to 
aggregation. Co-expression with GroEL-GroES or dnaKdnaJgrpE improved the solubility of 
aggregation-prone proteins from mutant E. coli cells deficient in HSPs, Japanese cedar pollen 
protein Cryj2 and recombinant humanised anti-epidermal growth factor receptor scFv antibody 
(Veisi et al., 2015; Nishihara et al., 1998; Gragerov et al., 1992).  
The GroEL-GroES and dnaKdnaJgrpE chaperones act synergistically to prevent protein 
aggregation (Gragerov et al., 1992). Five insoluble proteins co-expressed with different 
combinations of ClpB, GroEL-GroES, and dnaKdnaJgrpE chaperones resulted in soluble 
expression (de Marco et al., 2007). Induction of both GroEL-GroES and dnaKdnaJgrpE 
chaperones did not improve rPfC0760c297 solubility (Figure 4.1F).  
Like rPfC0760c297, some proteins remain insoluble when co-expressed with chaperones (de 
Marco et al., 2007). IL-2 tyrosine kinase and four P. falciparum glideosome proteins 
co-expressed with GroEL-GroES and both GroEL-GroES and dnaKdnaJgrpE remained 
insoluble when expressed at low temperatures (Joseph and Andreotti, 2008). The solubility of 
recombinant myosin A, gliding-associated protein-45 and gliding-associated protein-50 from 
P. falciparum was not improved when co-expressed with GroEL-GroES and dnaKdnaJgrpE 
(Guerra et al., 2016). 
4.4.2 Co-expression of rPfC0760c297 with E. coli chaperones in terrific broth 
Terrific broth  produced large amounts of rPfC0760c297, but doesn’t induce expression of 
plasmid-encoded chaperones. However, co-expression with any chaperone produced lower 
amounts of rPfC0760c297 in terrific broth. The majority of the rPfC0760c297 remained insoluble 
(Figure 4.3).  
rPfC0760c297 is expressed between 4 and 6 hours and is insoluble. It is possible that the 
chaperones are absent at this time, which can be confirmed by western blot with chaperone-
specific antibodies. Presence of the chaperone at the time of rPfC0760c297 expression could 
determine whether they are capable of folding rPfC0760c297. In the presence of large amounts 
of GroEL, the rPfC0760c297 remains insoluble (Figure 4.1 and Figure 4.5A). Soluble 
rPfC0760c297 may not be detected due to insufficient lysis observed in Figures 4.4 and 4.5. 
Interestingly, the truncated forms of rPfC0760c297 are absent after 6 – 8 hours (Figure 3.8B), 
but present with dnaKdnaJgrpE co-expression (Figure 4.3B).  
4.4.3 P. falciparum heat shock proteins  
The genome of P. falciparum encodes 6 HSP70 proteins and 43 HSP40 proteins, 
suggesting that chaperones play a key role in parasite survival (Botha et al., 2007). 
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Plasmodium chaperones function under a range of conditions, including the temperature of the 
mosquito host, natural body temperature of a human, and human body temperature during a 
febrile incident (Przyborski et al., 2015; Bell et al., 2011). It is therefore likely, that Plasmodium 
proteins require chaperone-assisted folding and protection under stressful conditions.  
4.4.4 Co-expression of recombinant proteins with non-E. coli chaperones 
Production of soluble IL-2 tyrosine kinase was achieved by co-expression with the 
Cpn60/10 chaperone in Oleispira antarctica at low temperatures (Joseph and Andreotti, 2008). 
Co-expression of proteins in E. coli with chaperones from the same species have been 
reported to improve the yield of soluble recombinant protein. The solubility of human 
cytochrome P450 1A2 and the long tail fibre protein gp37 from bacteriophage T4 were 
improved upon co-expression with same-species chaperones (Bartual et al., 2010; Ahn et al., 
2004).  
P. falciparum PFI1155w is an asparagine-repeat rich protein that formed inclusion bodies 
in a mammalian expression system. The solubility of P. falciparum PFI1155w was improved 
upon co-expression with the P. falciparum HSP110 chaperone (Muralidharan et al., 2012). 
P. falciparum HSP70 has been successfully expressed in E. coli, and improved the yield of 
soluble P. falciparum GTP cyclohydrolase I (Stephens et al., 2011; Matambo et al., 2004). A 
chimeric HSP70 (KPf) was engineered to co-operate with E. coli chaperones, and bind to 
Plasmodium proteins to enable folding (Makhoba et al., 2016; Shonhai et al., 2005). 
Co-expression of KPf improved the quality of P. falciparum S-adenosylmethionine 
decarboxylase (Makhoba et al., 2016). P. falciparum HSP70 (Accession: P11144.2) and E. coli 
dnaK (Accession: P0A6Y8.2) share ~44% amino acid sequence identity. The P. falciparum 
HSP70 and KPf are attractive candidates for co-expression with rPfC0760c297. 
Other chaperone co-expression avenues that may be explored include co-expression at 
lower temperatures and removal of the IPTG inducer after induction of recombinant protein 
expression. Other chaperones may also be evaluated for co-expression with rPfC0760c297 in 
E. coli, such as PfHSP70, KPf and PfHSP110 from P. falciparum, or E. coli ClpB or trigger 
factor. Chemical additives and different host cells may also be evaluated (Prasad et al., 2011). 
4.4.5 Conclusion 
None of the co-expression conditions that were evaluated in this study improved the 
solubility of rPfC0760c297. The optimized expression conditions allowed for higher expression 
of insoluble rPfC0760c297 compared to all the chaperone co-expression conditions. Based on 
the results presented in this chapter, and the ethanol experiment in Chapter 3, it is concluded 
that these E. coli chaperones are unable to correctly fold the rPfC0760c297 protein to allow for 
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its solubility. There is no evidence to suggest that the chaperones did or did not bind to 
rPfC0760c297.  
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Chapter 5: Protein-protein interactions between rPfC0760c297 and 
monocyte proteins 
5.1 Introduction  
5.1.1 White blood cells in the immune system 
White blood cells form an integral part of the innate immune system and are synthesized in 
the bone marrow (Serbina et al., 2008). These cells develop from a hematopoietic stem cell 
and differentiate into different cell types in the bone marrow. Unlike red blood cells, white blood 
cells are nucleated. Basophils, eosinophils, neutrophils, lymphocytes and monocytes are types 
of white blood cells, which are phenotypically different and perform specific immune functions 
(Tajuddin et al., 2016). White blood cell counts can be used as markers for infection, and are 
significantly low in acute P. falciparum and P. vivax malaria infections (Tangpukdee et al., 
2008).  
5.1.2 Function of monocytes 
Monocytes are a group of mononuclear white blood cells derived from hematopoietic stem 
cells, with a bean-shaped nucleus (Chua et al., 2013; Geissmann et al., 2003). They are the 
largest of the white blood cells that circulate in the bloodstream. Monocytes can further be 
divided into subsets based on the expression of different cell surface markers or receptors. 
Phagocytic monocytes express CD14, and monocytes involved in the activation of T-cells 
express CD16 (Serbina et al., 2008). On the cell surface, human monocytes express CD11b, 
CD11c and CD14, and mouse monocytes express CD11b and F4/80 (Geissmann et al., 2003). 
During an infection, CD11b-mediated activation of inflammatory cells is vital for parasite 
clearance (Serbina et al., 2008).  
Upon entry into tissues, monocytes differentiate into tissue-specific macrophages. 
Monocytes in the blood may also differentiate into dendritic cells, which can enter lymph nodes 
(Kantari et al., 2008). The functions of monocytes, dendritic cells and macrophages include 
phagocytosis of pathogens, apoptotic cells and infected red blood cells, antigen presentation 
to T-cells, and the release of proinflammatory cytokines and chemokines (Zhou et al., 2015; 
Kantari et al., 2008; Ziegler-Heitbrock, 2007). These functions are usually receptor-mediated. 
During a Plasmodium infection, monocyte-mediated phagocytosis is initiated by binding of 
complement and IgG to infected red blood cells (Turrini et al., 1992). 
Pattern recognition receptors expressed on the surface of monocytes detect an infection by 
recognition of pathogen-associated molecular patterns expressed by parasites or other 
pathogens (Sampaio et al., 2018; Kawai and Akira, 2009). Toll-like receptors are pattern 
58 
recognition receptors that are involved in Plasmodium parasite recognition (Kawai and Akira, 
2009). 
5.1.3 Protein-protein interactions 
Protein-protein interactions are defined as the intentional, specific physical contact and 
molecular docking between intracellular proteins or in an in vivo system (De Las Rivas and 
Fontanillo, 2010). Identification of protein-protein interactions is important for the determination 
of in vivo protein function and drug efficiency (Rao et al., 2014). Proteins seldom work alone 
when performing biological functions (De Las Rivas and Fontanillo, 2010). Interaction of a 
protein of unknown function with a protein of known function could help delineate the function 
of the unknown protein (Rao et al., 2014). Interaction of host immune proteins and cell surface 
receptors with parasite proteins may help understand disease pathogenesis. Understanding 
these interactions may also help clarify mechanisms underlying host immune detection of 
pathogens (Kawai and Akira, 2009). Disease management and novel drug design may be 
improved by interpretation of host immune interactions with Plasmodium parasites (Chua et 
al., 2013).  
In this study, proteins from U937 and J774A.1 cell lysates were analysed for protein-protein 
interactions with rPfC0760c297. Since PfC0760c is an uncharacterized protein with no known 
function or defined interactions, this study was conducted to determine if there are any 
mammalian proteins that interact with PfC0760c. The PfC0760c protein is predicted to localize 
in the parasite nucleus. Therefore, interactions of PfC0760c with monocytes and macrophages 
may occur after immunological processing of parasite-infected host cells. 
5.2 Results 
5.2.1 Selection of chicken IgY concentrations for far dot blot analysis  
 
 
 
Figure 5.1: Far dot blot analysis of chicken IgY probed with rPfC0760c297. Concentrations of 1, 10 
and 50 µg of (A) chicken anti-rPfC0760c297 IgY and (B) chicken anti-rabbit albumin IgY were dotted onto 
nitrocellulose. Blots were incubated with 5 µg rPfC0760c297, and interactions were detected with mouse 
anti-his6tag IgG and goat anti-mouse HRPO-IgG. 
Protein-protein interactions between his6tagged rPfC0760c297 and anti-rPfC0760c297 and 
anti-rabbit albumin chicken IgY antibodies were assessed by far dot blot. rPfC0760c297 
complexed to chicken IgY were detected with mouse anti-his6tag IgG and goat anti-mouse 
HRPO-IgG (Figure 5.1). No interaction is evident with 1 µg, a faint signal is observed with 10 
µg, and a stronger signal is observed with 50 µg chicken anti-rPfC0760c297 IgY (Figure 5.1A). 
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No interaction is observed with chicken anti-rabbit albumin IgY (Figure 5.1B). These antibodies 
were used as positive and negative controls respectively in further protein-protein interaction 
studies with rPfC0760c297.  
5.2.2 Detection of monocyte peroxidase activity by dot blot analysis 
Monocytes exhibit peroxidase activity (Bodel et al., 1977). To determine whether monocyte-
intrinsic peroxidase activity was evident in a dot blot, monocyte lysates were dotted onto 
nitrocellulose along with control proteins, and the substrate was applied. No peroxidase activity 
was evident in either the U937 or J774A.1 monocytes under these conditions (data not shown). 
The control proteins BSA, chicken anti-rabbit albumin IgY, chicken anti-rPfC0760c297 IgY and 
the rPfC0760c297 did not show peroxidase activity (data not shown). Therefore, reactions with 
rPfC0760c297 are due to the binding of the bait protein rPfC0760c297 to prey proteins on the 
blot, and not due to intrinsic monocyte peroxidase activity as a result of the addition of the 
peroxidase substrate.  
5.2.3 Far western blot analysis of control proteins 
 
Figure 5.2: Far western blot analysis of positive and negative controls probed with increasing 
concentrations of rPfC0760c297. (A) Proteins were resolved on 12.5% non-reducing SDS-PAGE and 
stained with Coomassie Blue. Lane 1: chicken anti-rPfC0760c297 IgY, lane 2: BSA, lane 3: rPfC0760c297. 
Far western blots of identical gels were probed with increasing concentrations of rPfC0760c297: (B) 5 
µg, (C) 10 µg, (D) 25 µg, (E) 50 µg and (F) 100 µg. Interactions were detected with mouse anti-his6tag 
IgG and goat anti-mouse HRPO-IgG, and developed by ECL. 
The bait protein used in all far western blot analyses was the rPfC0760c297 protein. To 
determine a suitable concentration of rPfC0760c297 for incubation, chicken 
anti-rPfC0760c297 IgY, BSA and rPfC0760c297 were analysed by far western blot. In the chicken 
anti-rPfC0760c297 IgY sample, several protein bands are present (Figure 5.2A, lane 1). The 
highest concentration of chicken anti-rPfC0760c297 IgY is present at a size which is smaller 
(lane 1) than the 56 kDa rPfC0760c297 (lane 3). Two protein bands in the chicken anti-
rPfC0760c297 IgY sample interacted with a range of concentrations of rPfC0760c297 (Figure 
5.2B – F, lane 1). This does not appear to be a concentration-dependent interaction. No 
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interaction was observed between BSA and rPfC0760c297 (Figure 5.2B – F, lane 2). 
rPfC0760c297 is detected by mouse anti-his6tag IgG (Figure 5.2B – F, lane 3).  
5.2.4 Western blot analysis of monocyte proteins 
Figure 5.3: Western blot of U937 and J774A.1 monocyte lysate proteins. (A) Proteins were resolved 
on 12.5% non-reducing SDS-PAGE and stained with Coomassie Blue. Lane 1: molecular weight marker. 
Lane 2: U937 lysate. Lane 3: J774A.1 lysate. Lane 4: BSA. Lane 6: chicken anti-rabbit albumin IgY. 
Lane 8: chicken anti-rPfC0760c297 IgY. Lane 10: rPfC0760c297. (B) Western blot of an identical gel 
probed with mouse anti-his6tag IgG and goat anti-mouse HRPO-IgG, and developed by ECL. 
To ensure that the primary and secondary antibodies in the detection system do not bind 
non-specifically to monocyte lysate proteins, a western blot was performed. The U937 and 
J774A.1 monocyte lysate proteins and control proteins were probed with mouse anti-his6tag 
IgG (Figure 5.3). The sizes of the proteins from the U937 and J774A.1 lysates ranged from 
smaller than 14 kDa to larger than 116 kDa (Figure 5.3A, lanes 2, 3). The mouse anti-his6tag 
IgG antibody and the goat anti-mouse HRPO-IgG did not detect any human or mouse 
monocyte lysate proteins or control proteins (Figure 5.3B, lanes 2 – 8). Purified rPfC0760c297 
was detected with the mouse anti-his6tag IgG antibody (Figure 5.3B, lane 10). The primary 
antibody binds specifically to his6tag-rPfC0760c297. BSA (Figure 5.3A, lane 4) appears smaller 
in size compared to the 66 kDa band in the molecular weight marker, as non-reducing 
conditions were used.  
5.2.5 Detection of monocyte peroxidase activity by western blot 
To determine if intrinsic monocyte peroxidase activity could be detected, monocyte lysate 
proteins and controls were assessed. Following electrophoretic protein transfer, the U937 and 
J774A.1 monocyte lysate proteins and the control proteins displayed no peroxidase activity 
(data not shown). This corroborates the results obtained by dot blot (Section 5.2.2).  
  
116
66
45
35
25
18
14
1 2 3 4 5 6 7 8 9 10
116
66
45
35
25
18
14
1 2 3 4 5 6 7 8 9 10
kDa kDaA B
61 
5.2.6 Far western blot analysis of monocyte lysate proteins and rPfC0760c297 
 
Figure 5.4: Far western blot analysis of U937 and J774A.1 lysates probed with rPfC0760c297. 
Monocytes were analysed for protein-protein interactions with the rPfC0760c297 protein. (A) Proteins 
were resolved on 12.5% non-reducing SDS-PAGE and stained with Coomassie Blue. Lane 1: molecular 
weight marker. Lane 2: U937 lysate. Lane 3: J774A.1 lysate. Lane 4: BSA. Lane 6: chicken anti-rabbit 
albumin IgY. Lane 8: chicken anti-rPfC0760c297 IgY. Lane 10: rPfC0760c297. (B) Far western blot of an 
identical gel probed with rPfC0760c297. rPfC0760c297-complexes were detected with mouse anti-his6tag 
IgG and goat anti-mouse HRPO-IgG. Results were determined by ECL. 
It was determined that the substrate, primary and secondary antibodies do not produce 
false positive results. These conditions were used to perform a far western blot to determine 
the binding of rPfC0760c297 to monocyte lysate proteins. An interaction is evident between 
several monocyte proteins and rPfC0760c297 (Figure 5.4B lanes 2 and 3). No interaction was 
detected with BSA and chicken anti-rabbit albumin IgY (Figure 5.4B lanes 4 and 6). In the 
chicken anti-rabbit albumin IgY sample, a prominent band of high molecular weight along with 
additional bands at 75 kDa and 45 kDa are present (Figures 5.4A, lane 6). The chicken 
anti-rPfC0760c297 IgY positive control showed a positive reaction, indicating that rPfC0760c297 
is able to bind proteins on the blot, and these interactions can be detected (Figure 5.4B, lane 
8). The rPfC0760c297 protein was detected with the mouse anti-his6tag IgG antibody (Figure 
5.4B, lane 10). The experiment was repeated, and identical results were obtained (data not 
shown). Thus, an interaction between the monocyte lysate proteins and rPfC0760c297 is 
evident.  
5.3 Discussion 
5.3.1 U937 and J774A.1 monocytes used in this study 
The human U937 cell line was propagated from a patient with generalised histiocytic 
lymphoma (Sundström and Nilsson, 1976). The mouse J774A.1 cell line was derived from a 
mouse reticulum cell sarcoma (Ralph and Nakoinz, 1975). These cell lines were chosen as 
they were available, well characterised, simple to culture, and are immune cells likely to interact 
with parasite-infected red blood cells in the bloodstream.  
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Partial characterisation of rPfC0760c297 was performed by determining its protein-protein 
interactions with these mammalian cells by means of far western blot analysis. The PfC0760c 
protein is predicted to be localized to the Plasmodium parasite nucleus. It is speculated that 
this protein may have other functions that are not associated with the nucleus.  
5.3.2 Far western blot of U937 and J774A.1 monocyte proteins with rPfC0760c297 
Protein-protein interactions between monocyte lysates and the rPfC0760c297 protein were 
assessed using the far western blot technique (Wu et al., 2007). This technique is able to 
detect specific proteins from a combination of proteins interacting with a bait protein, which 
may be useful in determining host-parasite interactions (Li et al., 2015). The bait protein may 
be biotinylated and detected with streptavidin, or radiolabelled and detected by 
autoradiography, or detected by an antibody (Hall, 2004). Far western blot analysis has 
successfully been used to determine protein-protein interactions between laminin and 
fibronectin with bacterial cell wall and extracellular matrix proteins (Li et al., 2015), DNA 
replication proteins with DNA repair proteins (Walsh et al., 2012), and erythropoietin with the 
erythropoietin receptor (Fecková et al., 2016).  
The far western blot showed interactions between a range of monocyte proteins from a 
human and mouse cell line, with rPfC0760c297. The far western blot was performed under non-
reducing conditions, as it seemed unlikely that a reduced form of the monocyte proteins would 
offer the correct structure for protein-protein interactions (Hall, 2004). The far western blot 
results indicate that an interaction between rPfC0760c297 with both cell lines is present, and 
not a result of non-specific binding of the antibodies or intrinsic monocyte peroxidase activity. 
5.3.3 Alternative methods to detect protein-protein interactions 
Coupling of rPfC0760c297 to an AminoLink™ resin, and passing the monocyte lysate over 
the resin may reveal protein-protein interactions between monocyte proteins and rPfC0760c297. 
Identification of these proteins may help elucidate the function of PfC0760c. Other in vitro 
methods for detection of protein-protein interactions include tandem affinity purification, co-
immunoprecipitation, protein arrays, protein fragment complementation, phage display, X-ray 
crystallography and nuclear magnetic resonance spectroscopy (Rao et al., 2014). 
5.3.4 Monocyte peroxidase activity 
Monocytes display peroxidase activity, which is localised to granules (Kantari et al., 2008). 
Monocytes prepared in PBS and in non-reducing SDS-PAGE treatment buffer did not display 
peroxidase-like activity. It is possible that these monocytes do not possess peroxidase activity, 
or cell lysis and storage conditions may have contributed to loss of peroxidase activity. 
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5.3.5 Interaction of monocytes with rPfC0760c297 in vivo 
Bioinformatics analyses (Chapter 6) indicates that rPfC0760c297 is likely associated with the 
parasite nucleus. No feasible Plasmodium export element (PEXEL) and transmembrane motifs 
were identified. This suggests that PfC0760c is unlikely to migrate to the infected red blood 
cell surface to facilitate cell-cell interactions. Therefore, it could be argued that an interaction 
may exist between monocyte lysate proteins and rPfC0760c297 as a result of phagocytosis, or 
processing of the infected red blood cells for antigen presentation. Thus, it could be shown by 
experimentation whether an interaction exists between the surface of intact monocytes and 
rPfC0760c297.  
5.3.6 Chicken anti-rPfC0760c297 IgY 
A prominent band at 45 kDa was present in the chicken anti-rPfC0760c297 IgY antibody 
samples on non-reducing SDS-PAGE (Figure 5.2A, lane 1, 5.3A and 5.4A, lane 8). A band of 
high molecular weight was also observed. The size of IgY antibodies under non-reducing 
conditions is ~170 kDa (Sun et al., 2001). The Fab region of IgY is 45 kDa (Sun et al., 2001). It 
is not understood why a higher concentration of protein is observed at 45 kDa. A dominant 
band of high molecular weight and a faint band at 45 kDa is observed for the anti-rabbit albumin 
IgY antibody sample (Figures 5.6A, 5.7A and 5.8A, lane 6).  
5.3.7 Conclusion 
Based on the far western blot, it can be concluded that rPfC0760c297 interacts with 
monocyte proteins. These interactions may be explored further by means of an AminoLink™ 
resin coupled to rPfC0760c297 with the monocyte lysate passed through to identify specific 
monocyte proteins, or in vivo studies. These studies may also be evaluated with native, 
full-length PfC0760c. Different types of cells may also be tested for protein-protein interactions 
with rPfC0760c297. Specific Plasmodium proteins or mammalian proteins may be used as prey 
proteins to determine protein-protein interactions with PfC0760c. 
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Chapter 6: Bioinformatics analyses of PfC0760c 
6.1 Introduction  
Bioinformatics is an invaluable tool that uses computational resources to organise and 
analyse biological data (Luscombe et al., 2001; Kearse et al., 2012). Data organization 
involves the use of databases, web services and search tools; and data analysis makes use 
of algorithms and statistical modelling (Kearse et al., 2012). Bioinformatics may be used to 
assess DNA, RNA, and amino acid sequences. Analyses by bioinformatics tools and 
databases may predict some features of a protein, such as its subcellular localization, 
structure, and characteristics, which may then be confirmed experimentally. Examples of 
databases that are routinely used include the National Centre for Biotechnology Information 
(NCBI) (https://www.ncbi.nlm.nih.gov/), and the ExPASy Bioinformatics Resource Portal 
(http://ww.expasy.org/). 
In this chapter, various bioinformatics tools were used to predict properties of the PfC0760c 
protein. Conserved peptides, epitope prediction, subcellular localization and possible protein 
structure were among the characteristics that were predicted.  
6.2 Methods 
6.2.1 Basic local alignment search tool and sequence alignment 
The Basic Local Alignment Search Tool (BLAST) is a bioinformatics tool used to compare 
sequence data (Altschul et al., 1990). The full-length amino acid sequence of PfC0760c in the 
FASTA format was uploaded to the Protein BLAST (BLASTp) server 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi), and the default BLASTp parameters were used. 
Sequences from human-, simian-, murine- and avian-infecting Plasmodium species were 
chosen. The BLASTp analysis was also performed using PlasmoDB (https://plasmodb.org/) 
and ExPASy (https://web.expasy.org/blast/). Multiple sequence alignment of the sequences 
obtained from the NCBI BLASTp server was performed using Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). Multiple sequence alignment aims to compare 
homologous sequences (Sievers et al., 2011). This program was designed to give fast and 
accurate sequence alignments (Sievers et al., 2011). The Plasmodium sequences (in the 
FASTA format) was uploaded to the server and the alignment was generated. The sequences 
were manually searched for conserved peptides. 
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6.2.2 Presence of B-cell epitopes within PfC0760c 
The B-cell epitopes were experimentally determined using immune sera (Villard et al., 
2007). The Immune Epitope Database and Analysis Resource (https://www.iedb.org/) was also 
scanned for additional B-cell epitopes.  
6.2.3 Prediction of T-cell epitopes within PfC0760c  
SYFPEITHI (http://www.syfpeithi.de/) (Rammensee et al., 1999) is a database compiled of 
ligands and peptide motifs that are known to bind to MHC I and MHC II molecules 
(Rammensee et al., 1999). The PfC0760c sequence was scanned for octamers, nonamers, 
decamers, and endecamers, as well as MHC II 15-mers. 
6.2.4 Predict7 analysis of PfC0760c 
Predict7 predicts protein structural features using algorithms for protein properties including 
hydrophilicity, surface probability, antigenicity and flexibility (Cármenes et al., 1989). 
Hydrophilicity values are calculated according to a Hopp and Woods (1981) scale, surface 
probability by Emini et al. (1985) and Janin et al. (1978), antigenicity by Welling et al. (1985) 
and flexibility by Karplus and Schulz (1985). The PfC0760c amino acid sequence is too long 
for analyses and hence was split into two segments.  
6.2.5 Plasmodium export element and transmembrane domain prediction  
The PfC0760c full-length amino acid sequence was scanned manually for the presence of 
a PEXEL motif with the sequence (K/R)xLx(E/Q) (Marti et al., 2005). The PSEApred server 
(Verma et al., 2008) is a server that is used to predict the secretion of malaria proteins 
(http://www.imtech.res.in/raghava/pseapred/). Prediction of transmembrane domains was 
performed using the TMHMM prediction server (Krogh et al., 2001), which uses a hidden 
Markov model (http://www.cbs.dtu.dk/services/TMHMM-2.0/). 
6.2.6 Functional site prediction of PfC0760c using ScanPROSITE 
Prediction of functional sites within an uncharacterised protein may help define certain 
characteristics. The full-length PfC0760c amino acid sequence was first manually analysed to 
determine the amino acid composition. The ScanPROSITE tool (de Castro et al., 2006) was 
used to predict possible phosphorylation, glycosylation and myristoylation sites 
(http://prosite.expasy.org/scanprosite/).  
To check the validity of the leucine zipper prediction, the full-length amino acid sequence 
was uploaded to the 2ZIP server (http://2zip.molgen.mpg.de/). As the server searches for the 
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leucine zipper motif, it simultaneously employs a coiled-coil prediction algorithm to rule out 
false positives (Bornberg-Bauer et al., 1998).  
6.2.7 Prediction of protein-protein interactions of PfC0760c  
Due to the uncharacterised nature of PfC0760c, determining the protein-protein interactions 
with other P. falciparum proteins would be of interest. The full-length PfC0760c amino acid 
sequence was uploaded to the Search Tool for Recurring Instances of Neighbouring Genes 
(STRING) network (https://string-db.org/). The STRING network aims to predict physical and 
functional interactions between proteins (Szklarczyk et al., 2015). Proteins are retrieved based 
on their genes occurring in the neighbourhood of the query sequence within the genome (Snel 
et al., 2000). The expressed proteins are likely to interact with one another (Snel et al., 2000). 
6.2.8 Detection of conserved domains within the PfC0760c protein 
Protein domains may be evolutionarily conserved. The presence of conserved domains may 
help determine possible functions and subcellular localization of uncharacterised proteins. For 
the identification of conserved domains within the protein, the full-length amino acid sequence 
of PfC0760c and homologous Plasmodium proteins were uploaded to NCBI’s Conserved 
Domain Database (CDD) (https://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi). This 
database compares a query sequence to its compilation of a manually curated collection of 
protein domains and protein family models (Marchler-Bauer et al., 2017). These models and 
domains were gathered from various sources including Pfam, Simple Modular Architecture 
Research Tool, Clusters of Orthologous Groups, TIGRFAMS, the NCBI Protein Clusters 
collection, and NCBI’s internal data collection effort (Marchler-Bauer et al., 2017). 
6.2.9 Prediction of the subcellular localization of PfC0760c 
Determination of protein subcellular localization may give an indication of the function the 
protein may perform (Blum et al., 2009). The MultiLoc2 program uses a support vector machine 
to predict the subcellular localization of proteins based on amino acid composition, presence 
of known protein sorting signals, gene ontology terms and phylogenetic profile of a protein 
(Blum et al., 2009)  (http://abi.inf.uni-tuebingen.de/Services/MultiLoc2).  
NucPred is a program that is able to distinguish proteins that spend time in the nucleus from 
non-nuclear associated proteins (Brameier et al., 2007). To confirm the data obtained from 
MultiLoc2, the NucPred server (https://nucpred.bioinfo.se/cgi-bin/single.cgi) was used. 
Nuclear-associated proteins are identified by the presence of nuclear localization signals (NLS) 
(Brameier et al., 2007). Proteins destined for transport to the nucleus after exo-nuclear 
synthesis contain these NLSs. These signals help mediate transport of these proteins to the 
nucleus (Brameier et al., 2007). NucPred works by assigning a “per-residue” score to each 
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amino acid based on its location in a sequence, and therefore its influence on a nuclear 
classification (Brameier et al., 2007). The PfC0760c protein sequence was uploaded to the 
NucPred server to predict its presence in the nucleus. 
6.2.10 Protein structural prediction of rPfC0760c297 
The PfC0760c protein was predicted to exhibit alpha-helical coiled-coil motifs (Villard et al., 
2007). The 3-D structure of PfC0760c has not yet been determined, thus, the Iterative 
Assembly Refinement (I-TASSER) program (Zhang, 2008) was used to predict the possible 
3-D structure (http://zhanglab.ccmb.med.umich.edu/I-TASSER/). The I-TASSER first threads 
the query sequence against a representative Protein Data Bank library using various alignment 
algorithms. A full-length model is then generated using continuous fragments cut from the 
threading aligned regions. The structure trajectories are clustered. The models are refined, 
and those with the least energy are chosen from each cluster (Zhang, 2008).  
The full-length of the amino acid sequence was too long for the I-TASSER server to process, 
hence the rPfC0760c297 sequence was uploaded. A confidence score (C-score) is assigned to 
each model, where a high confidence is indicated by a high C-score. 
6.3 Results 
6.3.1 BLASTp and multiple sequence alignment 
The PfC0760c amino acid sequence (Accession: O77384.1) was used as a query sequence 
for BLASTp analysis. The expect value, or E-value, defines the statistical significance of the 
match (Boratyn et al., 2013). From the BLASTp output, different Plasmodium sequences were 
chosen for further analysis. The details of each Plasmodial sequence is shown in Table 6.1. 
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Table 6.1: Results from NCBI BLASTp using PfC0760c as the query sequence. 
Plasmodium 
species 
Protein Accession no. Length  E-value 
P. falciparum conserved, unknown function  O77384.1 3394 - 
P. vivax conserved, unknown function  SCO72376.1 2954 2×10-146 
P. malariae conserved, unknown function  SBT01363.1 3628 0 
P. knowlesi conserved, unknown function  XP_002258886.1 2941 6×10-141 
P. reichenowi conserved, unknown function  SOV75936.1 3436 0 
P. cynomolgi hypothetical protein PCYB_083240 XP_004222110.1 3058 1×10-97 
P. coatneyi 
uncharacterised protein 
PCOAH_00021130 
XP_019914485.1 2831 2×10-149 
P. gonderi conserved, unknown function  GAW80650.1 3313 1×10-166 
P. inui hypothetical protein C922_02043 XP_008815864.1 2930 4×10-92 
P. gaboni conserved, unknown function  SOV10972.1 3438 0 
P. berghei conserved, unknown function  SCO59523.1 2841 5×10-80 
P. berghei ANKA conserved, unknown function  XP_672614.2 2840 5×10-80 
P. yoelii conserved, unknown function  XP_726266.2 2891 1×10-11 
P. yoelii 17X hypothetical protein YYC_02699 ETB60413.1 2879 1×10-78 
P. chabaudi 
chabaudi 
conserved, unknown function  SCM20838.1 2870 6×10-163 
P. chabaudi adami conserved, unknown function  SCM20066.1 2860 6×10-162 
P. vinckei vinckei hypothetical protein YYE_01881 XP_008623771.1 2818 2×10-161 
P. vinckei petteri hypothetical protein YYG_01058 EUD73968.1 2854 3×10-161 
P. gallinaceum  conserved, unknown function  CRG94286.1 2890 2×10-79 
Plasmodial human malaria species included P. malariae, P. vivax and P. knowlesi; simian 
malaria species included P. knowlesi, P. reichenowi, P. cynomolgi, P. coatneyi, P. gonderi, 
P. inui, and P. gaboni; mouse malaria species included P. berghei, P. berghei ANKA, P. yoelii, 
P. yoelii 17X, P. chabaudi chabaudi, P. chabaudi adami, P. vinckei vinckei, and P vinckei 
petteri. An avian malaria species, P. gallinaceum, was also identified. BLASTp analysis 
indicated that these Plasmodium proteins were all conserved with unknown functions. No 
homologous human proteins were identified using NCBI BLASTp or ExPASy (Appendix B, 
Table B.2). The sequences shown in Table 6.1 were aligned using Clustal Omega. 
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Figure 6.1: Relationship between PfC0760c and homologous Plasmodium protein sequences. 
The cladogram was generated after sequence alignment using Clustal Omega.  
The output from Clustal Omega generated a cladogram showing the relationship between 
the PfC0760c and homologous Plasmodium protein sequences. Curiously, the closest-related 
proteins to PfC0760c were P. reichenowi and P. gaboni infecting simians, and surprisingly, the 
avian-infecting parasite P. gallinaceum (Figure 6.1). Homologous PfC0760c proteins from 
Plasmodium species infecting humans are related to simian-infecting species. As expected, 
the sequences from mouse malaria were all closely related to each other.  
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A 
P. gaboni  HLHNI-EDKYKNIYERYFNLFNFNFSNVELSFDLFLRRFDKILR     1119 
P. falciparum  HIHNI-EDKYKKVYERYFNLFNFNFSNVELSFDLLIRRFDKILR     1205 
P. reichenowi  HIHNI-EDKYKKVYERYFNLFNFNFSNVELSFDLLIRRFDKILR     1161 
P. gonderi  NLYSM-DEKEKNVYERYYNLFNLNFSNVEISFDLLLNRFEKIVK     944 
P. cynomolgi  NLFDM-EAKYKVVYERYFNLFNLNFSNVEISFDLLLNRFERIIR     869 
P. inui   NLHDM-EEKYKLVYERYFNLFNLNFSNVEISFDLLLNRFERIIR     874 
P. vivax  NLVDVMEAKNKLVYERYFNLFNLNFSNVEISFELLLNRFERIIR     903 
P. knowlesi  NLFDM-EEKYKVVYERYFNLFNLNFSNVEISFDLLMNRFERIIR     863 
P. coatneyi  NLFDM-EEKYKVVYERYFNLFNLNFSNVEISFDLLLNRFERIIR     858 
P. yoelii  NLFNV-ETKHKNVYERYFNLFNLNFSNVEISFDLLLKRFYKILR     943 
P. yoelii 17X  NLFNV-ETKHKNVYERYFNLFNLNFSNVEISFDLLLKRFYKILR     940 
P. berghei ANKA NLFNV-ETKHKNVYERYFNLFNLNFSNVEISFDLLLKRFYKILR     939 
P. berghei  NLFNV-ETKHKNVYERYFNLFNLNFSNVEISFDLLLKRFYKILR     939 
P. vinckei vinckei NLFNS-ETKHKNVYERYFNLFNLNFSNVEISFDLLLKRFYQILR     941 
P. vinckei petteri NLFNN-ETKHKNVYERYFNLFNLNFSNVEISFDLLLKRFYKILR     941 
P. chabaudi chabaudi NLFNV-ETKHKNVYERYFNLFNLNFSNVEISFDLLLKRFYKILR     941 
P. chabaudi adami NLFNV-ETKHKNVYERYFNLFNLNFSNVEISFDLLLKRFYKILR     941 
P. malariae  NLYSIMDDKYKNVYERYFNLFNLNFSNVEISFDLLLRRFHQIVR     1047 
P. gallinaceum  NLYNI-ENEYKTIYERYFNLFNLNFSNVELSFDLLLRRFNKILR     826 
         :: .  : : * :****:****:******:**:*::.** :*:: 
 
 
B 
P. gaboni  NKEKNSSEEIYKYINENIDLTSELEKKNDIIDNYKNELKEKNEE     2091 
P. falciparum  NKERNLSQEIYKYINENIDLTSELEKKNDMLENYKNELKEKNEE     2209 
P. reichenowi  NKERNLSQEIYKYINENIDLTSELEKKNDMLENYKNELKEKNEE     2185 
P. gonderi  NEKTTVSVEIYKYINENIDLTAELENKNEFIDKLKEEVKEKEDQ     1778 
P. cynomolgi  TANTDVSLEIHKYISENIDLTAELENRNEVIEQCREEAKQKDKE     1672 
P. inui   ASTTDMPLEIHKYISENIDLTAELENRNEVIEQCREEARQKEME     1706 
P. vivax  GGTSKGPLEIYKYIGENIDLTAELENRNEVIEQCREEAREKDQQ     1693 
P. knowlesi  GNTSNVSLEIHKYISENIDLTAELENRNEVIEQCKEETRQKDKE     1675 
P. coatneyi  ANPSNVSIEIHKYISENIDLTAELENRNEVIEQCREEAKQKDKE     1672 
P. yoelii  SQNNQLSLEIYKYINENIDLTAELENKNDVIEQMKEDIKNKNKE     1773 
P. yoelii 17X  SQNNQLSLEIYKYINENIDLTAELENKNDVIEQMKEDIKNKNKE     1770 
P. berghei ANKA SQNNQVSLEIYKYINENIDLTAELENKNDIIEQMKEDVKNKNKE     1721 
P. berghei  SQNNQVSLEIYKYINENIDLTAELENKNDIIEQMKEDVKNKNKE     1721 
P. vinckei vinckei TQDNQVSLEIYKYINENIDLTAELENKNDIIEQMKEELNNKNME     1774 
P. vinckei petteri SQDNQVSLEIYKYINENIDLTAELENKNDMIEQMKEELNNKNME     1773 
P. chabaudi chabaudi SQDNQVSLEIYKYINENIDLTAELENKNDIIEQMKEELNNKNME     1773 
P. chabaudi adami SQDNQVSLEIYKYINENIDLTAELENKNDIIEQMKEELNNKNME     1773 
P. malariae  NEQQNVSLEIYKYINENIDLTAELENKYDVIEKCKDEIKVKNDE     1905 
P. gallinaceum  RNNEHISLEIYKYINENIDLTAELENKNELLDKFKEEIKQKNDE     1611 
           **:***.******:***:: :.::: ::: . *: : 
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C 
P. gaboni  DNIIIIKFNILKLFKLGSCYLYIINRNLKEIQILKNQIISLEES     2315 
P. falciparum  DNIIIIKFNILKLFKLGSCYLYIINRNLKEIQMLKNQILSLEES     2416 
P. reichenowi  DNIIIIKFNILKLFKLGSCYLYIINRNLKEIQMLKNQILSLEES     2440 
P. gonderi  EQIVIIKCNILKLFKLGSCYLYIINRNMKEIQVLKNQVNSLEQS     1952 
P. cynomolgi  EHIVIIKCNILKLFKLGSCYLYIINRNMKEIQILKNQVSSLKQN     1837 
P. inui   EHIVIIKCNILKLFKLGSCYLYIINRNLKEIQILKNQVSSLKES     1863 
P. vivax  EHIVIIKCNILKLFKLGSCYLYIINRNMKEIQILKNQVSSLKQS     1850 
P. knowlesi  EHIVIIKCNILKLFKLGSCYLYIINRNLKEIQVLKNEVSSLKQS     1832 
P. coatneyi  EHIVVIKCNILKLFKLGSCYLYIINRNLKEIQILKNQVSSLKQS     1826 
P. yoelii  DHITLIKCNILKMFKLGSCYLYIINRNLKEIKILKDKIHSFEEN     1964 
P. yoelii 17X  DHITLIKCNILKMFKLGSCYLYIINRNLKEIKILKDKIHSFEEN     1961 
P. berghei ANKA DHITLIKCNILKMFKLGSCYLYIINRNLKEIKILKDKINYLEEN     1987 
P. berghei  DHITLIKCNILKMFKLGSCYLYIINRNLKEIKILKDKINYLEEN     1985 
P. vinckei vinckei DHITLIKCNILKMFKLGSCYLYIINRNLKEIKILKDKINSLEEN     1961 
P. vinckei petteri DHITLIKCNILKMFKLGSCYLYIINRNLKEIKILKDKINSLEEN     1959 
P. chabaudi chabaudi DHITLIKCNILKMFKLGSCYLYIINRNLKEIKILKDKINSLEDN     1959 
P. chabaudi adami DHITLIKCNILKMFKLGSCYLYIINRNLKEIKILKDKINSLEEN     1959 
P. malariae  ENIIVIKCNILKLFKLGSCYLYIINRNLKEIQILKKQVSSLEEN     2146 
P. gallinaceum  DNIIIIKCNILKLFKLSSCYLYIINRNLKEIQNLKNQVSCLEQS     1770 
   ::* :** ****:***.**********:***: **.::  :::. 
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Figure 6.2: Multiple sequence alignment of PfC0760c and homologous Plasmodium proteins 
showing conserved peptides. Sequences were obtained by NCBI BLASTp and aligned with Clustal 
Omega. Conserved peptides are indicated in red. PfC0760c is shown from (A) N1163 – N1205, (B) 
N2166 – N2209, (C) N2373 – N2416. The . indicates a similar residue, the : indicates similar 
physicochemical properties, and * indicates an exact match. (D) Schematic of full-length PfC0760c 
indicating the positions of the three conserved peptides in red, and the expressed region in green. 
The homologous PfC0760c Plasmodial sequences shown in Table 6.1 were aligned using 
Clustal Omega, and three conserved peptides were identified (Figure 6.2). A conserved 
26-mer (N1175 – N1200) (denoted further as YERY), 17-mer (N2174 – N2190) (denoted 
further as EIYK) and 23-mer (N2381 – N2403) (denoted further as NILK) were identified. The 
YERY peptide, which was also found using sequences from ExPASy, corresponds to 
YERY(F/Y)NLFN(F/L)NFSNVE(L/I)SF(D/E)L(L/F)(I/L/M)(R/N/K)RF (Figure 6.2A). Alignment 
of homologous Plasmodium PfC0760c protein sequences from PlasmoDB revealed an 
identical conserved sequence, where the first substitution of phenylalanine to tyrosine is not 
seen. This substitution is only observed in the P. gonderi sequence, which was absent from 
the PlasmoDB BLASTp result. The EIYK and NILK peptides were 
EI(Y/H)KYI(N/G/S)ENIDLT(A/S)ELE and NILK(L/M)FKL(G/S)SCYLYIINRN(L/M)KEI 
respectively (Figure 6.2B and 6.2C), and identical results were obtained with the sequences 
from ExPASy and PlasmoDB. The NILK peptide is found within the rPfC0760c297 sequence. 
Apart from the substitution of arginine and leucine in PfC0760c with lysine and methionine 
N C
expressed region
YERY EIYK NILK
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respectively in Plasmodium species infecting mice (Figure 6.2A and 6.2C), there is no 
noticeable pattern in the differences observed within the conserved sequences. Accession 
numbers for the Plasmodium sequences obtained from PlasmoDB and ExPASy are included 
in Appendix B (Tables B.1 and B.2). The schematic of the PfC0760c protein sequence 
indicates the positions of the conserved peptides and the expressed region (Figure 6.2D) 
within the PfC0760c amino acid sequence.  
The conserved peptides were subject to NCBI BLASTp analysis. A threshold was included, 
where matches with an E-value above 0 were not considered. Species already present in 
Table 6.1 were also excluded. 
Table 6.2: BLASTp analyses of the PfC0760c conserved peptides YERY, EIYK and NILK. 
Plasmodium 
species 
Protein Accession no. 
E-value 
YERY EIYK NILK 
P. fragile 
hypothetical protein 
AK88_00579 
XP_012333650.1 1×10-15 2×10-5 1×10-15 
P. relictum conserved, unknown CRG99782.1 2×10-13 2×10-8 1×10-15 
P. ovale 
wallikeri 
conserved, unknown SBT34370.1 NA NA 2×10-8 
P. ovale curtisi conserved, unknown SBS82982.1 2×10-6 NA 4×10-7 
NA: not applicable, E-values above threshold 
Four additional Plasmodium species were identified (Table 6.2). These included P. fragile 
which infects simians, P. relictum which infects birds, and P. ovale wallikeri and P. ovale curtisi 
which infects humans. A match between the conserved peptides YERY and EIYK with P. ovale 
wallikeri, and the EIYK peptide with P. ovale curtisi is unlikely. 
NYLVNNLQLNKDNDNIIIIKFNILKLFKLGSCYLYIINRNLKEIQMLKNQILSLEESIKSLNEFINNLKNENEKN
ELIKINNFEEILKLKNNLQDNESCIQNLNNYLKKNEELNKINVKNIFKYKGYIIHLIQQSNVFCKIFKHFNENKI
IDQSIINKLLYLKKSFDFYMYDSVIQEIRENKNIIINQDFLTDEYFKHIQTFTKTCNVLIQRGYLSILKDTNNDF
FIQNKQSNQQGNQNGNHINMCNIYPDDEINVTADQQIFDGTENVQQSLQNEEDYVNNEEMYTDKMDLDNNMN 
Figure 6.3: Amino acid sequence of rPfC0760c297. The conserved peptide sequence and B-cell 
epitope are indicated in red and blue boxes respectively.  
The 297-amino acid sequence of rPfC0760c297 is illustrated, and the conserved NILK 
peptide and a B-cell epitope is indicated (Figure 6.3). The alignments of the conserved NILK 
peptide and B-cell epitope are shown in Figures 6.2C and Figure 6.4B. 
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6.3.2 Identification of B-cell epitopes within PfC0760c 
Two B-cell epitopes were identified by Villard et al. (2007). The multiple sequence alignment 
is illustrated. No additional B-cell epitopes were identified by the Immune Epitope Database 
and Analysis Resource. 
 
A 
P. gaboni  IIDNYKNELKEKNEEIYKLNDHINMLSNNCKKLKESIIMMENYK     2120 
P. falciparum  MLENYKNELKEKNEEIYKLNNDIDMLSNNCKKLKESIMMMEKYK     2238 
P. reichenowi  MLENYKNELKEKNEEIYKLNNDIDMLSNNCKKLKESIMMMEKYK     2214 
P. gonderi   FIDKLKEEVKEKEDQIRKLNDNMSNMSHSMDKLKESVIIMEKYK     1807 
P. cynomolgi   VIEQCREEAKQKDKEINKLHDEIAALSRSMTKLKESLLVMEQYK     1701 
P. inui   VIEQCREEARQKEMEIQKLHDDIASLSRSMTKLKESLIVMEQYK     1735 
P. vivax  VIEQCREEAREKDQQIKKLHEDVDALTRSMAKLKDSLSVMEQYK     1722 
P. knowlesi  VIEQCKEETRQKDKEIKKLHDDIAALSCSITKLKESLMLMEQYK     1704 
P. coatneyi  VIEQCREEAKQKDKEIKKLHEEITTLSSNIAKMKESLTLMEQYK     1701 
P. yoelii  VIEQMKEDIKNKNKEIAKLNKDVINLSTNYDKLKESIYMMEKHK     1802 
P. yoelii 17X  VIEQMKEDIKNKNKEIAKLNKDVINLSTNYDKLKESIYMMEKHK     1799 
P. berghei ANKA IIEQMKEDVKNKNKEIAKLNKDVINLSANYDKLKESIYMMEKHK     1800 
P. berghei  IIEQMKEDVKNKNKEIAKLNKDVINLSANYDKLKESIYMMEKHK     1800 
P. vinckei vinckei IIEQMKEELNNKNMELAKLNKDVINLSANYDKLKESIYMMEKHK     1803 
P. vinckei petteri MIEQMKEELNNKNMELAKLNKDIINLSTNYDKLKESIYMMEKHK     1802 
P. chabaudi chabaudi IIEQMKEELNNKNMELAKLNKDVINLSTNYDKLKESIYMMEKHK     1802 
P. chabaudi adami IIEQMKEELNNKNMELAKLNKDVINLSTNYDKLKESIYMMEKHK     1802 
P. malariae  VIEKCKDEIKVKNDEIDKLNKDISILSKRCNQFEESLIIMEKHK     1934 
P. gallinaceum  LLDKFKEEIKQKNDEINKLNDEILKLSRSCNKLNESIMIMEKHK     1640 
   .::: ::: . *: :: **:..:  ::    ::::*: :**::* 
B 
P. gaboni  NRNLKEIQILKNQIISLEESIKSLNEFINNLKNENEKNELIKIN     2339 
P. falciparum  NRNLKEIQMLKNQILSLEESIKSLNEFINNLKNENEKNELIKIN     2440 
P. reichenowi  NRNLKEIQMLKNQILSLEESIKSLNEFINNLKNENEKNELIKIN     2464 
P. gonderi  NRNMKEIQVLKNQVNSLEQSIESLNEFIKNLKNENKQNEIIRVN     1976 
P. cynomolgi  NRNMKEIQILKNQVSSLKQNIQTQNEFIHNLKAKNKNNEVIQVN     1861 
P. inui   NRNLKEIQILKNQVSSLKESIQTQNEFIQSLKTKNKNNEVIQVN     1887 
P. vivax  NRNMKEIQILKNQVSSLKQSIQTQNAFIQSLKKENKKNEVIQVN     1874 
P. knowlesi  NRNLKEIQVLKNEVSSLKQSIQTQNEFIQSLKTKNEKDRVIQVS     1856 
P. coatneyi  NRNLKEIQILKNQVSSLKQSIQTQNEFIQSLKTKNEKNEVIQVN     1850 
P. yoelii  NRNLKEIKILKDKIHSFEENIQSLNLFINNLKDQHKNNEMIKIN     1988 
P. yoelii 17X  NRNLKEIKILKDKIHSFEENIQSLNLFINNLKDQHKNNEMIKIN     1985 
P. berghei ANKA NRNLKEIKILKDKINYLEENIQSLNLFINNLKDQNKNNEVIKIN     2011 
P. berghei  NRNLKEIKILKDKINYLEENIQSLNLFINNLKDQNKNNEVIKIN     2009 
P. vinckei vinckei NRNLKEIKILKDKINSLEENIQSLNVFINNLKDQNKNNEVIKIN     1985 
P. vinckei petteri NRNLKEIKILKDKINSLEENIQSLNLFINNLKDQNKNNEVIKIN     1983 
P. chabaudi chabaudi NRNLKEIKILKDKINSLEDNIQSLNLFINNLKDQNKNNEVIKIN     1983 
P. chabaudi adami NRNLKEIKILKDKINSLEENIQSLNLFINNLKDQNKNNEVIKIN     1983 
P. malariae  NRNLKEIQILKKQVSSLEENIESLNQFINNLKDENNKNELINVS     2170 
P. gallinaceum  NRNLKEIQNLKNQVSCLEQSIESLNKFIDNLKDENNKNELIKVN     1794 
   ***:***: **.::  :::.*:: * **..** :::::.:*.:. 
 
Figure 6.4: Multiple sequence alignment of PfC0760c B-cell epitopes. Epitopes were identified 
(Villard et al., 2007), and sequences were aligned with Clustal Omega. Conserved amino acids are 
indicated in blue. The P. falciparum regions from (A) N2194 – N2238 and (B) N2396 - N 2440 are shown. 
The . indicates a similar residue, the : indicates similar physicochemical properties, and * indicates an 
exact match.  
74 
The B-cell epitopes appear to be conserved between PfC0760c, P. reichenowi and P. 
gaboni (Figure 6.4A and 6.4B). The first PfC0760c B-cell epitope (N2208 – N2235) is a 29-mer 
with the sequence EEIYKLNNDIDMLSNNCKKLKESIMMMEK and is found downstream from 
the conserved EIYK peptide. The second B-cell epitope (N2401 – 2429) is a 28-mer with the 
sequence KEIQMLKNQILSLEESIKSLNEFINNLKN found within the recombinant sequence, 
overlapping the conserved NILK peptide. Identification of these B-cell epitopes suggests that 
PfC0760c has immunogenic regions.  
6.3.3 Prediction of T-cell epitopes within PfC0760c 
Using the SYFPEITHI epitope prediction server, numerous (more than 100) T-cell epitopes 
were obtained using the cloned region PfC0760c sequence (data not shown). The program 
predicted numerous octamers, nonamers, decamers, and endecamers; and these epitopes 
overlap each other. Numerous MHC II epitopes were found for H2-Ad, H2-Ak, H2-Ed, H2-Ek, 
HLA-DRB1*0101, HLA-DRB1*0301, HLA-DRB1*0401 (DR4Dw4), HLA-DRB1*0701, 
HLA-DRB1*1101, and HLA-DRB1*1501 (DR2b). Epitopes were also found in the conserved 
sequence. Prediction of multiple T-cell epitopes suggests that the PfC0760c protein is 
immunogenic. 
6.3.4 Predict7 analysis of PfC0760c 
Predict7 uses statistical modelling to determine protein characteristics and was used to 
predict the hydrophilicity, surface probability, flexibility and antigenicity of rPfC0760c297 (Figure 
6.5). These characteristics were also analysed for the individual conserved peptide sequences 
(Figure 6.6) and B-cell epitopes (Figure 6.7). 
The rPfC0760c297 protein is largely hydrophobic, with 10 hydrophilic peaks across the 297-
amino acid region (Figure 6.5). Three peaks are observed for flexibility of the protein, and one 
peak for antigenicity. Large portions of the rPfC0760c297 protein have a high surface prediction, 
however, these regions are predicted to have a low hydrophilicity.
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Figure 6.5: Predict7 analysis of the 297-amino acid sequence of rPfC0760c297. The region from N2360 – N2656 was cloned. The conserved NILK peptide 
and 28-mer B-cell epitope are indicated in the red and blue boxes respectively. Hydrophilicity and surface probability are indicated on the primary axis, flexibility 
and antigenicity are indicated on the secondary axis.
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Figure 6.6: Predict7 analysis of conserved PfC0760c peptides. Conserved peptides were identified 
after multiple sequence alignment. Hydrophilicity and surface probability are indicated on the primary 
axis, antigenicity and flexibility are indicated on the secondary axis. The following peptides were 
analysed: (A) N1165 – N1211, and the conserved peptide YERY is from N1175 - N1200, (B) N2163 – 
N2179, and the conserved EIYK peptide is from N2174 – N2190 and (C) N2371 – N2413 and the 
conserved peptide NILK is from N2381 – N2403. 
The conserved YERY peptide is predicted to have a largely inflexible structure, with low 
hydrophilicity, surface probability and antigenicity (Figure 6.6A). The N-terminal of the EIYK 
peptide is predicted to have surface exposure, however with low hydrophilicity, antigenicity and 
flexibility, with the C-terminal having a higher hydrophilicity and flexibility (Figure 6.6B). The 
NILK peptide found in the recombinant protein sequence has a low probability of hydrophilicity, 
surface exposure, flexibility and antigenicity. These probabilities are increased at the C-
terminal of the peptide (Figure 6.6C). 
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Figure 6.7: Predict7 analysis of B-cell epitopes from PfC0760c. B-cell epitopes were identified 
(Villard et al., 2007). Hydrophilicity and surface probability are indicated on the primary axis, antigenicity 
and flexibility are indicated on the secondary axis. Peptides shown are from (A) N2198 – N2245 with 
the N2208 – 2235 29-mer B-cell epitope and (B) N2391 – 2439 with the N2401 – 2428 28-mer B-cell 
epitope. (Villard et al., 2007). 
A single region was observed within the 29-mer B-cell epitope corresponding to 
hydrophilicity, surface exposure, flexibility and antigenicity (Figure 6.7A), and a single region 
was observed for the 28-mer B-cell epitope, although at this peak, there is low antigenicity 
(Figure 6.7B) 
6.3.5 Identification of PfC0760c PEXEL motifs 
To predict whether PfC0760c is a secreted protein, the amino acid sequence was manually 
scanned for Plasmodium export element motifs with the consensus sequence (K/R)xLx(Q/E) 
(Marti et al., 2005).  
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Table 6.3: Detection of PEXEL motifs in the PfC0760c protein sequence. 
Sequence Position Sequence Position 
KYLRQ 298 – 304 KHLEQ 1845 – 1849 
KLLNE 704 – 708 RNLSQ 2169 – 2173 
KKLDE 718 – 722 RNLKE* 2398 – 2402 
KQLQE 1299 – 1303 KKLKE* 2225 – 2229 
KSLQE 1596 – 1600 KSLNE* 2418 – 2422 
* indicates sequences found within the cloned region. 
Ten PEXEL motifs were found within the PfC0760c protein, three of which are present in 
the recombinant protein (Table 6.3). For secretion, a Plasmodium PEXEL motif should lie at 
the N-terminus of the amino acid sequence (Marti et al., 2005). The PEXEL motif closest to 
the N-terminus corresponds to the sequence KYLRQ from position 298 – 304. Thus, the 
PfC0760c is unlikely to be secreted as none of the PEXEL motifs lie close to the N-terminus. 
PSEApred is a database comprising P. falciparum secreted and non-secreted proteins, which 
confirmed that PfC0760c is not a secreted protein (data not shown) (Verma et al., 2008). No 
transmembrane helices were predicted by TMHMM for PfC0760c (data not shown) (Krogh et 
al., 2001). 
6.3.6 Functional site predictions of PfC0760c 
To help characterise the PfC0760c protein, the prevalence of each amino acid was 
manually determined. The amino acid prevalence is expressed as a percentage of the length 
of the sequences (Figure 6.8A and 6.8B). 
 
Figure 6.8: Amino acid composition of PfC0760c and rPfC0760c297. Amino acids were expressed 
as a percentage of the sequences. (A) Full-length (3394 amino acids) PfC0760c and (B) rPfC0760c297 
(297 amino acids) sequences were analysed. 
The polar amino acid asparagine is the most prevalent amino acid, accounting for 21% and 
18% in the full-length and recombinant sequences respectively. Alanine, proline and 
tryptophan are the least prevalent amino acids in both sequences, and these are non-polar 
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residues. Only three tryptophan residues are present in the full-length protein, and none in the 
recombinant protein. 
Within the full-length sequence, 34 cysteine residues are present, which are likely to 
participate in disulfide bond formation (Sevier and Kaiser, 2002). 4 of these cysteine residues 
are conserved at positions N123, N176, N2391 and N3128. The cysteine at position N2391 is 
found in the rPfC0760c297 sequence. However, data obtained from PredictProtein, using the 
DISULFIND tool did not predict any disulfide bonds (data not shown) (Ceroni et al., 2006).  
Aspartate and lysine each account for ~11% of the protein, and 69 lysine residues are 
conserved throughout the species. The lysine residue at position N1269 of PfC0760c was 
found to be acetylated in the trophozoite nucleus (Miao et al., 2013). The multiple sequence 
alignment showing the PfC0760c lysine at position N1269 is shown (Figure 6.9). 
 
P. gaboni   INEKYLLLEKEYEEYQNKNLFINEQLE 1206  
P. falciparum PfC0760c  INEKYLILEKEYEEYQNKNIFINAQIE 1292 
P. reichenowi   INEKYFILEKEYKEYQNKNLFINEQIE 1248 
P. gonderi   MNTKHTMLENECKEHICKNNLLNGKYE 1031 
P. cynomolgi   VVNNHAVLQNECKEHKCKNDLLIDKYE 956 
P. inui    VINSHAVLQNECKEHKCKHDLLIEKYE 961 
P. vivax   VANNHAILQNECKEHKCKNDLLSDKYE 990 
P. knowlesi   MVNSQVILQNECKEHKCKHDLLVDKYE 950 
P. coatneyi   VLNNQVVLQNECKEHKCKHDHLLDMYE 945 
P. yoelii   ISEKYFQLEKEYNEYKNNNSLILEQYE 1030 
P. yoelii 17X   ISEKYFQLEKEYNEYKNNNSLILEQYE 1027 
P. berghei ANKA  INEKYFQLEKEYNEYKNNNCIIMEQYE 1026 
P. berghei   INEKYFQLEKEYNEYKNNNCIIMEQYE 1026 
P. vinckei vinckei  INEKYFQLEKEYNEYKNNNSLILEQYE 1028 
P. vinckei petteri  INEKYFQLEKEYNEYKNNNSLILEQYE 1028 
P. chabaudi chabaudi  INEKYFQLEKEYNEYKNNNSLILEQYE 1028 
P. chabaudi adami  INEKYFQLEKEYNEYKNNNSLVLEQYE 1028 
P. malariae   FNEKYLLLQNEYEECKNKNIFINELCE 1134 
P. gallinaceum    FNEKYILLQNEFHQYKNKYIFIIEEFE 913 
     .  .   *::* .:   :   :    * 
Figure 6.9: Multiple sequence alignment of PfC0760c with homologous proteins from 
Plasmodium species showing an acetylated lysine residue. The PfC0760c sequence shown is from 
N1266 – N1292. The acetylated lysine residue is N1269 in PfC0760c, indicated in orange. The . 
indicates a similar residue, the : indicates similar physicochemical properties, and * indicates an exact 
match. 
The acetylated lysine residue at position N1269 on PfC0760c is not conserved between the 
species (Figure 6.9). The aligned lysine residue in the P. cynomolgi, P. inui, P. vivax, P. 
knowlesi, P. coatneyi and P. inui sequences were substituted with asparagine and serine 
residues. 
To predict potential sites for enzymatic targeting and functional sites, the full-length amino 
acid sequence of PfC0760c was uploaded to the ScanPROSITE tool. The program scans the 
protein sequence against a database comprising different motifs.   
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Table 6.4: Analysis of the full-length PfC0760c protein sequence using the PROSITE prediction 
software. 
Motif Location 
Tyrosine Phosphorylation 
(K/RxxxD/ExxxY) 
15 - 21; 100 - 107; 222 - 230; 395 - 401; 581 - 589; 704 - 712; 
729 - 735; 1026 - 1032; 1084 - 1090; 1119 - 1127; 1222 - 1230; 
1659 - 1667; 1736 - 1742; 1845 - 1852; 2204 - 2211; 2353 - 2361; 
2522 - 2530; and 2800 - 2807.  
Casein Kinase II Phosphorylation 
(S/T*xxD/E) 
129 - 132 S; 172 - 175 T; 177 - 180 S; 534 - 537 T; 579 - 582 S; 
619 - 622 S; 750 - 753 S; 755 - 758 T; 781 - 784 S; 847 - 850 S; 
865 - 868 T; 923 - 926 S; 950 - 953 S; 988 - 991 S; 1049 - 1052 
S; 1067 - 1070 S; 1085 - 1088 S; 1122 - 1125 T; 1133 - 1136 S; 
1187 - 1190 S; 1436 - 1439 S; 1587 - 1590 S; 1597 - 1600 S; 
1621 - 1624 T; 1633 - 1636 S; 1660 - 1663 S; 1934 - 1937 S; 
1960 - 1963 T; 1996 - 1999 T; 2055 - 2058 T; 2082 - 2085 S; 
2111 - 2114 T; 2159 - 2162 T; 2187 - 2190 S; 2271 - 2274 S; 
2279 - 2282 S; 2290 - 2293 S; 2310 - 2313 T; 2412 - 2415 S; 
2419 - 2422 S; 2580 - 2583 T; 2806 - 2809 T; 2820 - 2823 S; 
2844 - 2847 T; 2962 - 2965 S; 2978 - 2981 S; 3040 - 3043 S; 
3064 - 3067 T; 3132 - 3135 S; 3133 - 3136 S; 3271 - 3274 S; 
3280 - 3283 T; 3315 - 3318 S; 3329 - 3332 S; and 3386 – 3389 T.  
Protein Kinase C Phosphorylation 
site (S/T*xK/R) 
177 - 179 S; 199 - 201 S; 368 - 370 S; 542 - 544 S; 546 - 548 S; 
555 - 557 S; 560 - 562 S; 579 - 581 S; 597 - 599 S; 781 - 783 S; 
865 - 867 T; 890 - 892 S; 896 - 898 T; 1104 - 1106 S; 1207 - 1209 
T; 1436 - 1438 S; 1442 - 1444 S; 1484 - 1486 S; 1555 - 1557 S; 
1625 - 1627 S; 1926 - 1928 T; 2031 - 2033 S; 2159 - 2161 T; 
2304 - 2306 S; 2416 - 2418 S; 2646 - 2648 T; 2994 - 2996 S; and 
3315 - 3317 S.  
N-Myristoylation site 
(G[N/I]xx[N/G/S][N/S/M/D]) 
28 - 33; 519 - 524; 2595 - 2600; 2599 - 2604; 2706 - 2711; and 
2935 - 2940.  
N-Glycosylation site (Nxxx) 
258 - 261; 287 - 290; 346 - 349; 366 - 369; 374 - 377; 408 - 411; 
539 - 542; 553 - 556; 594 - 597; 611 - 614; 617 - 620; 767 - 770; 
1047 - 1050; 1065 - 1068; 1083 - 1086; 1120 - 1123; 1185 - 1188; 
1431 - 1434; 1440 - 1443; 1456 - 1469; 1471 - 1474; 1499 - 1502; 
1532 - 1535; 1658 - 1661; 1890 - 1893; 1917 - 1920; 2157 - 2160; 
2170 - 2173; 2269 - 2272; 2300 - 2303; 2455 - 2458; 2614 - 2617; 
2715 - 2718; 2773 - 2776; 2813 - 2816; 2816 - 2819; 2937 - 2940; 
2941 - 2944; 2945 - 2948; 3050 - 3053; 3125 - 3128; 3141 - 3144; 
3295 - 3298; and 3305 - 3308. 
cAMP- and cGMP- dependent 
protein kinase phosphorylation site 
([K/R][K/R]xx) 
430 - 433; 878 - 881; 879 - 882; 893 - 896; 1384 - 1387; and 2998 
– 3001 
 
Leucine zipper 
(LxxxxxxLxxxxxxLxxxxxxL) 
2406 – 2427 
*Serine or threonine residue required for phosphorylation. Presence of serine (S) or threonine (T) 
residue is indicated with the sequence. 
Underlined sequences indicate that the sequence falls within the cloned region. Sequences shown in 
red indicate that the sequence is found within the conserved peptides YERY or EIYK. 
 
The positions of the amino acid sequences within PfC0760c that are predicted to participate 
in tyrosine phosphorylation, casein kinase II phosphorylation, protein kinase C 
phosphorylation, N-myristoylation, glycosylation, and cAMP- and cGMP-dependent protein 
kinase phosphorylation sites, as well as a leucine zipper are shown (Table 6.4). There are 
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many sites within the full-length PfC0760c protein for phosphorylation, most of which are for 
casein kinase II. Three casein kinase II phosphorylation sites, two protein kinase C 
phosphorylation, N-myristoylation and glycosylation sites, and one leucine zipper are predicted 
in the recombinant protein. The leucine zipper falls within the B-cell epitope. A casein kinase II 
phosphorylation site is found in the conserved YERY peptide sequence (1187 – 1190), and 
the serine is conserved in all the Plasmodial species. It is therefore likely for phosphorylation 
to occur at this site. A casein kinase II phosphorylation site is found within the conserved EIYK 
sequence (2187 – 2190); however, the serine residue is only conserved between P. 
falciparum, P. gaboni and P. reichenowi. A site for N-linked glycosylation is found in the YERY 
peptide (1185 – 1188) with the sequence NFSN and is conserved in all the Plasmodial species.  
To validate that the structure represented by the leucine zipper motif, the PfC0760c protein 
was analysed using the 2ZIP server (Bornberg-Bauer et al., 1998). The predicted leucine 
zipper motif was rejected as a valid leucine zipper due to the presence of adjacent coiled-coil 
structures (data not shown). The rPfC0760c297 amino acid sequence was also scanned using 
ScanPROSITE, and the same sequences corresponding to those indicated in blue (Table 6.4) 
were obtained (data not shown).  
6.3.7 Prediction of protein-protein interactions of PfC0760c 
Due to the uncharacterised nature of PfC0760c, it would be of interest to determine if any 
proteins in the P. falciparum proteome interact with PfC0760c, which may possibly give an 
indication to its function. The STRING database was scanned using the full-length PfC0760c 
protein as the query sequence (Szklarczyk et al., 2015; Snel et al., 2000). 
Table 6.5: Prediction of protein-protein interactions of PfC0760c with P. falciparum proteins 
using STRING. 
Protein Accession Protein 
PF07_0024 Inositol phosphatase 
PFF1185w Smarca-related protein; SNF2 helicase 
PF10_0079 Conserved unknown 
PFF0445w Conserved unknown 
PF10_0232* Chromodomain-helicase DNA binding protein homolog 
Protein indicated by * has been experimentally proven to interact with PfC0760c 
PfC0760c was predicted to interact with 5 P. falciparum proteins, including inositol 
phosphatase and Smarca-related protein (Table 6.5). Two proteins with unknown functions 
were identified. The interaction between PfC0760c and chromodomain-helicase DNA binding 
protein homolog (PF10_0232) was experimentally determined by means of a high throughput 
yeast two-hybrid screening assay (LaCount et al., 2005). This suggests that PfC0760c has 
some functions associated with the parasite nucleus. 
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6.3.8 Prediction of conserved domains in the PfC0760c protein sequence 
The presence of conserved domains within a protein sequence may help determine its 
function. The NCBI CDD was used to search the PfC0760c sequence and homologous 
Plasmodium protein sequences for conserved domains.  
Table 6.6: Conserved domains of Plasmodium species’ proteins homologous to PfC0760c. 
Plasmodium species Conserved domain  Position  
P. falciparum SMC N-terminus 139 - 404, 1190 - 1420, 1688 - 2023 
P. gaboni SMC N-terminus 144 - 412, 1113 - 1865, 1812 - 1945 
P. reichenowi SMC N-terminus 139 - 404, 1125 - 1916, 1856 - 2244 
P. gonderi SMC N-terminus 157 - 471, 914 - 1479, 1239 - 1843 
 dnaJ with C-terminal Zn finger 2411 – 2574 
P. cynomolgi SMC N-terminus 232 - 1081, 854 - 1585, 1291 - 1891 
 Rad50 zinc hook motif 213 – 399 
 Na+/Ca2+ exchanger 2065 – 2292 
P. inui SMC N-terminus 122 - 407, 1283 - 1638, 1681 - 1918 
 Na+/Ca2+ exchanger 2311 - 2427, 2542 - 2802, 2737 - 2929 
P. vivax SMC N-terminus 122 - 418, 885 - 1193, 1085 - 1742 
 Na+/Ca2+ exchanger 2112 – 2317 
 Tat-binding protein 1835 – 1920 
P. knowlesi SMC N-terminus 135 - 436, 854 - 1589, 1270 - 1918 
 Glutenin subunit  2477 – 2638 
 Na+/Ca2+ exchanger 2063 - 2300, 2292 - 2536 
P. coatneyi SMC N-terminus 102 - 385, 854 - 1447, 1191 - 1724 
 Na+/Ca2+ exchanger 2440 - 2699, 2624 - 2831 
P. yoelii SMC N-terminus 181 - 410, 925 - 1164, 1236 - 1825 
P. yoelii 17X SMC N-terminus 181 - 410, 922 - 1161, 1233 - 1822 
P. berghei ANKA SMC N-terminus 126 - 407, 926 - 1353, 1279 - 1819 
P. berghei SMC N-terminus 126 - 407, 926 - 1353, 1279 - 1819 
P. vinckei vinckei SMC N-terminus 141 - 433, 923 - 1148, 1237 - 1877 
 Midasin  2542 – 2818 
 Rho 2660 – 2784 
P. vinckei petteri SMC N-terminus 126 - 409, 923 - 1148, 1281 - 1821 
 Na+/Ca2+ exchanger 2164 – 2369 
 Midasin  2587 – 2814 
P. chabaudi chabaudi SMC N-terminus 183 - 456, 947 - 1494, 1237 - 1823 
 Midasin  2618 - 2830  
 CDC45-like protein 2755 – 2822 
P. chabaudi adami SMC N-terminus 183 - 456, 947 - 1494, 1237 - 1823 
 CDC45-like protein 2752 - 2821. 
P. malariae SMC N-terminus 225 - 471, 1050 - 1919 
 DUF1777 2646 – 2789 
 Rho 2594 – 2711 
P. gallinaceum SMC N-terminus 107 - 384, 873 - 1672, 1509 - 1844 
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Within the PfC0760c sequence, three domains consistent with the N-terminal domains of 
the structural maintenance of chromosomes (SMC) protein superfamily were predicted. All the 
homologous PfC0760c proteins contain two or three SMC domains. The second most 
commonly observed domain amongst the species is the sodium/calcium (Na+/Ca2+) exchanger 
protein.  
Table 6.7: Functions of domains from Plasmodium species identified by CDD.  
Domain Function 
SMC Chromosome segregation ATPase's 
Rho Transcription termination factor Rho 
dnaJ with Zn finger Molecular chaperone with Zn finger domain 
DUF1777 Unknown 
Na+/Ca2+ exchanger Sodium/Calcium exchanger: regulates intracellular Ca2+ 
Tat binding protein Role in degradation of ubiquitinated proteins 
Rad50 Zn hook Chromosome maintenance 
Midasin ATPase; involved in ribosome maturation 
CDC45 Required for initiation of DNA replication initiation 
  
The CDD identified 9 different domains that are prevalent in PfC0760c and homologous 
Plasmodium proteins. The functions of these domains are illustrated in Table 6.7. The SMC, 
Rho, Tat binding protein, Rad50 Zn hook, midasin and CDC45 domains are all associated with 
nuclear functions. DUF1777 is uncharacterised. 
6.3.9 Prediction of the subcellular localization of PfC0760c 
To predict the subcellular location of PfC0760c, the amino acid sequence was uploaded to 
the MultiLoc2 prediction program. The PfC0760c protein was predicted to be localised to the 
nucleus with a confidence of 63%. To validate this result, the PfC0760c amino acid sequence 
was uploaded to the NucPred server. The results indicated that the PfC0760c is located in the 
nucleus with a 97% confidence.  
To validate the findings from both MultiLoc2 and NucPred, protein sequences with known 
locations were uploaded to each server. The cytoplasmic protein P. falciparum aldolase 
(Knapp et al., 1990) and the nuclear protein P. falciparum DNA-guided RNA polymerase III 
(Oehring et al., 2012) were chosen. High confidence scores indicate the predicted location of 
the proteins. 
Table 6.8: MultiLoc2 analysis of Plasmodium proteins of known locations. 
Accession 
no. 
P. falciparum 
protein 
% Confidence  
Cytoplasm Nucleus Mitochondria Secreted 
AAA29716.1 Aldolase 73 7 19 1 
P27625 
DNA-guided RNA 
polymerase III 
4 90 1 5 
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The MultiLoc2 server was able to correctly predict the subcellular location of both aldolase 
and DNA-guided RNA polymerase III (Table 6.8).  
Table 6.9: Analysis of Plasmodium proteins of known locations using the NucPred server. 
Accession no.  Protein NucPred Score (%) 
AAA29716.1 Aldolase 9 
P27625 DNA-guided RNA 
polymerase III 
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NucPred correctly predicted the nuclear localization of the DNA-guided RNA polymerase III 
enzyme with a score of 93 % (Table 6.9). Aldolase had a low NucPred score of 9, indicating 
that it is unlikely to be found in the nucleus. The results presented in Tables 6.8 and 6.9 indicate 
that the data obtained from both the MultiLoc2 and NucPred servers are reliable.  
6.3.10 Prediction of rPfC0760c297 protein structure  
It had previously been determined that PfC0760c possessed multiple coiled-coil motifs 
(Villard et al., 2007). To date, there is no published data available showing the structure of 
PfC0760c. Thus, the I-TASSER 3-D protein structural prediction server was used. Longer 
amino acid sequences provide a significant limitation with such programs. The amino acid 
sequence for the rPfC0760297 protein was used for structural analysis. Five possible models 
were generated. All five predicted models for PfC0760c show helices separated by uncoiled 
segments (Figure 6.10). A clustered conformation of helices is observed with different 
arrangements (Figure 6.10A – C). Helices separated by strands and arranged in a linear 
pattern were also observed (Figure 6.10D and 6.10E). The highest C-score indicates the most 
likely structure, illustrated in Figure 6.10A, which shows a non-linear arrangement of stretches 
of helices separated by strands. 
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Figure 6.10: Predicted models of the rPfC0760c297 generated by I-TASSER. The recombinant amino 
acid sequence spanning N2360 – N2656 was uploaded to the I-TASSER server, producing 5 possible 
different models (A – E). The C-score for each model is indicated at the bottom right (Zhang, 2008). 
The I-TASSER server also predicted the possible conformation of each amino acid in the 
rPfC0760c297 sequence, along with a confidence score. A higher confidence score indicates 
the prediction is likely to be true. The conserved peptide and flanking B-cell epitope within 
rPfC0760c297 were analysed. 
 
Figure 6.11: Predicted conformation of amino acids in the conserved peptide and B-cell epitope 
of rPfC0760c297. The black box indicates the conserved peptide and overlapping B-cell epitope. The 
conserved peptide is underlined in red, and the B-cell epitope is underlined in blue. A confidence score 
is indicated. 
The conserved peptide is predicted to have a helix and strand flanked and separated by 
coils, and the B-cell epitope containing the leucine zipper sequence motif is predicted to be in 
a helical conformation (Figure 6.11). For the conserved peptide, the helix and strands are 
predicted with a high confidence, whereas the coiled sections have varying degrees of 
CB
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confidence for each amino acid. The B-cell epitopes’ helical prediction is met with high 
confidence scores, with only the last two amino acids having slightly lower confidence scores. 
6.4 Discussion 
6.4.1 PfC0760c is a conserved protein 
The PfC0760c protein is conserved amongst different strains and isolates of P. falciparum. 
Homologous proteins to PfC0760c were found in 18 other Plasmodial species infecting 
humans, simians, mice and birds, suggesting that PfC0760c is likely an important protein for 
parasite metabolism.  
Multiple sequence alignment of the homologous protein sequences revealed three 
conserved peptides. This is two more conserved sequences than the previously detected NILK 
peptide conserved in the Plasmodium species (Addicott, 2014). Identification of the additional 
conserved peptides is due to updated databases and sequences since the previous study. 
Conserved peptides may participate in protein-protein interactions, provide structural motifs or 
may be highly immunogenic. Conserved sites for casein kinase II phosphorylation were 
predicted in the YERY and EIYK peptides, and a conserved site for N-linked glycosylation was 
predicted in the YERY peptide. BLASTp analysis of the three conserved peptides revealed 
three additional protein homologs from P. fragile, P. relictum, and P. ovale. However, the 
P. ovale homologues did not align with all the conserved peptides (Table 6.2), and this possibly 
accounts for the absence of P. ovale species from the original BLASTp output (Table 6.1).  
Within the conserved peptides, a few amino acid substitutions were observed. This could 
possibly be attributed to substitutions of single nucleotides in the codons used, or mistakes 
during sequencing.  
6.4.2 Possible subcellular localization of PfC0760c 
Protein function is often associated with the subcellular localization, therefore the 
subcellular localization of PfC0760c was bioinformatically evaluated (Blum et al., 2009). Using 
the MultiLoc2 and NucPred servers, the PfC0760c protein was predicted to be found in the 
parasite nucleus with high confidence (Blum et al., 2009; Brameier et al., 2007). This result 
coincides with two studies placing PfC0760c in the nucleus of P. falciparum (Miao et al., 2013; 
Oehring et al., 2012). Subcellular localization can be experimentally confirmed by 
immunostaining P. falciparum parasites with fluorescent- or nanoparticle-labelled PfC0760c-
specific antibodies. 
There is no evidence to suggest whether PfC0760c is transported across the parasite 
membrane. Ten PEXEL motif sequences were found in the PfC760c protein. A true PEXEL 
motif lies approximately 80 amino acids downstream from the N-terminus (Marti et al., 2005). 
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None of the PEXEL motifs are within this range, therefore PfC0760c is unlikely to be 
transported.  
Protein-protein interactions were predicted for inositol phosphatase (PF07_0024), Smarca-
related protein (PFF1185w) and chromodomain helicase DNA binding protein (PF10_0232). 
All three proteins are associated with the nucleus (Shah et al., 2013; Oehring et al., 2012; Wu 
et al., 2009), further supporting the nuclear localization of PfC0760c. 
6.4.3 Predicted function of PfC0760c 
Structural maintenance of chromosome (SMC) proteins are vital to parasite survival as they 
play an important role in stabilizing the chromosome (Harvey et al., 2002). The characteristic 
SMC protein structure features a central hinge region between two long coiled-coils flanked by 
globular domains at the N- and C-terminals (Harvey et al., 2002; Melby et al., 1998). Eukaryotic 
SMC proteins dimerise with heterologous SMC proteins, and complex with other proteins to 
form cohesin, condensin and the SMC5/6 complex (Wu and Yu, 2012). Cohesin facilitates 
separation of sister chromatids, condensin is involved in chromosome condensation, and 
SMC5/6 is involved in DNA repair mechanisms (Brooker and Berkowitz, 2014; Wu and Yu, 
2012). SMC domains were predicted in the middle of the PfC0760c sequence and its 
homologous proteins, corresponding to the N-terminal globular domain. SMC globular 
C-terminus, coiled-coils and hinge domains were not predicted. It is debatable whether 
PfC0760c is likely to participate in the structural maintenance of chromosomes purely based 
on these results. A possible reason for this may be due to the absence of these domains in the 
PfC0760c sequence or the CDD.  
6.4.4 Protein motifs within the PfC0760c protein sequence 
6.4.4.1 Phosphorylation motifs in PfC0760c 
Multiple motifs were predicted for phosphorylation by several kinases, two of which were 
conserved. Protein phosphorylation is involved in the activation and deactivation of proteins 
and enzymes, and is often implicated in signal transduction pathways (Ardito et al., 2017). 
Phosphorylation is the driving force for trafficking of nuclear-associated proteins (Jans, 1995).  
6.4.4.2 Myristoylation sites within PfC0760c 
Myristate is a saturated fatty acid that is attached to an N-terminal glycine residue, catalysed 
by N-myristoyltransferase (Thinon et al., 2014; Farazi et al., 2001). This process occurs either 
during or post-translation (Thinon et al., 2014; Farazi et al., 2001). It is an essential, irreversible 
process required for signal transduction pathways, weak interactions between proteins and 
membrane proteins, and protein targeting (Farazi et al., 2001). The N-myristoyltransferase 
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enzyme has been validated as an antimalarial drug target (Wright et al., 2014). The PfC0760c 
protein is predicted to have several N-myristoylation motifs, indicating that PfC0760c may 
participate in signal transduction pathways or protein-protein interactions.  
6.4.4.3 Glycosylation of PfC0760c 
N-linked glycosylation involves the transfer of a lipid-associated carbohydrate to the 
nitrogen atom of an asparagine side chain (Burda and Aebi, 1999). N- and O-linked 
glycosylation are important for stability and folding of proteins, protein targeting and recognition 
(Nalivaeva and Turner, 2001). O-linked glycosylated proteins are typically found in the 
membrane or are transported proteins (Nalivaeva and Turner, 2001). The hydrophilicity of 
carbohydrates contributes to protein solubility by ensuring correct protein folding (Nalivaeva 
and Turner, 2001). N-linked glycosylation is essential for parasite development (Kimura et al., 
1996).  
Several sites for N-linked glycosylation were predicted for the PfC0760c protein, one of 
which lies within the conserved YERY peptide. These sites have not been confirmed 
experimentally. 
6.4.4.4 Prediction of leucine zippers in PfC0760c 
Leucine zippers are associated with the basic leucine zipper family of diverse transcription 
factors (Nijhawan et al., 2008). The characteristic motif for a leucine zipper, which is a common 
feature of some DNA-binding proteins, has a leucine in every 7th position over a stretch of 
approximately 30 amino acids (Landschulz et al., 1988). A basic domain flanks the leucine 
zipper, and the latter is found nine amino acids from the C-terminus (Nijhawan et al., 2008). A 
leucine zipper motif was found in the PfC0760c sequence, which together with the SMC 
domain prediction, suggests a role in the nucleus. However, conflicting results were obtained 
regarding the leucine zipper motif found in the PfC0760c sequence. The leucine zipper motif 
was not found at the C-terminus of PfC0760c, nor is it conserved. 
6.4.4.5 Lysine acetylation of PfC0760c 
Acetylation of lysine residues is a reversible, highly regulated post-translational modification 
associated with cellular signalling (Miao et al., 2013; Choudhary et al., 2014). Acetyl groups 
are transferred from the acetyl coenzyme A cofactor by lysine acetyltransferases, and 
deacetylation in the nucleus is mediated by sirtuin deacetylases (Choudhary et al., 2014). A 
single lysine residue was predicted to be acetylated in PfC0760c (Miao et al., 2013). It is 
possible that PfC0760c has a signalling role in the parasite nucleus.  
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6.4.5 Predicted structure of rPfC0760c297 
Typically, alpha-helical coiled-coils comprise heptad repeats, with non-polar amino acids 
occupying the first and fourth positions of the heptad (Burkhard et al., 2001). The PfC0760c 
was reported to possess an alpha-helical coiled-coil structure, and on this basis, a potential 
malaria vaccine candidate (Villard et al., 2007). Using the I-TASSER server, alpha helices were 
illustrated in all the predicted structures (Figure 6.10). Crystallization of the full-length protein 
may be used to confirm the structure of PfC0760c (McPherson and Gavira, 2014).  
6.4.6 Conclusion 
PfC0760c is an uncharacterised, conserved P. falciparum protein predicted to function in 
the nucleus, and interact with nuclear-associated proteins. The subcellular localization can be 
experimentally confirmed by staining the parasite nucleus, and counter-staining with labelled 
anti-PfC0760c antibodies. Further characterisation of protein-protein interactions of 
rPfC0760c297 with P. falciparum proteins may be experimentally evaluated by far-western blot. 
A DNA-binding assay may be used to assess the interaction between DNA and PfC0760c. 
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Chapter 7: Immunization of BALB/c mice with rPfC0760c297 
7.1 Introduction 
7.1.1 Mouse malaria pre-clinical trials 
Mouse models have often been used to test vaccines, and the immune response and 
longevity of a vaccine can be assessed (Teixeira and Gomes, 2013). It is difficult to copy the 
internal environment of a host in an in vitro study. An alternative is to use animal models such 
as mice (Wykes and Good, 2009). Inbred, gene knockout or transgenic mice may be used to 
understand the immune response to a vaccine (Teixeira and Gomes, 2013). For the study of 
the effects of a vaccine or the immunopathology of disease, advantages of using animal 
models such as mice include the availability of inbred or congenic mice, obtainability of ethical 
approval, practicality (Minkah et al., 2018; Wykes and Good, 2009), and mice are easily 
housed and monitored. Pre-clinical trials are conducted in animals to ensure safety and 
immunogenicity before trials are conducted in humans. 
The drawbacks of using mouse models include the fact that the outcome in humans cannot 
always be predicted (Teixeira and Gomes, 2013). Additionally, Plasmodial parasites infecting 
humans are unable to develop in vivo in rodents (Minkah et al., 2018).  
7.1.2 P. berghei as a model for malaria vaccines 
P. berghei, P. chabaudi and P. yoelii are often used to model different aspects of human 
Plasmodial infections (Huang et al., 2015; Wykes and Good, 2009). P. berghei can cause a 
lethal malaria infection in mice, and cerebral malaria (Wykes and Good, 2009). However, some 
laboratory strains of mice such as BALB/c are not susceptible to cerebral malaria (Wykes and 
Good, 2009). Hence, the selection of both the infective Plasmodial species and mouse strain 
should be carefully considered.  
7.1.3 PfC0760c as a potential malaria vaccine candidate 
Since the PfC0760c protein is conserved, homologous proteins are present in Plasmodial 
species infecting humans, monkeys, birds and mice, including P. berghei (Chapter 6). In this 
study, the rPfC0760c297 protein was evaluated for its potential to elicit an antibody response in 
BALB/c mice. It was then further evaluated in a P. berghei mouse malaria challenge model. 
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7.2 Results 
7.2.1 Detection of homologous PfC0760c protein in P. berghei  
Proteins homologous to PfC0760c were identified by BLASTp analysis, including proteins 
from Plasmodial species infecting mice (Chapter 6). The PfC0760c amino acid sequence was 
aligned with the homologous sequence from P. berghei. The alignment between the 
P. falciparum recombinant protein sequence and the corresponding sequence in P. berghei is 
shown in Figure 7.1. 
 
P. falciparum      N-YLVNNLQLNKDNDNIIIIKFNILKLFKLGSCYLYIINRNLKEIQ    2404       
P. berghei ANKA     NLSSSESREFSVSSDHITLIKCNILKMFKLGSCYLYIINRNLKEIK    1975 
       *    :. ::. ..*:* :** ****:******************: 
 
P. falciparum      MLKNQILSLEESIKSLNEFINNLKNENEKNELIKINNFEEILKLKN    2450 
P. berghei ANKA     ILKDKINYLEENIQSLNLFINNLKDQNKNNEVIKINNEEQIIQLKN    2021 
       :**::*  ***.*:*** ******::*::**:***** *:*::*** 
 
P. falciparum       NLQDNESCIQNLNNYLKKNEELNKINVKNIFKYKGYIIHLIQQSNV    2496 
P. berghei ANKA     SLQNNENCISNLNDNLKQKDEMNNSNIKNLIKYKSFIINLVHQSNI    2067 
                    .**:**.**.***: **:::*:*: *:**::***.:**:*::***: 
 
P. falciparum       FCKIFKHFNENKIIDQSIINKLLYLKKSFDFYMYDSVIQEIRENKN    2542 
P. berghei ANKA     FFHIFKIMNTQKVIQNSIYNQLTQLRKELDFYLNDYIMISELENKE    2113 
                    * :*** :* :*:*::** *:*  *:*.:***: * :: .  ***:        
 
P. falciparum       I----------IINQDFLTDEYFKHIQTFTKTCNVLIQRGYLSILK    2578 
P. berghei ANKA     KLNLSNIENNLLNIVSTFSYENYEHIQIFTNKFNFIIERGKVSIFS    2159                                                    
                               :   . :: * ::*** **:. *.:*:** :**:. 
 
P. falciparum       DTNN---------DFFIQNKQSNQQGNQNGNHINMCNIYPDDEINV    2615 
P. berghei ANKA     DGKIHPSQNDQTNNFFSNINSYFQNQNQYNNALNFKDLN-ENTIET    2204 
                    * :          :** : :.  *: ** .* :*: ::  :: *:. 
 
P. falciparum       TADQQIFDGTENVQQSLQNEEDYVNNEEMYTDKMDLDNN-------    2654 
P. berghei ANKA     PKDTQV--QTVQIYQETQNEEENIKNENIATQVNNQNDQIDALKNE    2248 
                      * *:   * :: *. ****: ::**:: *:  : :::        
 
P. falciparum       ------MN    2656                   
P. berghei ANKA     EYNDDQMY    2256 
                          *   
Figure 7.1: Sequence alignment of rPfC0760c297 and homologous sequence in P. berghei ANKA. 
The recombinant sequence of PfC0760c (077384.1) from N2360 – N2656 was aligned with the P. 
berghei ANKA sequence (XP_672614.2) from N1929 – N2256. The conserved peptide is indicated by 
a red box, and a B-cell epitope is indicated by a blue box (Villard et al., 2007). The . indicates a similar 
residue, the : indicates similar physicochemical properties, and * indicates an exact match.  
Of the 297 amino acids in the rPfC0760c297 sequence, 134 amino acids were conserved 
(Figure 7.1), accounting for 45% amino acid conservation between the rPfC0760c297 sequence 
and corresponding P. berghei sequence. Within the conserved peptide, a single amino acid 
substitution of leucine to methionine is observed (red box). 19 amino acids are conserved 
within the 29-mer B-cell epitope.  
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Polyclonal chicken IgY antibodies had previously been raised in-house against the 
rPfC0760c297 protein (Addicott, 2014). These antibodies were used to determine the presence 
of the homologous protein in a P. berghei-infected mouse blood sample.  
 
Figure 7.2: Detection of homologous rPfC0760c297 protein in P. berghei-infected blood. Uninfected 
and P. berghei-infected mouse blood was analysed. (A) Blood lysates were resolved on 12.5% reducing 
SDS-PAGE, and proteins were stained with Coomassie Blue. Lane 1: molecular weight marker. Lane 
2: uninfected mouse blood lysate. Lane 3: P. berghei-infected mouse blood lysate. (B) Western blot of 
an identical gel probed with chicken anti-rPfC0760c297 IgY and detected with rabbit anti-chicken HRPO-
IgG. 
The protein profile under reducing conditions for a sample of uninfected and P. berghei-
infected mouse blood shows proteins ranging in size from below 14 kDa to above 116 kDa 
(Figure 7.2A). The western blot shows a single band of high molecular weight detected in the 
P. berghei infected blood sample (Figure 7.2B, lane 3). No protein was detected by western 
blot in the uninfected blood sample (lane 2).  
7.2.2 Generation of anti-rPfC0760c297 antibodies in mice 
Mice were immunized with rPfC0760c297 on days 0, 14 and 28. On day 42, mice were 
sacrificed, and blood was collected. The serum was separated from the red blood cells and a 
checkerboard ELISA was performed. The serum from two mice immunized with buffer alone, 
and one non-immune mouse was also included for comparison. 
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Figure 7.3: Detection of anti-rPfC0760c297 antibodies from mice immunized with rPfC0760c297. 
Mice were immunized with rPfC0760c297 (PfC; square marker) or buffer (Sarc; round marker) on days 
0, 14 and 28.  A non-immune mouse was included. Serum was collected and analysed in a checkerboard 
direct ELISA for antibodies against rPfC0760c297. Plate was coated with decreasing concentrations of 
rPfC0760c297. Serial dilutions of mouse serum were prepared. Anti-rPfC0760c297 antibodies were 
detected with goat anti-mouse HRPO-IgG. ABTS-H2O2 was used as the substrate. 
Mice immunized with rPfC0760c297 was able to elicit an antibody response. It was also noted 
that at higher serum concentrations, there are antibodies present in the control samples Sarc1 
and Sarc2. The non-immune mouse serum showed no antibody response to the rPfC0760c297 
antigen. 
7.2.3 Immunization of mice with rPfC0760c297 followed by P. berghei challenge 
The capacity of rPfC0760c297 to protect mice from a malaria infection was assessed in a 
mouse malaria challenge model. BALB/c mice were immunized with solubilized rPfC0760c297 
on days 0, 14 and 28, and challenged with 105 P. berghei parasitized red blood cells on day 
40. Parasitaemia was monitored every second day by Giemsa-stained blood smears. Control 
mice were immunized with buffer. 
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Figure 7.4: Parasitaemia monitored over the course of P. berghei infection. Two groups of five 
mice were immunized with rPfC0760c297 (PfC; square marker) or the elution buffer (Sarc; round marker). 
rPfC0760c297-immunized mice were sacrificed on day 7 after challenge (dashed line). Control mice 
Sarc1 and Sarc2 were sacrificed on day 8, Sarc5 was sacrificed on day 9 and Sarc3 was sacrificed on 
day 10. The * indicates mouse death.  
Parasitaemia in all mice remained below 5% from days 0 – 4 after challenge. A sharp 
increase in parasitaemia was observed on day 6 in four of the five rPfC0760c297-immunized 
mice with parasitaemia above 25%. The remaining rPfC0760c297-immunized mouse had a 
parasitaemia of ~7% by day 6. All the rPfC0760c297-immunized mice were euthanized on 
day 7. Parasitaemia was monitored for the control mice, and as the parasitaemia approached 
20%, mice were euthanized. One mouse, Sarc4 was deceased on day 7, and the last recorded 
parasitaemia was below 15% on day 6. Sarc1 and Sarc2 control mice were euthanized on day 
8, and the parasitaemia was ~24% and 28% respectively. In the Sarc3 mouse, the 
parasitaemia remained below 5% until day 8 and increased to ~16% on day 9, and was 
sacrificed on day 10 at a parasitaemia of 19%. The parasitaemia in Sarc5 increased from 2% 
to ~16% between days 6 and 8 and the mouse was euthanized on day 9 at a parasitaemia 
of 20%. 
7.3 Discussion 
7.3.1 Immunization with rPfC0760c297  
Mice immunized with the rPfC0760c297 protein generated an antibody response. However, 
mice immunized with rPfC0760c297 followed by challenge with P. berghei blood stage parasites 
were not protected. One of the five rPfC0760c297-immunized mice had a lower parasitaemia 
on day 6 post-infection compared to the rest of the rPfC0760c297-immunized mice (Figure 7.4). 
This suggests that immunization with the rPfC0760c297 protein may have an influence on the 
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parasitaemia. However, this is not significant, and the experiment needs to be repeated. Three 
of the 5 control mice were able to survive for at least 8 days post-infection before sacrifice, 
with one mouse surviving for 10 days post-infection before sacrifice. The cause of death of the 
remaining mouse was not determined. Various factors could have contributed to the failure of 
rPfC0760c297 to protect the mice, including the choice of adjuvant, the antigen dose, the route 
of immunization, and the immunization schedule (Jones et al., 2001; Hu et al., 1989; Playfair 
and de Souza, 1986). PfC0760c297 is predicted to be a Plasmodium nuclear protein. Thus, 
based on the predicted subcellular localization and lack of protection observed in mice, it is 
possible that PfC0760c297 may not be a good malaria vaccine candidate. 
7.3.2 Solubilization of rPfC0760c297 
The rPfC0760c297 protein was solubilized using the SDS detergent, as outlined by Schlager 
et al. (2012). Residual SDS from the solubilization procedure could be present in the 
immunized mice. According to the SDS Material Safety Data Sheet, the LD50 in rats was 
established at 1288 µg/g. The concentration of SDS in the solubilization buffer is 1% (w/v), 
thus in the final immunization preparation, less than 0.05 µg of SDS was present, which is well 
below the LD50. Hence, it is unlikely that the presence of residual SDS could have affected the 
outcome of the immunization. To evaluate the toxicity of SDS in mice, mice can be immunized 
with SDS alone and the outcome can be assessed. 
7.3.3 Conformation of rPfC0760c297 
The structure of PfC0760c has not been determined at present, but several structures of 
rPfC0760c297 have been predicted (Figure 6.10). Although disulfide bonds were not predicted 
by the DISULFIND tool (Ceroni et al., 2006), rPfC0760c297 appears to be smaller in size when 
electrophoresed under non-reducing conditions (Figure 5.3 and 5.4, lane 10) compared to 
reducing conditions (Figure 3.12, lane 7). This suggests that disulfide bonds are present in the 
recombinant protein, as the protein is more compact and mobile (Scheele and Jacoby, 1982). 
Five cysteine residues are present in the rPfC0760c297 sequence, indicating that there may be 
two possible disulfide bonds. There are 34 cysteine residues present in the entire PfC0760c 
sequence and are likely to participate in disulfide bond formation, allowing the protein to fold 
into the correct structure, possibly forming 17 disulfide bonds. Since the structure of PfC0760c 
is unknown, the pairs of cysteine residues participating in disulfide bond formation are 
unknown. Several methods are described for the identification of disulfide bonds within a 
protein, including a combination of protein mass spectrometry and unique sequence tags 
(Shen et al., 2010), and immobilized trypsin and MALDI-TOF analysis (Tang and Speicher, 
2004). Site-directed mutagenesis may help identify cysteine residues participating in disulfide 
bond formation, by mutating specific cysteine residues to serine residues (Hattori et al., 2015).  
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The importance of immunization with correctly folded protein is indicated by a study by Ling 
et al. (1994). The MSP-1 protein was reduced and alkylated, thus changing the protein 
conformation. Mice immunized with this modified protein were unable to resolve a challenge 
infection, whereas mice immunized with the correctly folded MSP-1 protein were able to 
resolve the infection (Ling et al., 1994). This is an indication that the correct conformation of 
the antigen is imperative for providing protective immunity. Rabbits immunized with correctly 
folded RH5 from P. falciparum were able to generate antibodies that were able to prevent in 
vitro invasion and growth of P. falciparum parasites (Bustamante et al., 2013).  
7.3.4 Adjuvant used for immunization with rPfC0760c297 
Freund’s Adjuvants are water-in-mineral oil based, and the Freund’s Complete adjuvant 
contains deactivated Mycobacterium tuberculosis (Opie and Freund, 1937). The presence of 
M. tuberculosis encourages antibody production by stimulating the immune system (Trott et 
al., 2008). Comparing the use of Freund’s Complete and Incomplete adjuvants for 
immunization in mice showed that the antibody titres are influenced by the choice of adjuvant 
for primary and booster immunizations (Hu et al., 1989). The combination of Freund’s 
Complete adjuvant for primary immunization and boosting with Freund’s Incomplete adjuvant 
provoked the highest antibody response compared to other combinations of these adjuvants 
(Hu et al., 1989). This combination was used in the rPfC0760c297-immunization study. Freund’s 
Adjuvants are prohibited for use in humans due to their negative side effects (Gaspar et al., 
2018; Apostólico et al., 2016). It is unlikely that the toxicity of Freund’s adjuvant would have 
affected the outcome of the immunization in mice, as the mice would not have survived. No 
other adjuvants were tested. Evaluation of different adjuvants may alter the outcome of the 
experiment. Some adjuvants that may be tested include MagicMouseTM, aluminium hydroxide, 
Montanide ISA50 or TiterMaxTM (Greenfield, 2019; Leenaars et al., 1998; Bennet et al., 1992). 
7.3.5 Immunization of mice 
It was evident that the mice were able to mount an antibody response against the 
rPfC0760c297 protein (Figure 7.3). The antibody response was not evaluated in the mice that 
were challenged with P. berghei parasites. It is assumed that the mice which were immunized 
and challenged with P. berghei-infected red blood cells were able to mount similar antibody 
responses to the vaccine. It is therefore unclear at this stage the reason for the lack of 
protection in the rPfC0760c297-immunized mice. 
7.3.6 Further modifications to the rPfC0760c297 immunization study 
Several modifications of this study can be evaluated. For immunization of mice, the 
concentration of the rPfC0760c297 antigen can be varied and the antibody response can be 
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evaluated prior to challenge infection. The number of P. berghei parasites that are used for the 
challenge infection can be decreased. The corresponding region to rPfC0760c297 in the 
P. berghei sequence (Figure 7.1) can be tested in an immunization study to determine if it is 
capable of protecting against a homologous challenge infection. In this study, the T-cell 
response of the immunized and control mice was not evaluated. The T-cell responses in mice 
can be evaluated indirectly by the ELISPOT assay or proliferation assays (Brinke et al., 2017; 
Leehan and Koelsch 2015).  
7.3.7 Conclusion  
Chicken anti-rPfC0760c297 IgY antibodies were able to recognise the homologous protein 
in P. berghei infected mouse blood. Mice immunized with solubilized rPfC0760c297 were able 
to raise antibodies against the protein. However, immunization of mice with rPfC0760c297 did 
not protect them from a P. berghei challenge infection.  
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Chapter 8: General discussion and conclusions 
8.1 Premise of this study 
The lack of a malaria vaccine is a major obstacle preventing the control and eradication of 
malaria (Bygbjerg et al., 2018; Crompton et al., 2010). Many malaria proteins have been 
researched for vaccine development, and none have shown long-term protection (Wykes, 
2013). The most developed malaria vaccine is the RTS,S vaccine, which has been evaluated 
in clinical trials, but has not yet demonstrated satisfactory protection against malaria (Gosling 
and von Seidlein, 2016). To date, vaccination with attenuated sporozoites delivered by the bite 
of an infected mosquito has been shown to be the most effective vaccine at preventing clinical 
malaria (Lyke et al., 2017; Ishizuka et al., 2016; Spring et al., 2013; Hoffman et al., 2002). 
However, this mode of vaccination is not viable in humans (Hollingdale and Sedegah, 2016). 
Thus, there is a need to identify and evaluate new Plasmodial proteins for malaria vaccines.  
8.2 Uncharacterised Plasmodial proteins 
The PfC0760c protein is uncharacterised. Uncharacterised proteins may provide an 
invaluable tool for understanding, and possibly combatting diseases that are not well 
understood or deemed incurable. Characterisation of proteins with yet unknown functions may 
help delineate the pathogenesis of disease, enzymatic functions of the protein, substrates 
required by the protein, and pathways used by the parasite for disease progression. Detection 
of conserved functional domains within these proteins may lead to classification according to 
function or functional groups and substrate domains. Uncharacterised proteins may also 
provide new drug targets or potential vaccine candidates. 
8.3 PfC0760c as a potential malaria vaccine candidate 
The PfC0760c protein is a conserved malaria protein displaying alpha-helical coiled-coil 
domains. Several other Plasmodial proteins were identified as potential malaria vaccine 
candidates based on the presence of alpha-helical coiled-coil domains (Villard et al., 2007). 
Alpha-helical coiled-coil motifs are capable of folding correctly into stable structures, are likely 
to be recognised by “conformational dependent” antibodies, and are easily produced (Villard 
et al., 2007). An antibody response against a B-cell epitope (Figure 6.4B) of PfC0760c was 
found in adult human sera from individuals in Burkina Faso, Tanzania and Colombia (Villard 
et al., 2007). Many T-cell epitopes were predicted within the PfC0760c sequence (Rammensee 
et al., 1999). This suggests that PfC0760c is immunogenic in humans.  
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8.4 rPfC0760c297 is expressed as an insoluble protein in E. coli 
High levels of rPfC0760c297 expression was achieved in E. coli host cells using terrific broth, 
which resulted in aggregation of the protein in insoluble inclusion bodies. Modifications of the 
expression conditions did not produce soluble rPfC0760c297. Incorrect folding of the 
rPfC0760c297 protein in the E. coli cells could contribute to the expression of insoluble protein.  
However, several studies have shown that biologically active protein can be produced within 
bacterial inclusion bodies (Nahálka, 2008; Nahálka et al., 2006; García-Fruitós et al., 2005). 
Expression of recombinant Aβ42 fused to green fluorescent protein at 18°C – 42°C formed 
inclusion bodies. However, at lower temperatures of expression, higher fluorescence was 
noted within the inclusion bodies, suggesting that a higher ratio of correctly folded Aβ42 protein 
was present (de Groot and Ventura, 2006). At a lower temperature of expression, soluble 
rPfC0760c297 was undetected, and the quality of the inclusion bodies was not assessed. 
8.5 Expression of rPfC0760c297 in the presence of E. coli chaperones 
The addition of ethanol to the growth media of an E. coli culture encourages the expression 
of E. coli chaperones (Ziemienowicz et al., 1993; Steczko et al., 1991; Lindquist and Craig, 
1988) However, there is no evidence in this study to suggest that the expression of the E. coli 
chaperones was affected by the addition of ethanol, or that the E. coli chaperones are able to 
bind to the rPfC0760c297 protein. Western blot using chaperone-specific antibodies may 
illustrate the effects of ethanol on the expression of E. coli chaperones. The addition of ethanol 
to the culture media resulted in reduced expression of rPfC0760c297, which remained insoluble 
(Figure 3.10).  
In a separate experiment, E. coli cells were co-transformed with plasmids encoding the 
E. coli chaperones GroEL-GroES and dnaKdnaJgrpE, which were co-expressed with 
rPfC0760c297. The E. coli chaperones GroEL-GroES and dnaKdnaJgrpE had no impact on the 
expression of soluble rPfC0760c297 under several different conditions tested. 
Upregulation of the expression of E. coli chaperones was observed in Figure 4.5A, where 
higher concentrations of the inducer L-arabinose resulted in better expression of the 60 kDa 
GroEL chaperone. Upregulation of the expression of E. coli chaperones can be confirmed by 
western blot of E. coli lysates using antibodies raised against each chaperone. The GroEL and 
dnaK chaperones bind to unfolded proteins (Ryabova et al., 2013; Martin, 1998). Binding of 
the E. coli chaperones GroEL or dnaK to the rPfC0760c297 protein may be evaluated in vitro 
using an AminoLink™ column coupled to the chaperones, and passing a lysate of E. coli cells 
expressing rPfC0760c297. Bound proteins can be eluted and analysed for the presence of 
rPfC0760c297. Far western blot analysis using insoluble rPfC0760c297 as the prey protein and 
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purified GroEL or dnaK chaperones as the bait proteins. Antibodies raised against the 
chaperones can be used to confirm binding of the chaperones to rPfC0760c297. 
8.6 Properties of the PfC0760c protein 
Sequence alignment of PfC0760c with the homologous proteins from Plasmodium species 
infecting humans, monkeys, mice and birds revealed three conserved peptides. Bioinformatics 
analyses predicted various protein characteristics, including the structure, which has yet to be 
experimentally confirmed. 
PfC0760c is expressed during the sporozoite, merozoite and gametocyte stages of the 
P. falciparum life cycle (Florens et al., 2002). Nuclear proteomic studies and bioinformatics 
analysis have suggested that this protein localises to the parasite nucleus (Oehring et al., 2012; 
Blum et al., 2009; Brameier et al., 2007). This can be confirmed microscopically using 
nanoparticle- or fluorescent-labelled antibodies.  
8.7 Conclusion and future work 
The solubilized rPfC0760c297 was unable to protect mice from a heterologous P. berghei 
challenge infection. Using the current expression conditions for high yields of rPfC0760c297, an 
alternative means to purify soluble, correctly folded protein may be investigated. rPfC0760c297 
can be purified under reducing conditions followed by dialysis to remove the reducing agent. 
Additionally, the rPfC0760c297 protein can be fused to the green-fluorescent reporter protein to 
assess the presence of correctly folded rPfC0760c297 (de Groot and Ventura, 2006). 
Alternatively, the rPfC0760c297 inclusion bodies may be purified (Carrió et al., 2000), which can 
then be used to immunize mice. A different region of the PfC0760c protein including the 
conserved EIYK or YERY peptides may be considered for immunization. Mice may be 
immunized with the homologous PfC0760c protein from P. berghei and challenged with a 
homologous P. berghei infection. Additionally, changes in the immunization regime may be 
evaluated, where mice are immunized, then infected with Plasmodium parasites, followed by 
drug-cure (Makobongo et al., 2003). These mice can then be challenged with a Plasmodium 
infection. A different strain of mice may also be immunized and challenged, and the outcome 
compared to the current study (Brando et al., 2007). To determine whether the PfC0760c 
protein is vital for parasite survival, a PfC0760c gene knockout study may be conducted in 
Plasmodium parasites, and these parasites can be cultured and assessed for viability.  
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Appendix A: Annotated full-length amino acid sequence of PfC0760c 
An annotated full-length amino acid sequence for the PfC0760c is shown. The sequence 
was obtained from the NCBI database, and subject to various online bioinformatics tools. 
Selected properties of the protein are indicated. 
>gi|74764611|sp|O77384.1|LRR4_PLAF7 RecName: Full=Protein PFC0760c 
MNNDFMKNEKDDYDKVNEEEYSLENFRGIDMNNNVDISNMNNNLNDVGELINIDNNDKYDEDQLSLIKESLEYGE
LLLSNVKEEDENNRREHFKKNDYMKDTEDVHYKESKIGQDKRFMHSLCVKELKSTEEGELFDDEKYKDKDTLINM
LRKKLEIKIKDYNLIMDTLILTKEECSKKEEQLKDYKMKYNKMEKECYSLKNEIERKNNEKHLNIGSFSFYKNEY
DDMKYKLLKCEEKNKILLNKNQELHQTIIQMKNDSYNQNIKFKKDIDVLTEDKKNILIQNKNFTKQNKILIDKYL
RQEKIIYKLKKHNEEQEIIIKECHKKIEFVNKNSVNHLNKVRDVLNKSLIKSEEHVKLYTNLKKENDSLKIEYNK
SKTNIQQLNEQLVNYKNFIKEMEKKYKQLVVKNNSLFSITHDFINLKNSNIIIIRRTSDMKQIFKMYNLDIEHFN
EQDHLSVIYIYEILYNTNDNNNNDNDNNNDNNNNNNNNNDNNNNNNNDNNNNNNNYNNIMMMIENMNSGNHPNSN
NLHNYRHNTNDENNLSSLKTSFRYKINNKSGKSRSIKSRSHFSGDNEYIQDQLSNREMKDHYNYIERYNHSSNRN
DIHNLYYMEENVSHNNNKSDYDEDGDAENNNYYIKIKKNKYKKLNDLLNKAQMKIITLTRANEMFEKYCSNIKNT
LIRDDMKKFRKPDISDVHILHNEKIYLEKLLNEKLNYIKDIEKKLDELHGVINKNKEDIYILQVEKQTLIKVISS
VYDYTKMESENHIFKMNTTWNKMLNNVHMSSNKDYNNQNNQNIENNQNIENNQNNQNIENNQNIENNQNNQNNQN
NQNNQNNQNNQNNQNNAGIHISPDDFLKYRMSLEKFIQFTIKEHIVYIMKDEKKKTSNIIKESISLKKKHTKKSI
INNNNDNNNEDDDDNDMLSVMYSNDDVIKNKRKENNKEILEEHVSFSSFSNNEYIAHSFNSILLQLSNYIFNIEC
KQMEYFKNSNLLSYVDDYTITIELFYRLKKYNNIFSIEQILGTQYPSILQKLHDGIYCLKDNNKKKNNDGDNKSQ
EDDDGNKKKNNDGDNKSQEDDDGNKKKNNDGDNKSQEDDYGNKKKNNDDDDDDSYKIELIVDELNKCKKNYTDEE
LYELMKGSDFDIFKKYKNFYLNHFININNIFSTIISFHIHNIEDKYKKVYERYFNLFNFNFSNVELSFDLLIRRF
DKILRLTKKYEQLLEENYEKIKNKNEKEEYLHACIKELEMNLERYNNEKIILDEQINEKEKKINIINEKYLILEK
EYEEYQNKNIFINAQIENLEKEKKQLQEEIIQKDMINVKLNEKNCDIIKIYEKEKQYLHTLLQENKDSHNYLKDK
FENLLNLNEKLKYDHDISLNKINTLWLEEKENNKKNTFHMNNLRVENNNLLLKMKELQNKYNIIKKELNERIKQI
NVFRNNVSTLSLRDNRSTRGSIHQINNMYMNNTHLGFMGASKINNNISNLYYSNMIHMSHRGSIIKNKEDAEGNS
TQARMNNKDSTDNIINNIHNTDNINNMNNINNNTLNSINSNHLYYPFPFHNNVNSPKMVGMCDVTLASGVNKKDD
FLLNLEENEENSFLEYEIRIKSLQEELCDKESEILKIKGEKNILITCIETWKCFCKNSKEEISRLKEICKEQLEK
HKEFLLINKSNEDKLKYINSLLCDEKDKYDIVVKDIKNNMRNEIDKLNNDINEKSYEIKLLKHENNNLINEMNIL
KNKETENMNIKQKEEDYIKLIKKDKTNIQNEYNDLLEKYNEVVVKNNMLYNDMNVLLKEHKEEIFLLKENIKILQ
KDNTYLNDMFKNQINYVDNNLLKNRLDQLFNINQDLQKHLDTNQKHLEQLKYDYIEIKERLKIEKTKINKQEKYI
IQLQKDNNLILNDFNSTTTTTNNNNNNDNNNDNNNDNNDNNNDTYQQFIHSLKANLENSRLELKELSNLNEKIQL
SDEKNRMKITILEDKLFKNEKDKMKLQQIIDDNNKNYMIQYNKLKTNLDMLSEENRMLLLNKEEYEKQIEQLNHD
HKLFISTKNNDIQIIENEKLQEQVDQYITTINEKDKIIVHLNLQIKKLANQNEHMRSRCDIFNVAHSQDNIKNDH
MVVGEDIMGDTNHDVNKNIDQGTNQHINQGTNQHINQGTNQHDTCDGPNYNYVKVQNATNREDNKNKERNLSQEI
YKYINENIDLTSELEKKNDMLENYKNELKEKNEEIYKLNNDIDMLSNNCKKLKESIMMMEKYKIIMNNNIQEKDE
IIENLKNKYNNKLDDLINNYSVVDKSIVSCFEDSNIMSPSCNDILNVFNNLSKSNKKVCTNMDICNENMDSISSI
NNVNNINNVNNINNVNNINNVNNINNVKNIVDINNYLVNNLQLNKDNDNIIIIKFNILKLFKLGSCYLYIINRNL
KEIQMLKNQILSLEESIKSLNEFINNLKNENEKNELIKINNFEEILKLKNNLQDNESCIQNLNNYLKKNEELNKI
NVKNIFKYKGYIIHLIQQSNVFCKIFKHFNENKIIDQSIINKLLYLKKSFDFYMYDSVIQEIRENKNIIINQDFL
TDEYFKHIQTFTKTCNVLIQRGYLSILKDTNNDFFIQNKQSNQQGNQNGNHINMCNIYPDDEINVTADQQIFDGT
ENVQQSLQNEEDYVNNEEMYTDKMDLDNNMNGDDDDDDDDDDDDDNNNNNNNNNNNNNNNMGDEDNHLVNAFNNH
NLLTNGNVKSDQINNETLERYEENIIQNIYTNDNVDNNQVIENINKILIKDKQDIINNDELKNEHNNLIRLINES
IENAHNLENVYVQNDANNLINDNIKKEETLTYVDEKDNVSNESNSKCDDDKKENEDIIQAKNENYPVSTHYDNND
DINKDNINNDNNNDNINDDNNNDNINNDNNNDNINNDNINNDNINNDNNNDNNNDNSNNGFVCELSSNINDFNNI
LNVNKDNFQGINKSNNFSTNLSEYNYDAYVKIVEAGSALENKKQQDKKRKYFSDSEITKENGYLGESNSIKIRKV
SVGGDNDNNDDDNNDDNDDDDNDDDNNDDDNNNDDDNDDSYDDEEKEQENYSNDVNTELNNHVTFEDISVHNNIQ
ENKKNYFSNVHENTFNLHVDENVHEDLQNYEDYVNNNNNNNDDDNEEESNNSCYIISSDDEGDKKNVSKQNDDDE
DDDDNGDDDDNEDDDDNEDDDNGDDDDNEDDDNGDDDDNEDDNYDDEDNDNYENEDDDNYANEDDDNYENDDDDN
YENDDDDNYENDDDNYENDDDDNYENGDDDNDNDHNDDNNDEEKYSCHDDKNEHTNNDLLNIDHDNNKNNITDEL
YSTYNVSVSHNKDPSNKENEIQNLISIDSSNENDENDENDENDENDENDENDENDENDENDENDEKDENDENDEN
DENFDNNNEGTLNEMNSEE 
Figure A.1: Full-length amino acid sequence of PfC0760c with key sequences indicated. Red 
boxes: conserved peptides. Blue boxes: B-cell epitopes. Yellow highlight: acetylated lysine. Green: 
recombinant sequence. C in bold: conserved cysteine 
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Appendix B: BLAST output from PlasmoDB and ExPASy 
The PfC0760c protein sequence was subject to PlasmoDB BLAST. The accession 
numbers, species name and protein characteristics are illustrated in Table 1. The protein 
sequences were aligned with Clustal Omega and compared to the Clustal Omega output using 
protein sequences from NCBI BLASTp. 
Table B.1: PlasmoDB BLAST analysis of PfC0760c protein sequence. 
Accession number Plasmodium species Protein characteristics 
PFIT_0317300 P. falciparum IT conserved, unknown 
PVP01_0822800 P. vivax P01 conserved, unknown 
PVX_095365 P. vivax Sal-1 conserved hypothetical protein 
PmUG01_08038800 P. malariae UG01 conserved, unknown 
PKNH_0824500 P. knowlesi strain H conserved, unknown 
PKNOH_S100053000 P. knowlesi strain Malayan Strain Pk1 A uncharacterised protein 
PRG01_0320800 P. reichenowi G01 conserved, unknown 
C922_02043 P. inui San Antonio 1 hypothetical protein 
PBLACG01_0317800 P. blacklocki G01 conserved, unknown 
PCOAH_00021130 P. coatneyi Hackeri uncharacterised protein 
PCYB_083240 P. cynomolgi strain B hypothetical protein 
PcyM_0824600 P. cynomolgi strain M conserved, unknown 
PGABG01_0316700 P. gaboni strain G01 conserved, unknown 
PGSY75_0317300 P. gaboni strain SY75 hypothetical protein 
PRCDC_0316600 P. reichenowi CDC conserved, unknown 
AK88_00579 P. fragile strain nilgiri hypothetical protein 
PADL01_0316200 P. adleri G01 conserved, unknown 
PBILCG01_0316800 P. billcollinsi G01 conserved, unknown 
PPRFG01_0318800 P. praefalciparum strain G01 conserved, unknown 
PBANKA_0807900 P. berghei ANKA conserved, unknown 
PCHAS_0808200 P. chabaudi chabaudi conserved, unknown 
PY05757 P. yoelii yoelii 17XNL hypothetical protein 
PY07424 P. yoelii yoelii 17XNL hypothetical protein 
PY17X_0811100 P. yoelii yoelii 17X conserved, unknown 
PYYM_0810900 P. yoelii yoelii YM conserved, unknown 
YYE_01881 P. vinckei vinckei strain vinckei hypothetical protein 
YYG_01058 P. vinckei petteri strain CR hypothetical protein 
PGAL8A_00399000 P. gallinaceum 8A conserved, unknown 
PRELSG_0820800 P. relictum SGS1-like conserved, unknown 
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The PfC0760c protein sequence was subject to BLAST analysis using ExPASy. The 
accession numbers, species name and protein characteristics are illustrated in Table 2. The 
protein sequences were aligned with Clustal Omega and compared to the Clustal Omega 
output using protein sequences from NCBI BLASTp. 
Table B.2: Protein sequences from ExPASy were aligned with PfC0760c using Clustal Omega. 
Accession number Plasmodium species Protein function 
A0A0J9VIP9 (PLAVI) P. vivax uncharacterised 
A0A1D3PAQ5 (PLAMA) P. malariae uncharacterised 
A0A060RNN0 (PLARE) P. reichenowi  uncharacterised 
A0A2P9BQW6 (9APIC) P. gaboni uncharacterised 
A0A0D9QU16 (PLAFR) P. fragile uncharacterised 
W7A291 (9APIC) P. inui uncharacterised 
A0A1Y1JEH3 (PLAGO) P. gonderi uncharacterised 
K6UJR3 (9APIC) P. cynomolgi uncharacterised 
A0A1B1DYG9 (9APIC) P. coatneyi uncharacterised 
A0A1D3RT35 (PLACH) P. chabaudi chabaudi uncharacterised 
A0A1C6Y9T1 (PLACH) P. chabaudi adami uncharacterised 
A0A077XDQ7 (PLABA) P. berghei ANKA uncharacterised 
A0A0Y9VZ01 (PLABE) P. berghei uncharacterised 
W7ARB4 (PLAVN) P. vinckei petteri uncharacterised 
V7PPZ5 (9APIC) P. yoelii 17X uncharacterised 
A0A078K6G8 (9APIC) P. yoelii uncharacterised 
A0A1J1H4E4 (PLARL) P. relictum uncharacterised 
A0A1J1GPR7 (PLAGA) P. gallinaceum uncharacterised 
 
 
